An Ethologically Relevant Animal Model of Post-Traumatic Stress Disorder: Physiological, Pharmacological and Behavioral Sequelae in Rats Exposed to Predator Stress and Social Instability by Zoladz, Phillip R
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
11-5-2008
An Ethologically Relevant Animal Model of Post-
Traumatic Stress Disorder: Physiological,
Pharmacological and Behavioral Sequelae in Rats
Exposed to Predator Stress and Social Instability
Phillip R. Zoladz
University of South Florida
Follow this and additional works at: https://scholarcommons.usf.edu/etd
Part of the American Studies Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.
Scholar Commons Citation
Zoladz, Phillip R., "An Ethologically Relevant Animal Model of Post-Traumatic Stress Disorder: Physiological, Pharmacological and
Behavioral Sequelae in Rats Exposed to Predator Stress and Social Instability" (2008). Graduate Theses and Dissertations.
https://scholarcommons.usf.edu/etd/584
 
 
An Ethologically Relevant Animal Model of Post-Traumatic Stress Disorder: 
Physiological, Pharmacological and Behavioral Sequelae in Rats Exposed to        
Predator Stress and Social Instability 
 
 
 
by 
 
 
 
Phillip R. Zoladz 
 
 
 
 
 
A dissertation submitted in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
Department of Psychology 
College of Arts and Sciences 
University of South Florida 
 
 
 
Major Professor: David Diamond, Ph.D. 
Paula Bickford, Ph.D. 
Cheryl Kirstein, Ph.D. 
Edward Levine, Ph.D. 
Kristen Salomon, Ph.D. 
 
 
Date of Approval: 
November 5, 2008 
 
 
 
Keywords: PTSD, glucocorticoids, hippocampus, amygdala, antidepressants 
 
© Copyright 2008, Phillip R. Zoladz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For my loving wife, Meagan. If it were not for you, I would never have made it this far. 
 
 
 
 
 
Acknowledgements 
 
 I would like to thank Dr. David Diamond for his guidance and expertise. I truly 
appreciate all of the opportunities with which I have been provided, and I thank you for 
the encouragement and words of wisdom that you have offered me. I would also like to 
thank Dr. Paula Bickford, Dr. Ed Levine, Dr. Cheryl Kristein and Dr. Kristen Salomon 
for being on my dissertation committee and Dr. Eric Bennett for agreeing to serve as the 
chairperson of my dissertation defense. Each of you has made this process very enjoyable 
for me. I would like to thank the laboratory of Monika Fleshner from the University of 
Colorado for assaying so many serum samples from this dissertation. I can truly say that 
it would not have gotten finished without your help! Also, my lab colleagues, Josh 
Halonen, Collin Park, Shyam Seetharaman and Alvin Jin, and I have developed very 
strong professional and personal relationships over the past few years. I am very thankful 
for each one of you. 
 I would also like to thank my family for all of their love and support. Meagan, 
you gave up everything for me to pursue my graduate studies, and I could never express 
how much you mean to me. I love you with all of my heart. To my parents, you have 
always been there for me, and now as I start a life of my own, I only hope that I can be as 
good of a parent as you both have been to me. Finally, I would like to thank God for what 
He has done in my life. I have always needed You, but it was not until recently that I 
accepted this need. Thank you for always loving me, even in spite of who I used to be.  
  i
 
 
 
 
Table of Contents 
 
List of Tables vii 
 
List of Figures viii 
 
Abstract xiii 
 
Chapter One: Background 1 
 Definition of Post-Traumatic Stress Disorder 1 
 Susceptibility to Post-Traumatic Stress Disorder 2 
 Heightened Arousal in Post-Traumatic Stress Disorder 2 
  Elevated Sympathetic Nervous System Activity 2 
  Contribution of the Parasympathetic Nervous System to 
       Sympathetic Overdrive 7 
  Conclusion on Sympathetic Overdrive in Post-Traumatic 
       Stress Disorder 8 
 Abnormal Functioning of the Hypothalamus-Pituitary-Adrenal 
      Axis in Post-Traumatic Stress Disorder 10 
  Abnormal Baseline Levels of Cortisol and Its Hormone 
       Precursors 11 
  Mechanisms Underlying Abnormal Hypothalamus- 
        Pituitary-Adrenal Axis Functioning in Post-Traumatic 
        Stress Disorder 15 
 Structural and Functional Brain Abnormalities in Post-Traumatic 
     Stress Disorder 17 
  Smaller Hippocampal Volume 17 
  Cognitive Impairments 19 
  Interactions between the Amygdala and Prefrontal Cortex 20 
 Pharmacotherapy for Post-Traumatic Stress Disorder 22 
  Selective Serotonin Reuptake Inhibitors 22 
  Tricyclic Antidepressants and Monoamine Oxidase 
        Inhibitors 23 
  Noradrenergic Modulators 25 
  The Antidepressant Tianeptine 26 
 Animal Models of Post-Traumatic Stress Disorder 28 
  Existing Models of Post-Traumatic Stress Disorder in 
       Rodents 28 
  Our Laboratory’s Recently Developed Animal Models of 
       Post-Traumatic Stress Disorder 30 
  ii
 Purpose of the Present Experiments 34 
 
Chapter Two: Experiment One 35 
 Chronic Psychosocial Stress Produces a Reduction in Basal 
      Glucocorticoid Levels in Rats: Further Validation of an Animal 
      Model of PTSD 35 
 Methods 36 
  Rats 36 
  Psychosocial Stress Procedure 36 
   Acute Stress Sessions 36 
   Daily Social Stress 37 
  Assessment of Basal and Stress-Induced Glucocorticoid 
       Levels 37 
   Preparation 37 
   Blood Sampling and Post-Mortem Dissection 38 
  Statistical Analyses 39 
   Experimental Design 39 
   Growth Rate, Adrenal Gland Weight and Thymus 
        Weight 39 
   Corticosterone Levels 39 
 Results  40 
  Growth Rates 40 
  Adrenal Gland Weights 40 
  Thymus Weights 40 
  Corticosterone Levels 41 
 Discussion of Findings 42 
 
Chapter Three: Experiment Two 46 
 Chronic Psychosocial Stress Results in Enhanced Suppression of 
      Corticosterone Levels following Dexamethasone 
      Administration: Evidence for Enhanced Negative Feedback of 
      the Hypothalamus-Pituitary-Adrenal Axis 46 
 Methods  47 
  Rats  47 
  Psychosocial Stress Procedure 47 
  Assessment of Post-Dexamethasone Basal and Stress- 
       Induced Glucocorticoid Levels 47 
   Preparation 47 
   Pharmacological Manipulations 48 
   Blood Sampling and Post-Mortem Dissection 48 
  Statistical Analyses 49 
   Experimental Design 49 
   Growth Rate, Adrenal Gland Weights and Thymus 
        Weights 49 
  iii
   Corticosterone Levels 49 
 Results  50 
  Growth Rates 50 
  Adrenal Gland Weights 50 
  Thymus Weights 50 
  Corticosterone Levels 51 
 Discussion of Findings 54 
 
Chapter Four: Experiment Three 58 
 Differential Effectiveness of the Pharmacological Agents 
     Amitriptyline, Clonidine and Tianeptine in Blocking the PTSD- 
     Like Physiological and Behavioral Sequelae in Rats 58 
 Methods  60 
  Rats  60 
  Psychosocial Stress Procedure 60 
  Pharmacological Agents 62 
  Behavioral Testing 62 
  Behavioral Apparatus 63 
   Contextual and Cue Fear Memory 63 
   Elevated Plus Maze 64 
   Startle Response 64 
   Novel Object Recognition 65 
   Preparation for Blood Sampling 66 
   Blood Sampling and Cardiovascular Activity 66 
  Statistical Analyses 67 
   Experimental Design and General Analyses 67 
   Fear Memory 67 
   Elevated Plus Maze 68 
   Startle Response 68 
   Novel Object Recognition 68 
   Corticosterone Levels 69 
   Heart Rate and Blood Pressure 69 
   Growth Rates, Adrenal Gland Weights and Thymus 
        Weights 69 
 Results  70 
  Fear Memory 70 
   Stress Session One 70 
   Stress Session Two 70 
   Context Test Immobility 72 
   Context Test Fecal Boli 73 
   Cue Test Immobility – No Tone 74 
   Cue Test Immobility – Tone 75 
   Cue Test Fecal Boli 76 
  Elevated Plus Maze 77 
  iv
   Percent Time in Open Arms, 5-Minute Trial 77 
   Percent Time in Open Arms, First Minute 78 
   Ambulations, 5-Minute Trial 80 
   Ambulations, First Minute 81 
  Startle Response 82 
   90 dB Auditory Stimuli 82 
   100 dB Auditory Stimuli 83 
   110 Auditory Stimuli 84 
  Novel Object Recognition 85 
   Habituation 85 
   Training 87 
   Testing, 5-Minute Trial 88 
   Testing, First Minute 89 
  Corticosterone Levels 89 
  Cardiovascular Activity 91 
   Heart Rate 91 
   Systolic Blood Pressure 92 
   Diastolic Blood Pressure 94 
  Growth Rates 95 
  Adrenal Gland Weights 96 
  Thymus Weights 98 
 Discussion of Findings 99 
  Amitriptyline 101 
  Clonidine 105 
  Tianeptine 107 
  Limitations and Future Research 112 
  Summary and Applications to Pharmacotherapy for Post- 
       Traumatic Stress Disorder 113 
 
Chapter Five: Experiment Four 115 
 Temporal Dynamics of the Physiological and Behavioral Sequelae 
       Induced by Chronic Psychosocial Stress 115 
 Methods  115 
  Rats  115 
  Psychosocial Stress Procedure 116 
  Behavioral Testing 118 
  Behavioral Apparatus 118 
   Contextual and Cue Fear Memory 118 
   Elevated Plus Maze 119 
   Startle Response 119 
   Novel Object Recognition 119 
   Preparation for Blood Sampling 119 
   Blood Sampling and Cardiovascular Activity 119 
  Statistical Analyses 120 
  v
   Experimental Design and General Analyses 120 
   Fear Memory 120 
   Elevated Plus Maze 120 
   Startle Response 121 
   Novel Object Recognition 121 
   Corticosterone Levels 122 
   Heart Rate and Blood Pressure 122 
   Growth Rates, Adrenal Gland Weights and Thymus 
        Weights 122 
 Results  122 
  Fear Memory 122 
   Stress Session One 122 
   Stress Session Two 123 
   Stress Session Three 124 
   Context Test Immobility 124 
   Context Test Fecal Boli 125 
   Cue Test Immobility – No Tone 127 
   Cue Test Immobility – Tone 127 
   Cue Test Fecal Boli 127 
  Elevated Plus Maze 128 
   Percent Time in Open Arms, 5-Minute Trial 128 
   Percent Time in Open Arms, First Minute 128 
   Ambulations, 5-Minute Trial 130 
   Ambulations, First Minute 130 
  Startle Response 132 
   90 dB Auditory Stimuli 132 
   100 dB Auditory Stimuli 132 
   110 dB Auditory Stimuli 133 
  Novel Object Recognition 133 
   Habituation 133 
   Training 134 
   Testing 135 
  Corticosterone Levels 136 
  Cardiovascular Activity 136 
   Heart Rate 136 
   Systolic Blood Pressure 138 
   Diastolic Blood Pressure 138 
  Growth Rates 138 
  Adrenal Gland Weights 140 
  Thymus Weights 140 
 Discussion of Findings 141 
  Conclusions and Limitations 142 
 
Chapter Six: Concluding Remarks 145 
  vi
 
References   149 
 
About the Author  End Page 
  vii
 
 
 
 
List of Tables 
 
Table 1 Growth Rates, Adrenal Gland Weights and Thymus 
 Weights (± SEM) for the Groups in Experiment 1 41 
 
Table 2 Growth Rates, Adrenal Gland Weights and Thymus 
 Weights (± SEM) for the Psychosocial Stress and No 
 Psychosocial Stress Groups (collapsed across all 
 dexamethasone conditions) in Experiment 2 51 
 
Table 3 Time (seconds ± SEM) Spent with Each Object during 
 Object Recognition Training for all Groups in Experiment 3 87 
  viii
 
 
 
 
List of Figures 
Figure 1. Chronic Psychosocial Stress Produced a Reduction of Basal 
 Glucocorticoid Levels in Rats 42 
 
Figure 2. Chronic Psychosocial Stress Increases Sensitivity of the 
 HPA Axis to Dexamethasone 52 
 
Figure 3. Effects of Chronic Psychosocial Stress on Corticosterone 
 Responses Following Different Doses of Dexamethasone 53 
 
Figure 4. Amount of Immobility during the 3-Minute Chamber 
 Exposure during Stress Session One 70 
 
Figure 5. Amount of Immobility during the 3-Minute Chamber 
 Exposure during Stress Session Two 71 
 
Figure 6. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Immobility during the 5-Minute Context Test 72 
 
Figure 7. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Fecal Boli Produced during the 5-Minute Context Test 74 
 
Figure 8. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Immobility during the First 3 Minutes of the Cue Test 75 
 
Figure 9. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Immobility during the Tone 76 
 
Figure 10. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Fecal Boli Produced during the 6-Minute Cue Test 77 
 
Figure 11. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Percent Time Spent in the Open Arms during the 
 5-Minute Trial on the Elevated Plus Maze 78 
 
Figure 12. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Percent Time Spent in the Open Arms during the First 
 Minute of the 5-Minute Trial on the Elevated Plus Maze 79 
 
  ix
Figure 13. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Ambulations Made during the 5-Minute Trial on the 
 Elevated Plus Maze 80 
 
Figure 14. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Ambulations Made during the First Minute of the 
 5-Minute Trial on the Elevated Plus Maze 81 
 
Figure 15. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Startle Responses to the 90 dB Auditory Stimuli 82 
 
Figure 16. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Startle Responses to the 100 dB Auditory Stimuli 84 
 
Figure 17. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Startle Responses to the 110 dB Auditory Stimuli 85 
 
Figure 18. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Locomotor Activity during the 5-Minute Object 
 Recognition Habituation Period 86 
 
Figure 19. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Object Recognition Memory during the Entire 5-Minute 
 Testing Trial 88 
 
Figure 20. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Object Recognition Memory during the First Minute of 
 the Testing Trial 89 
 
Figure 21. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Serum Corticosterone Levels 90 
 
Figure 22. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Heart Rate 92 
 
Figure 23. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Systolic Blood Pressure 93 
 
Figure 24. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Diastolic Blood Pressure 94 
 
Figure 25. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Growth Rate 96 
 
  x
Figure 26. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Adrenal Gland Weight 97 
 
Figure 27. Effects of Chronic Psychosocial Stress and Drug Treatment 
 on Thymus Weight 98 
 
Figure 28. Experimental Groups in Experiment 4 117 
 
Figure 29. Amount of Immobility upon Chamber Exposure during 
 Stress Session One 123 
 
Figure 30. Amount of Immobility upon Chamber Exposure during 
 Stress Session Two 123 
 
Figure 31. Amount of Immobility upon Chamber Exposure during 
 Stress Session Three 124 
 
Figure 32. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Immobility during the 5-Minute Context Test 125 
 
Figure 33. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Fecal Boli Produced during the 5-Minute 
 Context Test 126 
 
Figure 34. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Immobility during the First 3 Minutes of the 
 Cue Test 126 
 
Figure 35. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Immobility during the Last 3 Minutes of the 
 Cue Test 127 
 
Figure 36. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Fecal Boli Produced during the 6-Minute  
 Cue Test 128 
 
Figure 37. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Percent Time Spent in the Open Arms during 
 the 5-Minute Trial on the Elevated Plus Maze 129 
 
Figure 38. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Percent Time Spent in the Open Arms during 
 the First Minute of the 5-Minute Trial on the Elevated Plus 
 Maze 129 
  xi
Figure 39. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Ambulations Made during the 5-Minute Trial 
 on the Elevated Plus Maze 130 
 
Figure 40. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Ambulations Made during the First Minute of 
 the 5-Minute Trial on the Elevated Plus Maze 131 
 
Figure 41. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Startle Responses to the 90 dB Auditory 
 Stimuli 131 
 
Figure 42. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Startle Responses to the 100 dB Auditory 
 Stimuli 132 
 
Figure 43. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Startle Responses to the 110 dB Auditory 
 Stimuli 133 
 
Figure 44. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Object Recognition Memory during the 
 Entire 5-Minute Testing Trial 134 
 
Figure 45. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Object Recognition Memory during the First 
 Minute of the Testing Trial 135 
 
Figure 46. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Serum Corticosterone Levels 136 
 
Figure 47. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Heart Rate 137 
 
Figure 48. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Systolic Blood Pressure 137 
 
Figure 49. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Diastolic Blood Pressure 138 
 
Figure 50. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Growth Rate 139 
 
 
  xii
Figure 51. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Adrenal Gland Weight 139 
 
Figure 52. Effects of Differential Chronic Psychosocial Stress 
 Paradigms on Thymus Weight 140  
  xiii
 
 
An Ethologically Relevant Animal Model of Post-Traumatic Stress Disorder: 
Physiological, Pharmacological and Behavioral Sequelae in Rats Exposed to          
Predator Stress and Social Instability 
 
Phillip R. Zoladz 
 
ABSTRACT 
 
 Post-traumatic stress disorder (PTSD) is a debilitating mental illness that results 
from exposure to intense, life-threatening trauma. Some of the symptoms of PTSD 
include intrusive flashback memories, persistent anxiety, hyperarousal and cognitive 
impairments. The finding of reduced basal glucocorticoid levels, as well as a greater 
suppression of glucocorticoid levels following dexamethasone administration, has also 
been commonly observed in people with PTSD. Our laboratory has developed an animal 
model of PTSD which utilizes chronic psychosocial stress, composed of unavoidable 
predator exposure and daily social instability, to produce changes in rat physiology and 
behavior that are comparable to the symptoms observed in PTSD patients. The present set 
of experiments was therefore designed to 1) test the hypothesis that our animal model of 
PTSD would produce abnormalities in glucocorticoid levels that are comparable to those 
observed in people with PTSD, 2) examine the ability of antidepressant and anxiolytic 
agents to ameliorate the PTSD-like physiological and behavioral symptoms induced by 
our paradigm and 3) ascertain how long the physiological and behavioral effects of our 
stress regimen could be maintained. 
  xiv
 The experimental findings revealed that our animal model of PTSD produces a 
reduction in basal glucocorticoid levels and increased negative feedback sensitivity to the 
synthetic glucocorticoid, dexamethasone. In addition, chronic prophylactic administration 
of amitriptyline (tricyclic antidepressant) and clonidine (α2-adrenergic receptor agonist) 
prevented a subset of the effects of chronic stress on rat physiology and behavior, but 
tianeptine (antidepressant) was the only drug to block the effects of chronic stress on all 
physiological and behavioral measures. The final experiment indicated that only a subset 
of the effects of chronic stress on rat physiology and behavior could be observed 4 
months following the initiation of chronic stress, suggesting that some of the effects of 
our animal model diminish over time. Together, these findings further validate our animal 
model of PTSD and may provide insight into the mechanisms underlying trauma-induced 
changes in brain and behavior. They also provide guidance for pharmacotherapeutic 
approaches in the treatment of individuals suffering from PTSD. 
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Chapter One: Background 
Definition of Post-Traumatic Stress Disorder 
Individuals who are exposed to intense trauma that threatens physical injury or 
death, such as rape, wartime combat and motor vehicle accidents, are at significant risk 
for developing post-traumatic stress disorder (PTSD). People who develop PTSD respond 
to a traumatic experience with intense fear, helplessness or horror (American Psychiatric 
Association, 1994) and subsequently endure chronic psychological distress by repeatedly 
reliving their trauma through intrusive, flashback memories (Ehlers et al., 2004; 
Hackmann et al., 2004; Reynolds & Brewin, 1998; Reynolds & Brewin, 1999; Speckens 
et al., 2006; Speckens et al., 2007). These intrusions are frequently precipitated by the 
presence of cues associated with the traumatic event; therefore, PTSD patients make 
great efforts to avoid stimuli that remind them of their trauma. The re-experiencing and 
avoidance symptoms of the disorder significantly hinder everyday functioning in PTSD 
patients and foster the development of several additional debilitating symptoms, 
including persistent anxiety, exaggerated startle, cognitive impairments, diminished 
extinction of conditioned fear and pharmacological abnormalities, such as an increased 
sensitivity to yohimbine (Brewin et al., 2000; Elzinga & Bremner, 2002; Nemeroff et al., 
2006; Newport & Nemeroff, 2000; Stam, 2007a). 
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Susceptibility to Post-Traumatic Stress Disorder 
 Only about 25% of traumatized individuals develop PTSD (Ozer et al., 2003; 
Ozer & Weiss, 2004; Yehuda, 2004). While nearly every traumatized person displays re-
experiencing, avoidance and hyperarousal symptoms in the acute aftermath of trauma 
(McFarlane, 2000), only a minority continue to exhibit these symptoms for a period of at 
least 1 month and fulfill the requirements set forth by the Diagnostic and Statistical 
Manual of Mental Disorders (American Psychiatric Association, 1994) for a diagnosis of 
PTSD (Yehuda & LeDoux, 2007). Thus, in approximately 75% of traumatized 
individuals, the re-experiencing, avoidance and hyperarousal symptoms subside within a 
1-month time frame, and at least one-third of those who continue to display the 
symptoms at 1-month post-trauma recover within 3 months (Kessler et al., 1995). Thus, 
the natural response to trauma is recovery, and only a subset of traumatized individuals 
develops chronic forms of the disorder. 
Heightened Arousal in Post-Traumatic Stress Disorder 
Elevated Sympathetic Nervous System Activity 
PTSD is characterized by a complex aberrant biological profile involving several 
physiological systems, one of which is the sympathetic nervous system (SNS). Extensive 
work has demonstrated that PTSD patients exhibit greater baseline and stress-induced 
elevations of sympathetic activity than control subjects (Buckley & Kaloupek, 2001; 
Pole, 2007). In response to traumatic reminders and standard laboratory stressors, people 
with PTSD display significantly greater increases in heart rate (HR), blood pressure (BP), 
skin conductance, epinephrine (EPI) and norepinephrine (NE) than do control subjects 
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(Blanchard et al., 1982; Blanchard et al., 1991; Casada et al., 1998; Kolb & Mutalipassi, 
1992; Malloy et al., 1983; McFall et al., 1990; Orr et al., 1998; Pitman et al., 1987; Rabe 
et al., 2006; Schmahl et al., 2004; Shalev et al., 1993; Veazey et al., 2004). In addition, 
PTSD patients exhibit significant elevations of baseline HR, systolic BP and diastolic BP 
(Buckley & Kaloupek, 2001; Pole, 2007), findings that resonate with recent work 
reporting an association between PTSD and increased risk for cardiovascular disease 
(Boscarino & Chang, 1999; Kubzansky et al., 2007; Sawchuk et al., 2005). 
A vast literature has also implicated increased baseline noradrenergic activity in 
individuals suffering from PTSD. Several studies have shown that PTSD patients exhibit 
abnormally high levels of baseline NE (Geracioti et al., 2001; Kosten et al., 1987; 
Southwick et al., 1999a; Strawn & Geracioti, 2008; Yehuda et al., 1998), levels that have 
been shown to positively correlate with the severity of symptoms in PTSD patients 
(Geracioti et al., 2001). Another indication of accentuated sympathetic activity in people 
with PTSD is the hyperresponsivity they exhibit to the administration of yohimbine, an α2 
adrenergic receptor antagonist which blocks noradrenergic autoreceptors and leads to 
increased central norepinephrine activity (Rasmusson et al., 2000; Southwick et al., 1993; 
Southwick et al., 1999c; Southwick et al., 1999a; Southwick et al., 1999b). Southwick 
and colleagues (Southwick et al., 1993) found that, following yohimbine administration, 
70% of PTSD patients experienced panic attacks, and 40% experienced flashbacks. 
PTSD patients also exhibited significantly greater HR, systolic BP, anxiety-related 
behavior and acoustic startle responses to the drug (Morgan et al., 1995b). 
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Bremner and colleagues (Bremner et al., 1997a) suggested that these findings may 
be related to reduced NE catabolism in PTSD patients. To test this hypothesis, the 
investigators gave PTSD patients a single bolus of [F-18]2-fluoro-2-deoxyglucose, a 
compound that is taken up by high-glucose-using cells, immediately prior to intravenous 
injections of yohimbine. Approximately an hour later, the investigators measured cerebral 
metabolic activity in participants by employing positron emission tomography (PET). 
The PET scans revealed that, relative to healthy controls, PTSD patients displayed 
significantly lower levels of glucose metabolism in several neocortical brain regions that 
are highly innervated by noradrenergic nerve fibers, suggesting the presence of reduced 
NE catabolism in people with PTSD. The anxiogenic effects of yohimbine in people with 
PTSD have also been linked to the presence of fewer and less sensitive α2 adrenergic 
receptors and lower levels of plasma neuropeptide Y (NPY) in PTSD patients (Perry et 
al., 1990; Perry, 1994; Rasmusson et al., 2000). NPY is a peptide neurotransmitter that is 
colocalized with NE in most sympathetic nerve fibers and within the locus coeruleus, an 
area of the dorsal pons that contains the major cell bodies of the noradrenergic system. 
The peptide typically inhibits the release of the neurotransmitter with which it is 
colocalized. Rasmusson et al. (2000) found that PTSD patients had lower baseline plasma 
levels of NPY, as well as a smaller increase in NPY levels in response to a yohimbine 
challenge paradigm. This finding could explain the presence of greater baseline NE 
levels, as well as greater reactivity to yohimbine, in PTSD patients. 
Related to the symptoms of hyperarousal and greater noradrenergic activity, an 
exaggerated startle response is often presented as a core symptom of PTSD (Grillon et al., 
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1996). The startle response is defined as the rapid sequence of flexor motor movements 
that occurs after the onset of a briefly-presented, intense stimulus (Morgan, 1997). 
Approximately 85-90% of trauma survivors with PTSD subjectively report having an 
increased startle response (Shalev et al., 1997). However, empirical investigations 
examining the startle response in PTSD patients have presented conflicting results. While 
some studies have found heightened startle in people with PTSD (Butler et al., 1990; 
Grillon et al., 1998; Morgan et al., 1995a; Morgan et al., 1996; Morgan et al., 1997; Orr 
et al., 1995; Shalev et al., 1997), others have found no differences between PTSD patients 
and control subjects (Elsesser et al., 2004; Grillon et al., 1996; Lipschitz et al., 2005; Orr 
et al., 1997; Siegelaar et al., 2006). The exaggerated startle response often observed in 
PTSD patients may not be due to a stable trait of these individuals, but rather an acute 
state of conditioned fear or anxiety (e.g., anticipatory anxiety) that they experience during 
the experimental assessment. In support of this hypothesis, several studies have found 
that manipulations of the experimental context or the presentation of explicit threat cues 
consistently leads to enhanced startle responses in PTSD patients (Grillon et al., 1998; 
Grillon & Morgan, 1999; Pole et al., 2003). 
Investigators have also faced the challenge of determining whether or not the 
exaggerated startle response observed in people with PTSD is a secondary effect of the 
disorder or a predisposing risk factor that increases one’s susceptibility to develop the 
disorder. In a recent study, Guthrie and Bryant (2005) assessed the auditory startle 
response of firefighters before and after they had been exposed to trauma. Although none 
of the firefighters who were exposed to trauma developed PTSD during the course of the 
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study, they did display more symptoms (e.g., intrusive memories, avoidance) of the 
disorder after the trauma than firefighters who had not been exposed to a traumatic event. 
More importantly, the investigators found that the magnitude of the pre-trauma startle 
response predicted the development of acute PTSD symptoms. These findings suggest 
that an exaggerated startle response may not necessarily be a secondary effect of PTSD; 
rather, it could be a pre-existing factor that increases one’s susceptibility to develop the 
disorder. 
Despite the inconsistent findings on baseline startle responses in PTSD patients, 
research has reliably shown that upon exposure to briefly-presented, intense stimuli (e.g., 
loud tones), people with PTSD exhibit significantly greater autonomic reactivity than do 
controls (Metzger et al., 1999; Orr et al., 1995; Orr et al., 1997; Shalev et al., 1997; 
Shalev et al., 2000; Siegelaar et al., 2006). This includes a failure to physiologically 
habituate to the stimuli, in addition to the elicitation of greater autonomic responses from 
the onset of the stimuli. In a recent study, Siegelaar et al. (2006) found that although 
PTSD patients did not display an exaggerated startle response, relative to control 
subjects, they did exhibit significantly greater autonomic reactivity, in the form of 
galvanic skin response, to the test stimuli. The investigators contended that the presence 
of greater autonomic activity following the presentation of startling stimuli may explain 
why PTSD patients subjectively report exaggerated startle responses, despite not 
exhibiting them behaviorally. Ultimately, these findings suggest that while it is unclear 
whether or not individuals with PTSD exhibit a heightened baseline startle response, they 
do tend to display exaggerated autonomic reactivity to sudden, intense stimulation. 
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Contribution of the Parasympathetic Nervous System to Sympathetic Overdrive 
The parasympathetic nervous system (PNS), which is metaphorically considered 
the brakes on the SNS since it reduces SNS activity, makes a significant contribution to 
the maintenance of HR (Berntson et al., 1993). The vagus nerve, which is an important 
part of the PNS, innervates the sinoatrial node on the right atrium of the heart, where 
electrical impulses are generated to trigger cardiac contraction. By modulating the 
sinoatrial node, the vagus nerve slows HR and helps to maintain a balance between the 
SNS and PNS. Vagal modulation of HR is important for reactions to and recovery from 
stressful situations, and has been considered a possible mechanism for the differences in 
basal HR and changes in HR due to trauma-related cues in individuals with PTSD (Sahar 
et al., 2001). 
Most studies monitoring PNS activity in PTSD patients have utilized heart-rate 
variability (HRV) as the primary dependent measure. HRV is a measure of beat-to-beat 
alterations in heart rate, or more specifically, the variability of the intervals between R 
waves. The two main frequency bands that are examined during HRV assessment are the 
Low-Frequency (LF) band (0.04 to 0.15 Hz), which is influenced primarily by the SNS, 
and the High-Frequency (HF) band (0.15 to 0.40 Hz), which is influenced primarily by 
the PNS (Sahar et al., 2001). Cohen and colleagues (Cohen et al., 1997; Cohen et al., 
1998; Cohen et al., 2000a) found that, at rest, PTSD patients displayed greater HR and 
lower HRV than healthy control subjects. Furthermore, these patients demonstrated lower 
HF and higher LF components than controls, suggestive of enhanced sympathetic and 
reduced parasympathetic tone, respectively. Sahar et al. (2001) examined the vagal 
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modulation of HR in PTSD patients in response to a mental challenge by using 
respiratory sinus arrhythmia (RSA) as their dependent measure. RSA is the natural 
fluctuation in heart rate that occurs during the breathing cycle, and changes in RSA have 
been shown to reflect activity of the vagus nerve (Berntson et al., 1993). Sahar and 
colleagues (Sahar et al., 2001) found that PTSD patients and traumatized control subjects 
did not differ on resting levels of parasympathetic activity. However, when faced with a 
challenging arithmetic task, control subjects showed a significant increase in RSA (which 
was highly correlated with their HR), while PTSD patients showed no such increase. 
Thus, vagal mechanisms contributed to HR regulation in control subjects, but not in 
PTSD patients. These findings suggest that vagal modulation of HR may be impaired in 
PTSD patients, resulting in poor control of stress-induced changes in HR and increased 
risk for exaggerated sympathetic tone. 
Conclusion on Sympathetic Overdrive in Post-Traumatic Stress Disorder 
Sympathetic overdrive has been hypothesized to contribute to the hyperarousal 
symptoms observed in PTSD patients. It is also potentially responsible for their enhanced 
acquisition of conditioned fear and their “over-consolidation” of the original traumatic 
memory (Cahill et al., 1994; Cahill & McGaugh, 1998; McGaugh et al., 1996; Pitman, 
1989). Many researchers have used conditioning theory to explain the development of 
PTSD (Garakani et al., 2006; Wessa & Flor, 2002). These investigators have speculated 
that during the trauma, the plethora of cues (CSs) to which an individual is exposed 
becomes associated with the life-threatening experience (US) that he or she is enduring 
and eventually elicits feelings of intense fear (CRs) similar to those (URs) experienced 
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during the original traumatic event. In theory, individuals who are more susceptible to 
developing the disorder would exhibit more intense fear responses to the trauma, which 
would then be more strongly associated with the cues from the environment. This would 
subsequently cause these individuals to exhibit exaggerated physiological and behavioral 
responses to the presence of trauma-related cues and compel them to avoid reminders of 
their trauma. One mechanism that could explain the enhanced consolidation of traumatic 
memories in PTSD patients is excessive adrenergic activity at the time of trauma (Cahill 
et al., 1994; Cahill & McGaugh, 1998; McGaugh et al., 1996; Pitman, 1989). Decades of 
animal research has shown that the administration of EPI or NE following learning 
enhances the storage of emotional memories (Gold et al., 1977; Gold & Van Buskirk, 
1975; McGaugh, 2004), and a substantial amount of work in traumatized people has 
found that those individuals who exhibit greater HR responses to the traumatic event are 
at a much greater risk of developing PTSD (Bryant et al., 2000; Bryant et al., 2004; 
Bryant, 2006; Bryant et al., 2007; Shalev et al., 1998; Zatzick et al., 2005). As PTSD is a 
disorder of memory, in which an individual repeatedly relives his or her trauma through 
intrusive, flashback memories, an exaggerated sympathetic response to trauma could 
foster a development of a powerful, unrelenting traumatic memory that in some 
individuals becomes incapacitating over time. 
Although sympathetic activity facilitates a rapid response to threat in one’s 
environment, chronic activation of the system can have detrimental effects on an 
individual’s health (McEwen, 1998; McEwen, 2003; McEwen & Wingfield, 2003). As 
mentioned above, some studies have indicated that PTSD is associated with increased 
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risk for cardiovascular disease, including myocardial infarctions and atrioventricular 
conduction abnormalities (Boscarino & Chang, 1999; Kubzansky et al., 2007; Sawchuk 
et al., 2005). The finding of reduced PNS activity in PTSD patients could exacerbate this 
problem. Research has shown that diminished PNS activity is associated with increased 
susceptibility to cardiac arrhythmias and increased mortality in myocardial infarction 
patients (La Rovere et al., 1988; La Rovere et al., 1998; Verrier & Dickerson, 1994). 
Thus, the presence of chronic sympathetic activity and a hyperaroused physiological state 
can lead to a significant decline in the overall physical health of PTSD patients. 
Abnormal Functioning of the Hypothalamus-Pituitary-Adrenal Axis in Post-Traumatic 
Stress Disorder 
Stress involves activation of the hypothalamus-pituitary-adrenal (HPA) axis, 
which entails the paraventricular nucleus of the hypothalamus secreting corticotrophin-
releasing hormone (CRH), which travels through the median eminence via the portal 
vasculature to the anterior pituitary gland. Within the anterior pituitary gland, CRH 
stimulates the release of adrenocorticotrophin (ACTH), which then circulates through the 
bloodstream to stimulate the adrenal cortex to synthesize and release corticosteroids 
(primarily corticosterone in rodents and cortisol in humans). Corticosteroids help 
coordinate an individual’s ability to cope with stress and divert energy to tissues with 
greater demands (de Kloet et al., 1999). Although corticosteroids are critically involved 
in the stress response, they also play a role in regulating baseline physiology by 
influencing metabolism, the immune system and memory consolidation (de Kloet et al., 
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1999; Deuschle et al., 1997; Hartmann et al., 1997; Raison & Miller, 2003; Tsigos & 
Chrousos, 2002). 
Abnormal Baseline Levels of Cortisol and Its Hormone Precursors 
The HPA axis has been one of the most researched biological systems in people 
with PTSD. Researchers initially considered PTSD to be characterized by 
hypocortisolism, as a majority of the initial studies in this area of research reported 
abnormally low levels of baseline cortisol in people with PTSD (for reviews, see Yehuda, 
2002; Yehuda, 2005). However, this view has steadily evolved over the past decade, in 
light of new work that has reported baseline cortisol levels in PTSD patients that are 
either greater than, or no different from, those of controls (see de Kloet et al., 2006 for a 
review). Given such a complex set of findings, “it has recently been suggested that there 
may be no static hypo- or hypercortisolism in PTSD, but a tendency of HPA tone to 
‘hyperregulate’ in both [an] upward and downward direction” (Stam, 2007a, p. 536). 
Researchers have addressed several factors that could underlie the complexity of 
baseline cortisol findings in people with PTSD. One factor has been the considerable 
variability in the characteristics of PTSD patients across studies. According to Yehuda 
(2005, p. 373), “the absence of cortisol alterations in some studies [implies] that 
alterations associated with low cortisol…are only present in a biologic subtype of PTSD” 
(italics added for emphasis). The nature of baseline HPA axis alterations in PTSD 
patients may be dependent, at least in part, on the type of trauma that led to their 
psychopathology. For instance, a majority of the studies examining people with abuse-
related (i.e., sexual or physical abuse, including rape) PTSD have reported greater 
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baseline cortisol levels in PTSD patients than controls (Bremner et al., 2003a; De Bellis 
et al., 1999a; Elzinga et al., 2003; Inslicht et al., 2006a; Inslicht et al., 2006b; Lemieux & 
Coe, 1995), while a majority of the studies examining people with combat-related PTSD 
have reported lower baseline cortisol levels in PTSD patients than controls (Boscarino, 
1996; Kanter et al., 2001; Thaller et al., 1999; Yehuda et al., 1996b; Yehuda et al., 
1993a). 
Other factors that could have influenced studies examining baseline cortisol levels 
in people with PTSD are the type (i.e., peripheral vs. central) of cortisol that was assayed 
and when (i.e., time of day) the assay was performed. Most of the studies in this area of 
research have used peripheral measures (e.g., urine, saliva, serum) to examine cortisol 
levels in PTSD patients (for reviews, see de Kloet et al., 2006; Yehuda, 2002; Yehuda, 
2005). The only study to assess central levels of cortisol in people with PTSD reported 
that combat veterans with the disorder exhibited significantly greater CSF cortisol levels 
than healthy controls (Baker et al., 2005). While cortisol is mostly free (i.e., unbound) 
and biologically active in CSF, it is largely bound to corticosteroid-binding globulin 
(CBG) in serum (Dunn et al., 1981; Pardridge, 1981); and, one study found that people 
with PTSD displayed significantly greater levels of serum CBG than controls (Kanter et 
al., 2001). Thus, baseline cortisol levels in PTSD patients could vary based on the type of 
cortisol being measured.  
Many of the studies examining baseline cortisol levels in PTSD have collected 
biological samples for cortisol analysis at a single time point or have pooled the samples 
over a 12- or 24-hour period. These methodologies could have failed to detect a 
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difference between PTSD patients and control subjects due to measuring cortisol levels at 
a time of day when no true differences exist or by masking potential differences through 
pooling a number of samples spread across the day. To address this issue and study the 
circadian rhythm of cortisol levels in PTSD patients, Yehuda et al. (1996b) examined 
baseline levels of cortisol in combat veterans with PTSD at 30-minute intervals over a 
24-hour period of bed rest. Their results revealed that individuals with PTSD had lower 
levels of cortisol than controls during the late evening (i.e., ~10:00 p.m.) and early 
morning (i.e., ~5:00 a.m.) hours, which appeared to result from a prolonged nadir and 
short-lived peak response in the cycle of cortisol release. In addition to this finding, 
several other studies reporting lower levels of cortisol in PTSD patients have collected 
samples for cortisol analysis in the early morning hours (Brand et al., 2006; Goenjian et 
al., 1996; King et al., 2001; Lindauer et al., 2006; Rohleder et al., 2004; Seedat et al., 
2003; Wessa et al., 2006), suggesting that this may be the time of day when these 
individuals display hypocortisolism. 
In addition to cortisol level abnormalities, investigators have also reported 
significantly elevated levels of CRH in people with PTSD (Baker et al., 1999; Geracioti 
et al., 2001). If most PTSD patients display abnormally low baseline cortisol levels, these 
findings would create a paradox – that is, how could PTSD patients exhibit lower 
baseline levels of cortisol if they have significantly elevated levels of CRH? Smith and 
colleagues (Smith et al., 1989) found that in a CRH challenge paradigm, PTSD patients 
displayed significantly lower levels of ACTH than healthy control subjects (however, see 
Kellner et al., 2003; Rasmusson et al., 2001), and Kellner et al. (2000) reported 
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significantly lower levels of ACTH in PTSD patients following the administration of 
cholecystokinin tetrapeptide (CCK-4), a potent stimulator of ACTH. In addition, several 
studies have reported no differences in baseline ACTH levels between PTSD patients and 
controls (Baker et al., 2005; Duval et al., 2004; Kanter et al., 2001; Liberzon et al., 
1999a; Newport et al., 2004; Neylan et al., 2003; Neylan et al., 2006; Otte et al., 2007; 
Rasmusson et al., 2001; Yehuda et al., 1996a; Yehuda et al., 2004b). One possibility is 
that PTSD patients have desensitized CRH receptors and/or enhanced negative feedback 
inhibition at the level of the pituitary, which results in a blunted release of ACTH upon 
CRH receptor stimulation. 
Support for this hypothesis has been provided by studies using the 
dexamethasone-CRH challenge paradigm (de Kloet et al., 2006). In this paradigm, 
participants are treated with dexamethasone, a synthetic glucocorticoid, the night before 
the experiment. Since the HPA axis is regulated through a negative feedback system, the 
dexamethasone pre-treatment significantly reduces HPA axis activity. On the following 
morning, the participants are treated with CRH, and their levels of ACTH and cortisol are 
measured. The advantage of this paradigm is that, since all participants are treated with a 
relatively high dose of dexamethasone the night prior to the study, by the time of CRH 
administration, both the PTSD patients and control subjects should display the same 
amount of dexamethasone-induced cortisol suppression (i.e., the same “baseline”). Of the 
four studies examining the effects of this challenge paradigm on HPA axis functioning in 
PTSD patients, two (Rinne et al., 2002; Strohle et al., 2008) have reported that, following 
CRH administration, participants with PTSD displayed significantly lower ACTH levels 
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than controls. The other two (de Kloet et al., 2008; Muhtz et al., 2008) reported no 
significant group differences, which are likely a result of using too high of a dose of 
dexamethasone (see Strohle et al., 2008). Therefore, given that PTSD patients exhibited 
significantly less ACTH release upon CRH administration, it would suggest that the 
disorder is characterized by reduced CRH receptor sensitivity and/or enhanced 
glucocorticoid negative feedback at the level of the pituitary. 
Mechanisms Underlying Abnormal Hypothalamus-Pituitary-Adrenal Axis Functioning in 
Post-Traumatic Stress Disorder 
Several hypotheses have been proposed to explain the abnormal HPA axis 
functioning observed in people with PTSD (de Kloet et al., 2006). As referenced above, 
one hypothesis has been that PTSD patients display pituitary insufficiency or reduced 
pituitary sensitivity to CRH stimulation. Although findings have been mixed, the reports 
above indicating that PTSD patients exhibited lower ACTH levels following CRH 
administration, relative to controls, support this hypothesis. Another hypothesis has 
suggested that PTSD is characterized by adrenal insufficiency or reduced adrenal 
sensitivity to ACTH. However, this scenario seems unlikely, as non-pharmacological 
challenge paradigms have indicated that PTSD patients exhibit a robust stress-induced 
increase in cortisol that is greater than that of control subjects (Bremner et al., 2003a; 
Elzinga et al., 2003). Moreover, if adrenal insufficiency or desensitization were the 
reason for HPA axis dysfunction in PTSD, one would expect PTSD patients to exhibit 
lower cortisol levels than controls following an ACTH challenge paradigm. On the 
contrary, the administration of ACTH has actually been shown to result in significantly 
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greater cortisol levels in people with PTSD, relative to control subjects (Rasmusson et al., 
2001). 
Another hypothesis, which has received the most empirical support, is that PTSD 
patients have enhanced negative feedback inhibition of the HPA axis. When cortisol is 
released into the bloodstream, it exerts negative feedback on the HPA axis by binding to 
glucocorticoid receptors throughout the body. Research has shown that PTSD patients 
have an increased number and sensitivity of glucocorticoid receptors (Rohleder et al., 
2004; Stein et al., 1997b; Yehuda et al., 1991; Yehuda et al., 1993a; Yehuda et al., 1995). 
In addition, studies have reported an increased suppression of cortisol and ACTH in 
PTSD patients following the administration of dexamethasone, a synthetic glucocorticoid 
(Duval et al., 2004; Goenjian et al., 1996; Grossman et al., 2003; Newport et al., 2004; 
Stein et al., 1997b; Yehuda et al., 1993b; Yehuda et al., 1995; Yehuda et al., 2002; 
Yehuda et al., 2004b). This finding suggests that dexamethasone produces greater 
negative feedback inhibition of the HPA axis in PTSD patients, which leads to a greater 
suppression of cortisol and ACTH in these individuals. Some have also observed 
increased activation of the pituitary gland in PTSD patients following the administration 
of metyrapone, a glucocorticoid antagonist that blocks the conversion of 11-deoxycortisol 
to cortisol (or 11-deoxycorticoterone to corticosterone in rodents) (Otte et al., 2006; 
Yehuda et al., 1996a). Both of these studies found that following the administration of 
metyrapone, PTSD patients exhibited a significantly greater increase in ACTH and 11-
deoxycortisol, two of the primary precursors to cortisol release, relative to controls. Since 
metyrapone prevents the production of cortisol, it hinders the negative feedback 
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component of the HPA axis. In theory, PTSD patients in these studies demonstrated 
greater increases in ACTH and 11-deoxycortisol because metyrapone removed the 
enhanced negative feedback inhibition initially present in these individuals. 
Structural and Functional Brain Abnormalities in Post-Traumatic Stress Disorder 
Smaller Hippocampal Volume 
Investigators have reported smaller hippocampal volume in people who 
developed PTSD following combat exposure (Bremner et al., 1995a; Gurvits et al., 1996; 
Hedges et al., 2003; Vythilingam et al., 2005; Woodward et al., 2006a), firefighting (Shin 
et al., 2004b), police work (Lindauer et al., 2004b; Lindauer et al., 2006), childhood 
abuse (Bremner et al., 1997b; Bremner et al., 2003b; Stein et al., 1997a), and mixed types 
of events, such as motor vehicle accidents and assaults (Villarreal et al., 2002; Wignall et 
al., 2004; Winter & Irle, 2004). In general, these studies have detected smaller 
hippocampal volume in individuals with PTSD after adjusting for the total brain volume 
and age of each subject. Nevertheless, numerous other studies have not replicated these 
findings; they reported no differences in hippocampal volume between individuals 
diagnosed with PTSD and control subjects (Bonne et al., 2001; De Bellis et al., 1999b; 
De Bellis et al., 2001; Fennema-Notestine et al., 2002; Jatzko et al., 2006; Pederson et al., 
2004; Schuff et al., 2001; Tupler & De Bellis, 2006; Yamasue et al., 2003; Yehuda et al., 
2007). The inconsistencies of these findings raise an important issue: is hippocampal 
volume reduced by trauma, or is a smaller hippocampus a pre-existing risk factor that 
increases one’s susceptibility to develop the disorder? 
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 Work conducted by Gilbertson and colleagues (Gilbertson et al., 2002) had a 
substantial impact on how the scientific community interpreted smaller hippocampal 
volume in PTSD patients. These investigators used MRI to measure hippocampal volume 
of monozygotic twins discordant for trauma exposure, which, in this case, was combat. 
Consistent with previous findings, those individuals who were exposed to combat and 
had developed PTSD exhibited smaller hippocampal volume than combat-exposed 
individuals who did not develop PTSD. The important finding, though, was that the non-
exposed twin brothers of those individuals who developed PTSD also displayed smaller 
hippocampal volume than trauma-exposed individuals who did not develop PTSD. Thus, 
these individuals had smaller hippocampal volume than controls, even though they were 
not exposed to a traumatic event. This finding supported the idea that smaller 
hippocampal volume was a pre-existing familial risk factor that enhanced the likelihood 
of the combat-exposed brother to develop PTSD. 
 In another study employing the same strategy, Gilbertson et al. (2007) assessed 
allocentric (i.e., related to configural relationships among distal stimuli) spatial 
processing, a hippocampus-dependent task, in monozygotic twins discordant for trauma 
exposure, which was combat. The investigators found that those individuals who were 
exposed to combat and had developed PTSD, as well as their twin brothers, made 
significantly more errors on the spatial task than those individuals who were exposed to 
combat and did not develop PTSD. These findings extended the earlier report by 
Gilbertson and colleagues by demonstrating that impaired hippocampal function, in 
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addition to smaller hippocampal volume, may also be a pre-existing familial risk factor 
for the development of PTSD. 
Cognitive Impairments 
Since there is extensive evidence supporting the presence of smaller hippocampal 
volume in PTSD patients, it is not surprising that numerous studies have reported 
declarative and working memory impairments, along with deficits in attention, in these 
individuals as well (Bremner et al., 1993; Bremner et al., 1995b; Bremner et al., 1995a; 
Gil et al., 1990; Gilbertson et al., 2001; Golier et al., 2002; Jenkins et al., 1998; Moradi et 
al., 1999; Sachinvala et al., 2000; Uddo et al., 1993; Vasterling et al., 1998; Yehuda et al., 
2004a). Bremner and colleagues (Bremner et al., 1993; Bremner et al., 1995b; Bremner et 
al., 1995a) reported verbal memory deficits in both combat-related and abuse-related 
PTSD patients. More importantly, Bremner et al. (1995a) found that these verbal memory 
deficits were significantly associated with the smaller right hippocampus of PTSD 
patients, suggesting the possibility of a relationship between these two phenomena. Other 
work has reported that PTSD patients have significant attentional impairments, which are 
believed to be due to a bias for the processing of emotional information and the persistent 
intrusiveness of memories related to the traumatic event (Bryant & Harvey, 1997; 
Buckley et al., 2000; Ehlers et al., 2006; Michael et al., 2005; Moradi et al., 2000; 
Paunovic et al., 2002). Some studies have reported enhanced memory for trauma-related 
information in PTSD patients (Golier et al., 2003; McNally, 1997), providing support for 
greater attentional resources devoted to processing emotional, especially trauma-relevant, 
information in these individuals.  
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Interactions between the Amygdala and Prefrontal Cortex 
Extensive work has implicated involvement of the amygdala, an almond-shaped 
medial temporal lobe structure, in the acquisition and expression of fear memories 
(Fanselow & Gale, 2003; LeDoux, 2003; Maren et al., 1996; Maren, 2003; McGaugh, 
2002; McGaugh, 2004). Inactivation of the amygdala impairs the acquisition of fear 
conditioning in rodents (Gale et al., 2004; Maren, 1999; Wallace & Rosen, 2001; 
Wilensky et al., 1999), and people with lesions of the amygdala have difficulty acquiring 
conditioned fear (LaBar et al., 1995) and recognizing fearful stimuli (Adolphs, 2002; 
Scott et al., 1997; Wang et al., 2002). Likewise, neuroimaging studies in humans have 
consistently reported amygdala activation during fear conditioning (Buchel & Dolan, 
2000; Cheng et al., 2003; Knight et al., 2004; LaBar et al., 1998). Investigators have 
speculated that PTSD patients may display abnormal amygdala functioning, which would 
lead to an aberrant stress response and an enhanced amygdala-induced augmentation of 
emotional memories (Elzinga & Bremner, 2002). Several studies have reported amygdala 
hyperresponsivity in PTSD patients during the presentation of traumatic scripts and 
stimuli (Driessen et al., 2004; Hendler et al., 2003; Liberzon et al., 1999b; Pissiota et al., 
2002; Protopopescu et al., 2005; Rauch et al., 1996; Shin et al., 1997; Shin et al., 2004a), 
the presentation of non-trauma-relevant emotional stimuli (Rauch et al., 2000; Shin et al., 
2005; Williams et al., 2006) and during the acquisition of fear conditioning (Bremner et 
al., 2005). Others have found a positive relationship between activation of the amygdala 
and PTSD symptom severity (Armony et al., 2005; Protopopescu et al., 2005; Rauch et 
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al., 1996; Shin et al., 2004a). These findings suggest an important role of the amygdala in 
the expression of PTSD symptomatology. 
 The prefrontal cortex (PFC) is located in the anterior part of the frontal lobe and is 
involved in working memory processes, attention, and decision making (Braver et al., 
1997; Curtis & D'Esposito, 2003; Funahashi & Kubota, 1994; McCarthy et al., 1996; 
Postle et al., 2000). This area of the brain has been shown to play a major role in more 
complex cognition, such as the planning and organization of behavior (Koechlin et al., 
1999; Koechlin et al., 2000; Tanji & Hoshi, 2001). Reciprocal connections between the 
PFC and amygdala allow for dynamic interactions between these two brain regions 
(Amaral & Insausti, 1992; Ghashghaei & Barbas, 2002; McDonald, 1987; McDonald, 
1991; Sesack et al., 1989). The PFC allows for the inhibition of inappropriate cognitive 
and emotional responses that are mediated in part by the amygdala (Elzinga & Bremner, 
2002). Such a role of the PFC has led researchers to speculate that PTSD patients may 
have impaired PFC functioning and that such an impairment may allow for hyperactivity 
of the amygdala and exaggerated emotional responsiveness. In agreement with this 
hypothesis, several studies have shown that PTSD patients have a smaller volume of 
major regions of the PFC (e.g., anterior cingulate cortex, medial frontal gyrus) (Carrion et 
al., 2001; De Bellis et al., 2002; Fennema-Notestine et al., 2002; Rauch et al., 2003; 
Woodward et al., 2006b; Yamasue et al., 2003) and perform more poorly on tasks 
dependent upon an intact PFC (Koenen et al., 2001). 
In addition, the PFC is involved in the extinction of fear memories. Animal 
studies have shown that lesions of the medial PFC impair the extinction of conditioned 
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fear (Lebron et al., 2004), while stimulation of this area facilitates this process (Milad et 
al., 2004). Research has shown that PTSD patients are impaired at extinguishing fear (Orr 
et al., 2000; Peri et al., 2000) and demonstrate reduced activity of PFC regions during 
extinction trials (Bremner et al., 2005). Moreover, these individuals exhibit less activity 
of, or a complete failure to activate, PFC brain regions during the presentation of trauma-
relevant stimuli (Bremner, 1999; Bremner et al., 1999; Britton et al., 2005; Lanius et al., 
2001; Lindauer et al., 2004a; Shin et al., 1999; Shin et al., 2004a). In theory, reduced 
activation of the PFC, in conjunction with amygdala hyperactivity, could promote the 
intrusive emotional thoughts and memories that PTSD patients often experience. Such a 
system could lead to greater governance of behavior by lower brain areas, such as the 
amygdala and hypothalamus, rather than the prefrontal areas, which allow for adaptation, 
behavioral flexibility and coherent cognitive processing. 
Pharmacotherapy for Post-Traumatic Stress Disorder 
Selective Serotonin Reuptake Inhibitors 
The fact that a subset of people with PTSD exhibit significant improvement in 
some of their symptoms following treatment with selective serotonin reuptake inhibitors 
(SSRIs) suggests a role of the serotonergic system in this disorder (Asnis et al., 2004; 
Davidson, 2003; Davis et al., 2006; Hidalgo & Davidson, 2000; Ipser et al., 2006; Stein 
et al., 2006). Research has shown that several SSRIs, such as fluoxetine, fluvoxamine and 
citalopram, exert positive effects on people with PTSD and lead to significant 
improvements in quality of life (Brady et al., 2000; Brady et al., 1995; Cavaljuga et al., 
2003; Connor et al., 1999; Davidson et al., 2001; De Boer et al., 1992; English et al., 
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2006; Escalona et al., 2002; Figgitt & McClellan, 2000; Friedman et al., 2007; Londborg 
et al., 2001; March, 1992; Martenyi et al., 2002a; Martenyi et al., 2002b; Martenyi & 
Soldatenkova, 2006; McRae et al., 2004; Meltzer-Brody et al., 2000; Neylan et al., 2001; 
Robert et al., 2006; Schwartz & Rothbaum, 2002; Seedat et al., 2001; Smajkic et al., 
2001; Van der Kolk et al., 1994). However, the response rates to SSRIs in PTSD patients 
rarely exceeds 60%, and full remission from the disorder is achieved following SSRI 
treatment only 20-30% of the time (Stein et al., 2002). In addition, SSRIs tend to blunt 
only the depressive components of PTSD, while having little effect on the memory- and 
anxiety-related symptoms of the disorder (Asnis et al., 2004; Boehnlein & Kinzie, 2007; 
Brady et al., 2000; Van der Kolk et al., 1994). Some forms of PTSD, such as combat-
related PTSD, are incredibly resistant to SSRI treatment (Jakovljevic et al., 2003; 
Rothbaum et al., 2008; Stein et al., 2002). SSRIs are also anxiogenic early in the 
treatment phase and only exert anxiolytic effects after a substantial delay (Browning et 
al., 2007; Burghardt et al., 2004; Humble & Wistedt, 1992). Given the numerous caveats 
to the efficacy of SSRIs in treating PTSD, there is a need for additional research in 
people with PTSD and in animal models of the disorder to facilitate the development of 
more effective treatments for PTSD. 
Tricyclic Antidepressants and Monoamine Oxidase Inhibitors 
 Tricyclic antidepressants, named for their three-carbon ring molecular structure, 
inhibit the reuptake of serotonin and NE to varying degrees. They also antagonize, to a 
lesser extent, dopaminergic, histaminergic, adrenergic and cholinergic receptor sites, 
which often produces an array of adverse secondary side effects (Albucher & Liberzon, 
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2002). Few randomized, placebo-controlled studies have been conducted to assess the 
effects of tricyclic antidepressants on PTSD, but those that have been performed have 
reported positive effects on PTSD symptomatology (Bisson, 2007). Some studies found 
that amitriptyline (Davidson et al., 1990; Davidson et al., 1993) and imipramine 
(Burstein, 1984; Frank et al., 1988; Kosten et al., 1991) significantly reduced global 
scores of PTSD severity and were particularly effective in ameliorating the avoidance, 
intrusion and re-experiencing symptoms in PTSD patients. Another study found that 
desipramine effectively reduced symptoms of depression in PTSD patients but had no 
effect on the anxiety-related symptoms that are specific to PTSD (Reist et al., 1989). 
Monoamine oxidase inhibitors (MAOIs) prevent the enzyme monoamine oxidase 
from breaking down monoamine transmitter substances. This leads to a significant 
increase in the synaptic release of monoamines, such as dopamine, norepinephrine, 
epinephrine and serotonin. Several studies have shown that MAOIs, such as phenelzine 
(Kosten et al., 1991; Shestatzky et al., 1988), brofaromine (Baker et al., 1995; Katz et al., 
1994) and moclobemide (Neal et al., 1997), are effective in reducing avoidance, intrusion 
and hyperarousal symptoms associated with PTSD, and MAOIs appear to be more 
effective in treating PTSD than tricyclic antidepressants (Albucher & Liberzon, 2002).  
Despite the positive effects of tricyclic antidepressants and MAOIs on PTSD 
symptoms, these agents are rarely used as the first line of treatment for PTSD and, 
instead, are typically only employed when SSRIs are ineffective (Albucher & Liberzon, 
2002). Due to the numerous side effects of both drug classes, the dropout rates for these 
agents are very high (e.g., 30-50%). Additionally, patients who take MAOIs must adhere 
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to a special low tyramine diet to avoid a potential life-threatening hypertensive crisis. 
Thus, tricyclic antidepressants and MAOIs, although effective treatments for some PTSD 
symptoms, are difficult to tolerate and therefore frequently avoided. 
Noradrenergic Modulators 
People with PTSD have significantly elevated baseline levels of NE and EPI and 
demonstrate adverse reactions (e.g., panic attacks, flashbacks) to agents that increase 
adrenergic activity, such as yohimbine. These adrenergic abnormalities are believed to 
contribute to the hyperarousal, intrusion and avoidance symptoms, as well as the sleep 
disturbances, that are often reported in PTSD patients (Boehnlein & Kinzie, 2007; Strawn 
& Geracioti, 2008). Thus, recent work has begun testing the effects of pharmacological 
agents that reduce adrenergic activity on PTSD symptomatology. Some studies have 
found that propranolol, a β-adrenergic receptor antagonist, may be effective in preventing 
the disorder’s development (Pitman et al., 2002; Taylor & Cahill, 2002; Vaiva et al., 
2003). For instance, Vaiva et al. (2003) found that propranolol treatment shortly after 
experiencing a traumatic event significantly reduced the incidence and symptoms of 
PTSD in individuals 2 months later, and Pitman and colleagues (Pitman et al., 2002) 
reported that post-trauma administration of propranolol ameliorated sympathetic 
responses to traumatic reminders at a 1-month follow-up visit. Additional work has 
shown that propranolol can effectively reduce PTSD symptoms if administered following 
the re-experiencing of a trauma (Taylor & Cahill, 2002), suggesting that it may be 
effective at preventing the reconsolidation of the traumatic memory (Brunet et al., 2008). 
These findings suggest that propranolol may be an effective treatment for PTSD if 
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administered immediately after the traumatic event or after the re-experiencing of a 
traumatic event. 
Other work has shown that clonidine, an α2-adrenergic receptor agonist, and 
prazosin, an α1-adrenergic receptor antagonist, can significantly ameliorate symptoms of 
heightened anxiety and hyperarousal in people with PTSD (Boehnlein & Kinzie, 2007). 
Clonidine works by facilitating α2-adrenergic autoreceptors, which ultimately leads to 
decreased NE levels. Though many studies have examined the effects of clonidine on 
PTSD and found it to be effective at reducing intrusive memories and hyperarousal 
(Harmon & Riggs, 1996; Porter & Bell, 1999; Viola et al., 1997), no randomized, 
placebo-controlled studies of clonidine’s effects on PTSD have been performed 
(Boehnlein & Kinzie, 2007). Prazosin, on the other hand, works by inhibiting post-
synaptic α1-adrenergic receptors, which, similar to clonidine, leads to a reduction of NE 
activity. Recent work has shown that prazosin is an effective treatment for hyperarousal 
symptoms, intrusive thoughts, recurrent distressing dreams and sleep disturbances in 
PTSD (Brkanac et al., 2003; Peskind et al., 2003; Raskind et al., 2002; Raskind et al., 
2003; Taylor & Raskind, 2002; Taylor et al., 2006). Collectively, these studies suggest 
that the reduction of adrenergic activity in PTSD patients is an effective approach to 
ameliorating many of the disorder’s debilitating symptoms. 
The Antidepressant Tianeptine 
Tianeptine is most commonly known to exert antidepressant effects and 
ameliorate symptoms of MDD, but it has been shown to have beneficial effects in 
treating PTSD as well (Onder et al., 2006). Early studies on tianeptine’s mechanism of 
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action showed that the drug led to significantly lower extracellular levels of serotonin, a 
finding that was hypothesized to result from enhanced serotonin reuptake (Fattaccini et 
al., 1990; Labrid et al., 1992; Mennini et al., 1987; Mocaer et al., 1988). However, 
tianeptine’s effects on the serotonergic system may be an indirect consequence of the 
drug’s influences on an alternative neurotransmitter system because later studies failed to 
show any direct effects of tianeptine on serotonergic neurotransmission (Pineyro et al., 
1995a; Pineyro et al., 1995b). Additionally, research has shown that tianeptine does not 
alter the density or affinity of any serotonin receptor subtype, and tianeptine’s affinity for 
the serotonin transporter is very low (Kato & Weitsch, 1988; Svenningsson et al., 2007). 
Some have also contested the validity of the original studies on tianeptine’s mechanism 
of action based on technical limitations that were present at the time (Malagie et al., 
2000). 
Recently, extensive work has suggested that tianeptine’s therapeutic effects are 
more associated with modulation of the glutamatergic system (Brink et al., 2006; Kasper 
& McEwen, 2008; Zoladz et al., in press). Glutamate is the primary excitatory 
neurotransmitter of the central nervous system, and one of its roles is to regulate calcium 
influx by acting on postsynaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors (Riedel et al., 2003). 
Extensive work has implicated hyperactivity of the glutamatergic system in the 
deleterious effects of stress on brain structure and function. Experiments conducted 
primarily on the hippocampus have shown that stress significantly increases glutamate 
levels (Bagley & Moghaddam, 1997; Lowy et al., 1993; Lowy et al., 1995; Moghaddam, 
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1993; Reznikov et al., 2007), inhibits glutamate uptake (Yang et al., 2005), increases the 
expression and binding of glutamate receptors (Bartanusz et al., 1995; Krugers et al., 
1993; McEwen et al., 2002) and increases calcium currents (Joels et al., 2003). 
Accordingly, researchers have shown that administration of NMDA receptor antagonists 
blocks the effects of stress on behavioral, morphological and electrophysiological 
measures of hippocampal function (Kim et al., 1996; Magarinos & McEwen, 1995; Park 
et al., 2004). 
Tianeptine appears to protect the hippocampus and prefrontal cortex from the 
deleterious effects of stress by normalizing the stress-induced modulation of 
glutamatergic activity. Researchers have also shown that tianeptine inhibits the acute 
stress-induced increase in extracellular levels of glutamate in the amygdala (Reznikov et 
al., 2007). In addition to its glutamatergic modulation, tianeptine reduces the expression 
of CRH mRNA in the amygdala and the bed nucleus of the stria terminalis, a brain region 
that is highly innervated by amygdala fibers (Kim et al., 2006). CRH neurotransmission 
in both of these regions has been implicated in the expression of anxiety-like behaviors 
(Holsboer, 1999; Strohle & Holsboer, 2003). These findings suggest that tianeptine could 
be an effective pharmacological treatment for PTSD. 
Animal Models of Post-Traumatic Stress Disorder 
Existing Models of Post-Traumatic Stress Disorder in Rodents 
Preclinical researchers have used several types of stressors to model aspects of 
PTSD in rodents (see Stam, 2007b for a review). Such stressors have included electric 
shock (Garrick et al., 2001; Li et al., 2006; Milde et al., 2003; Pynoos et al., 1996; Rau et 
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al., 2005; Sawamura et al., 2004; Servatius et al., 1995; Shimizu et al., 2004; Shimizu et 
al., 2006; Siegmund & Wotjak, 2007a; Siegmund & Wotjak, 2007b; Wakizono et al., 
2007), underwater trauma (Cohen et al., 2004; Richter-Levin, 1998), stress-restress 
paradigms and single prolonged stress paradigms (Harvey et al., 2003; Khan & Liberzon, 
2004; Kohda et al., 2007; Liberzon et al., 1997; Takahashi et al., 2006) and exposure to 
predators (Adamec, 1997; Adamec et al., 2007; Adamec et al., 1999; Adamec et al., 
2006; Adamec & Shallow, 1993; Blanchard et al., 1998; Park et al., 2001) or predator-
related cues (Cohen et al., 2000b; Cohen et al., 2004; Cohen et al., 2006; Cohen et al., 
2007; Cohen & Zohar, 2004). The stressors employed in these studies typically produced 
increased behavioral signs of anxiety, and in some cases, exaggerated startle, cognitive 
impairments, enhanced fear conditioning and reduced social interaction. Although these 
studies have reported physiological and behavioral changes resembling those observed in 
people with PTSD, most have utilized only a small set of assessments, such as stress-
induced changes in anxiety, without assessing other measures common in people with 
PTSD, such as an impairment in cognition. Moreover, many of these studies have 
evaluated stress-induced changes in responses for a relatively short period of time. Thus, 
while these studies have provided insight into how stress or fear conditioning changes 
aspects of behavior and physiology, the field would benefit from an animal model of 
PTSD that takes into account how traumatic stress produces long-lasting PTSD-like 
changes in rats given multiple behavioral and physiological diagnostic tests. 
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Our Laboratory’s Recently Developed Animal Model of Post-Traumatic Stress Disorder 
Our laboratory has developed an animal model of PTSD in which rats are exposed 
to a cat (predator stress) on two separate occasions, in conjunction with daily social 
stress, and tested 3 weeks after the second cat exposure (Zoladz et al., 2008). We found 
that rats stressed in this paradigm exhibited reduced growth rate, greater adrenal gland 
weight, reduced thymus weight, heightened anxiety, an exaggerated startle response, 
impaired hippocampus-dependent memory, greater cardiovascular and corticosterone 
reactivity to an acute stressor and an exaggerated physiological and behavioral response 
to yohimbine. Importantly, all of these physiological and behavioral abnormalities are 
commonly observed in people with PTSD. 
Our animal model of PTSD was developed to expose rats to conditions which, 
based on DSM-IV criteria, are analogous to conditions that produce PTSD in people. 
Specifically, a subset of the DSM-IV criteria for the diagnosis of PTSD includes the 
following three conditions: (1) PTSD can be triggered by an event that involves 
threatened death or a threat to one’s physical integrity; (2) a person's response to the 
event involves intense fear, helplessness or horror; and (3) in the aftermath of the trauma, 
the person feels as if the traumatic event were recurring, including a sense of reliving the 
experience (American Psychiatric Association, 1994).  
The behaviors that rats exhibit in response to forced exposure to a cat are 
consistent with the first two components of the DSM-IV criteria for PTSD. That is, rats 
exhibit an intense fear response when exposed to a predator, which is a condition that is a 
threat to their survival. In addition, we have observed that rats typically direct their 
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posture away from the cat’s gaze, which provides the rat with an element of control over 
its confrontation with the cat. As control critically influences the expression of the stress 
response, in general (Kim & Diamond, 2002), and a loss of control exacerbates 
behavioral and physiological responses to stress conditions (Amat et al., 2005; Bland et 
al., 2006; Bland et al., 2007; Kavushansky et al., 2006; Maier et al., 1993; Maier & 
Watkins, 2005; Shors et al., 1989), we immobilized the rats during predator exposure. 
The immobilization component of our animal model, therefore, may provide a rodent 
analogue to the sense of helplessness and a loss of control which feature prominently in 
the DSM-IV criteria for PTSD. 
Another component of our model is that rats are exposed to the cat on two 
occasions, separated by 10 days. PTSD develops in some people only after they have 
repeated traumatic experiences (Resnick et al., 1995; Taylor & Cahill, 2002), and 
prolonged exposure to trauma increases the likelihood of developing symptoms of PTSD 
(Gurvits et al., 1996). Therefore, the repeated inescapable cat exposure was designed to 
increase the likelihood that the manipulations would produce effects in the rats that could 
be broadly applied to people who develop PTSD as a result of multiple traumatic 
experiences. In addition, people who develop PTSD in response to only a single trauma 
experience powerful episodes of anxiety and panic as a result of their repeated reliving of 
the trauma through intrusive, flashback memories (Reynolds & Brewin, 1999). As 
mentioned above, the repeated reliving of the original experience through disturbing 
intrusive memories is a criterion for the diagnosis of PTSD. The second exposure of the 
rats to the cat forced them to re-experience the original stress experience, which can be 
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considered analogous to how people with PTSD report that they feel as if they relive their 
original trauma when they have an intrusive memory of the experience. 
The second reason why the rats were re-exposed to the cat pertained to the issue 
of predictability. The first predator exposure occurred during the light cycle and the 
second predator exposure occurred during the dark cycle, thereby adding an element of 
unpredictability as to when the rats might re-experience the traumatic event. A lack of 
predictability in one’s environment is a major factor in the development of PTSD, as a 
means with which to increase the susceptibility of a subset of people to develop PTSD in 
response to trauma, as well as to influence the later expression of PTSD symptoms (Orr 
et al., 1990; Regehr et al., 2000; Solomon et al., 1989; Solomon et al., 1988). 
Lastly, McEwen and colleagues observed increased spine density on dendritic 
arbors of amygdala neurons 10 days after a single immobilization experience (Mitra et 
al., 2005). Therefore, the second stress session reinforced stress-induced changes in brain 
and behavior which were presumably initiated by the first stress session. In theory, the 
reinforcement of morphological plasticity in the amygdala through a reminder of the 
original experience would augment the PTSD-like syndrome in psychosocially stressed 
rats. The strengthening of plasticity in the amygdala, which may be expressed in a 
number of different ways, such as dendritic hypertrophy (Fuchs et al., 2006; McEwen & 
Chattarji, 2004; Mitra et al., 2005; Vyas et al., 2002; Vyas et al., 2003; Vyas et al., 2006) 
or as stress-induced long-term potentiation (Kavushansky & Richter-Levin, 2006; 
Manzanares et al., 2005; Vouimba et al., 2004; Vouimba et al., 2006), lends itself to 
experimentation via pharmacological manipulations of the reconsolidation process, which 
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is likely to occur in response to traumatic memory recall (Cai et al., 2006; Debiec et al., 
2002; Debiec & LeDoux, 2004; Debiec & LeDoux, 2006; Maroun & Akirav, 2008; 
Nader et al., 2000; Przybyslawski et al., 1999; Przybyslawski & Sara, 1997; Sara, 2000; 
Suzuki et al., 2004).  
In addition to the two acute cat exposures, we included chronic unstable housing 
conditions in the psychosocial stress paradigm to mimic the lack of social support and 
chronic mild stress experienced by people with PTSD (Andrews et al., 2003; Boscarino, 
1995; Brewin et al., 2000; Solomon et al., 1989; Ullman & Filipas, 2001). We 
hypothesized that the daily anxiety produced by unstable housing would exacerbate any 
adverse effects on the rats induced by predator exposure, alone. This hypothesis was 
supported by our finding that the combination of two cat exposures with social instability 
produced greater anxiogenic effects on rat behavior than either manipulation in isolation. 
Chronic social instability, alone, had no negative effects on behavior and may have even 
been beneficial for rats, as it led to a small increase in growth rate and significantly 
greater motor activity on the elevated plus maze. 
In sum, the primary goal of this preliminary work was to develop an animal 
model of PTSD based on the factors that are known to be involved in the etiology and 
persistence of PTSD symptoms in people. To accomplish this goal, we combined a life-
threatening stress experience (i.e., unavoidable predator exposure) with a re-experiencing 
of the trauma and chronic social instability, all of which are well-described risk factors 
for PTSD. This approach enabled us to produce an animal model that targets the subset of 
people who actually develop PTSD in response to trauma and affords us the opportunity 
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to explore the mechanisms responsible for the effects of traumatic stress on brain and 
behavior. 
Purpose of the Present Experiments 
 The purpose of the present experiments was to further examine the 
neurobiological mechanisms responsible for the PTSD-like sequelae induced by our 
laboratory’s animal model and to explore the longevity of the effects induced by our 
chronic psychosocial stress paradigm. Specifically, the present set of experiments were 
designed to 1) test the hypothesis that our animal model of PTSD would produce 
abnormalities in glucocorticoid levels that are comparable to those observed in people 
with PTSD, 2) examine the ability of antidepressant and anxiolytic agents to ameliorate 
the PTSD-like physiological and behavioral symptoms induced by our laboratory’s 
paradigm and 3) ascertain how long the physiological and behavioral effects of our 
laboratory’s stress regimen could be maintained. 
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Chapter Two: Experiment One 
Chronic Psychosocial Stress Produces a Reduction in Basal Glucocorticoid Levels in 
Rats: Further Validation of an Animal Model of PTSD 
 Although findings have been mixed, extensive work has reported abnormally low 
baseline levels of cortisol in people with PTSD (for reviews, see de Kloet et al., 2006; 
Yehuda, 2002; Yehuda, 2005). Additionally, some (Bremner et al., 2003a; Elzinga et al., 
2003), but not all (Geracioti et al., 2008), studies have reported significantly greater 
stress-induced elevations of cortisol in PTSD patients, relative to control subjects. 
Therefore, to further validate our laboratory’s animal model of PTSD, Experiment One 
was designed to examine the effects of chronic psychosocial stress, composed of two 
acute predator exposures and daily social instability, on baseline and stress-induced 
serum corticosterone levels in rats. While previous studies in our laboratory have 
examined rat serum corticosterone levels following the proposed stress paradigm (Zoladz 
et al., 2008), these studies did not obtain undisturbed, baseline measures of corticosterone 
from psychosocially stressed animals. In each case, the rats were transported to the 
laboratory, and in some cases injected, prior to blood sampling, which could have 
induced a stress response in the rats. Moreover, the rats in these studies had been exposed 
to several behavioral assessments on the days prior to blood sampling. Both of these 
factors could have hindered an accurate interpretation of the data. Therefore, in order to 
obtain undisturbed, baseline measures of corticosterone, the rats in the present study were 
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exposed to only one endpoint manipulation, which was blood sampling, and the first 
blood sample was obtained immediately after removing the rats from their housing 
rooms. In light of the PTSD literature, I hypothesized that rats exposed to chronic 
psychosocial stress would display significantly lower baseline, but significantly greater 
stress-induced, corticosterone levels than control (i.e., unstressed) animals. 
Methods 
Rats 
Experimentally naïve adult male Sprague-Dawley rats (225-250 g upon delivery) 
obtained from Charles River laboratories (Wilmington, Massachusetts) were used for the 
present experiment. The rats were housed on a 12-hr light/dark schedule (lights on at 
0700) in standard Plexiglas cages (two per cage) with free access to food and water. The 
colony room temperature and humidity were maintained at 20±1ºC and 60±3%, 
respectively. Upon arrival, all rats were given 1 week to acclimate to the housing room 
environment, as well as cage changing procedures, before any experimental 
manipulations took place. All procedures were approved by the Institutional Animal Care 
and Use Committee at the University of South Florida. 
Psychosocial Stress Procedure 
Acute Stress Sessions. Following the 1-week acclimation phase, rats were brought 
to the laboratory, weighed and assigned to “psychosocial stress” or “no psychosocial 
stress” groups (N = 10 rats/group). Rats in the psychosocial stress group were 
immobilized in plastic DecapiCones (Braintree Scientific; Braintree, MA) and placed in a 
perforated wedge-shaped Plexiglas enclosure (Braintree Scientific; Braintree, MA; 20 x 
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20 x 8 cm). Then, the rats, still immobilized in the plastic DecapiCones within the 
Plexiglas enclosure, were taken to the cat housing room where they were placed in a 
metal cage (24 x 21 x 20 in) with an adult female cat for 1 hour. The Plexiglas enclosure 
prevented any contact between the cat and rats, but the rats were still exposed to all non-
tactile sensory stimuli associated with the cat. Canned cat food was smeared on top of the 
Plexiglas enclosure to direct cat activity toward the rats. An hour later, the rats were 
returned to the laboratory. Rats in the no psychosocial stress group remained in their 
home cages in the laboratory for the 1-hour stress period. Rats were exposed to two acute 
stress sessions, which were separated by 10 days. The first stress session took place 
during the light cycle, between 0800 and 1300 hours, and the second stress session took 
place during the dark cycle, between 1900 and 2100 hours. 
Daily Social Stress. Beginning on the day of the first stress session, rats in the 
psychosocial stress group were exposed to unstable housing conditions for the next 31 
days. Rats in the psychosocial stress group were still housed two per cage, but every day, 
their cohort pair combination was changed. Therefore, no rat in the psychosocial stress 
group had the same cage mate on two consecutive days during the 31-day stress period. 
Assessment of Basal and Stress-Induced Glucocorticoid Levels 
Preparation. Twenty days after the second stress session, rats in the psychosocial 
stress and no psychosocial stress groups were brought to the laboratory and weighed. 
Then, the hind legs of all rats were shaved to allow access to their saphenous veins. The 
rats were then taken back to the housing room and left undisturbed for the remainder of 
the day. The hind legs of all rats were shaved 1 day prior to blood sampling to minimize 
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the amount of time it took the experimenter to obtain baseline blood samples on the 
following day. 
Blood Sampling and Post-Mortem Dissection. Twenty-four hours later, rats were 
brought, one cage (i.e., 2 rats) at a time, to a nearby procedure room for blood sampling. 
Petroleum jelly was applied to each rat’s hind leg, and the saphenous vein of each rat was 
punctured with a sterile, 27-gauge syringe needle. A 0.2 cc sample of blood was then 
collected from each rat in a microcentrifuge tube. The first blood sample was considered 
a “baseline” measure of corticosterone and was collected within 2 minutes after the rats 
were removed from the housing room. After obtaining this sample, the rats were 
immobilized in plastic DecapiCones for 20 minutes. Then, the rats were removed from 
the DecapiCones, and another 0.2 cc sample of blood was collected in a microcentrifuge 
tube via saphenous vein venipuncture. This blood sample served to examine the 
hormonal responses of rats to acute immobilization stress. After collecting this sample, 
the rats were returned to their home cages. An hour later, one last blood sample (trunk 
blood) was collected following rapid decapitation. This sample was collected to examine 
the recovery of corticosterone levels following acute immobilization stress. Following 
rapid decapitation, the adrenal and thymus glands were removed and weighed. Once all 
of the blood had clotted at room temperature, it was centrifuged (3000 rpm for 8 
minutes), and the serum was extracted and stored at -80º C until assayed by Monika 
Fleshner at the University of Colorado at Boulder.  
Most studies have reported abnormal cortisol levels in PTSD patients in the early 
morning hours, when the levels of cortisol reach their peak in people (Brand et al., 2006; 
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Goenjian et al., 1996; King et al., 2001; Lindauer et al., 2006; Rohleder et al., 2004; 
Seedat et al., 2003; Wessa et al., 2006). Since rats are nocturnal, their circadian rhythm is 
reversed (Meaney et al., 1992). Rats exhibit very low morning corticosterone levels that 
slowly rise throughout the day and peak in the early evening hours (e.g., around 1800 
hours). Thus, in order to avoid a floor effect and allow room for between-group 
differences in basal corticosterone levels, as well as to relate the present findings to the 
PTSD literature, all blood sampling for this study took place between 1700 and 2000 
hours. 
Statistical Analyses 
 Experimental Design. The present study utilized a single factor, between-subjects 
design. The between-subjects factor was psychosocial stress (psychosocial stress, no 
psychosocial stress). 
Growth Rate, Adrenal Gland Weight and Thymus Weight. Growth rates, 
expressed as grams per day (g/day), were calculated for all rats by dividing their total 
body weight gained during the course of the experiment by the total number of days in 
the experiment (i.e., 31 days). The adrenal glands and thymuses were weighed and 
expressed as milligrams per 100 grams of body weight (mg/100 g b.w.). Independent 
samples t-tests were used to compare the growth rates, adrenal gland weights and thymus 
weights between the psychosocial stress and no psychosocial stress groups. 
Corticosterone Levels. Since the purpose of the present experiment was to 
examine whether the proposed animal model of PTSD would produce reduced baseline 
glucocorticoid levels, a planned comparison (independent samples t-test) was used to 
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compare the baseline corticosterone levels of the psychosocial stress and no psychosocial 
stress groups. Additionally, a mixed-model ANOVA was employed to analyze the 
corticosterone levels of the psychosocial stress and no psychosocial stress groups from all 
three time points. In the ANOVA, psychosocial stress served as the between-subjects 
factor, and time point (baseline, stress, return-to-baseline) served as the within-subjects 
factor. 
For all statistical analyses, alpha was set at 0.05, and Holm-Sidak post hoc 
comparisons were employed when necessary. 
Results 
Growth Rates (see Table 1) 
 The psychosocial stress group tended to display a reduced growth rate, relative to 
the no psychosocial stress group, but this difference did not reach statistical significance, 
t(18) = 2.02, p = 0.058. 
Adrenal Gland Weights (see Table 1) 
 The psychosocial stress group exhibited significantly larger adrenal glands than 
the no psychosocial stress group, indicative of chronic stress-induced adrenal 
hypertrophy, t(16) = 4.26, p < 0.001. 
Thymus Weights (see Table 1) 
 The psychosocial stress group exhibited significantly smaller thymuses than the 
no psychosocial stress group, indicative of chronic stress-induced suppression of the 
immune system, t(16) = 2.12, p = 0.05. 
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Table 1 
Growth Rates, Adrenal Gland Weights and Thymus Weights (± SEM) for the Groups in 
Experiment 1 
 
    Growth Rate          Adrenal Gland       Thymus Weight 
            (g/day)               Weight       (mg/100 g b.w.) 
              (mg/100 g b.w.) 
 
 
No Psychosocial Stress  4.75 ± 0.26            7.45 ± 0.64              115.18 ± 7.31 
 
Psychosocial Stress   3.72 ± 0.43           10.66 ± 0.44              96.47 ± 4.98 
 
 
Corticosterone Levels (see Figure 1) 
 A planned comparison indicated that the psychosocial stress group (2.42 ± 0.41 
μg/dL) displayed significantly lower baseline corticosterone levels than the no 
psychosocial stress group (3.96 ± 0.43 μg/dL), t(17) = 2.60, p < 0.05. 
 The mixed-model ANOVA revealed a significant main effect of time point, 
F(2,32) = 23.19, p < 0.001. Post hoc tests indicated that both groups demonstrated a 
significant increase in corticosterone levels following 20 minutes of acute immobilization 
stress and that these levels remained significantly elevated, relative to baseline, 1 hour 
later (p’s < 0.05). There was no significant main effect of psychosocial stress, F(1,16) = 
0.85, and the Time Point x Psychosocial Stress interaction was not significant, F(2,32) = 
0.38 (p’s > 0.05). 
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Figure 1. Chronic psychosocial stress produced a reduction of basal glucocorticoid levels 
in rats. The data are presented as mean corticosterone levels (µg/dL) ± SEM. * = p < 0.05 
relative to the no psychosocial stress group. 
Discussion of Findings 
As expected, psychosocially stressed rats exhibited significantly larger adrenal 
glands, significantly smaller thymuses and a marginally significant reduction in growth 
rate, relative to control rats. Yet, the most important finding of the present experiment is 
that rats exposed to chronic psychosocial stress exhibited significantly lower baseline 
levels of corticosterone than control animals. This difference was observed in the early 
evening hours (i.e., 1700-2000 hours), a time when serum corticosterone levels begin to 
rise in rats, and is comparable to much of the literature in PTSD patients. Several studies 
have reported abnormally low baseline levels of cortisol in people with PTSD in the early 
morning hours, when levels of cortisol begin to rise in humans (Brand et al., 2006; 
Goenjian et al., 1996; King et al., 2001; Lindauer et al., 2006; Rohleder et al., 2004; 
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Seedat et al., 2003; Wessa et al., 2006). However, as indicated above, the findings 
regarding baseline levels of cortisol in PTSD patients have been mixed, and the presence 
of abnormally low levels of baseline cortisol may only be present in a biologic subtype of 
PTSD (for reviews, see de Kloet et al., 2006; Yehuda, 2002; Yehuda, 2005). If this is the 
case, then it is important to consider what subtype of PTSD our laboratory’s chronic 
psychosocial stress paradigm is modeling. Since abnormally low levels of baseline 
cortisol have predominantly been reported in patients with combat-related PTSD 
(Boscarino, 1996; Kanter et al., 2001; Thaller et al., 1999; Yehuda et al., 1996b; Yehuda 
et al., 1993a), it is possible that our stress regimen models a subtype related to that which 
is caused by exposure to wartime combat. However, future work must clarify what 
specific biologic subtypes of PTSD exist before such a conclusion can be drawn with 
certainty. 
 Many animal models have reported that chronic stress, such as daily restraint 
stress (6 hours/day for 21 days), results in significantly elevated baseline glucocorticoid 
levels (Blanchard et al., 1993; Kant et al., 1987; Lepsch et al., 2005; Marin et al., 2007; 
Mizoguchi et al., 2001; Patterson-Buckendahl et al., 2001; Touyarot & Sandi, 2002). 
Few, however, have been shown to produce abnormally low baseline glucocorticoid 
levels similar to those reported here. Those animal models that have reported 
significantly reduced baseline glucocorticoid levels have employed either the single 
prolonged stress paradigm or a stress-restress paradigm consisting of situational 
reminders of the original stress experience (Diehl et al., 2007; Harvey et al., 2003). The 
single prolonged stress paradigm involves exposing rats to 2 hours of restraint, followed 
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by 20 minutes of swim stress, which is then terminated with exposure to ether vapors 
until anesthesia is induced. Investigators have reported that, up to 1 week later, such a 
paradigm results in abnormally low baseline glucocorticoid levels  and enhanced negative 
feedback of the HPA axis, among other behavioral impairments (e.g., heightened anxiety, 
cognitive impairments, exaggerated startle response) (Diehl et al., 2007; Harada et al., 
2008; Harvey et al., 2003; Iwamoto et al., 2007; Kohda et al., 2007; Liberzon et al., 1997; 
Takahashi et al., 2006; Wang et al., 2008). The present experiment therefore extends 
these findings by demonstrating that similar HPA axis abnormalities can be produced in 
rats by exposure to acute predator stress and daily social instability more than 4 weeks 
after the initial stress experience. 
 Psychosocially stressed rats did not display a greater acute stress-induced increase 
in corticosterone levels than control animals. This null effect could potentially be due to 
the time of day during which the blood samples were collected. Previous work has shown 
that the stress-induced increase in rodent corticosterone levels is not as robust during the 
dark cycle as it is during the light cycle (Kant et al., 1986; Yamada & Iwasaki, 1994). 
Therefore, it is possible that psychosocially stressed animals were limited in the extent to 
which their corticosterone levels could be increased by immobilization. Additionally, this 
null finding, although unexpected, is consistent with some of the PTSD literature 
reporting a blunted stress-induced increase in cortisol levels in PTSD patients. For 
instance, Geracioti et al. (2008) found that combat veterans with PTSD, despite reporting 
significantly greater levels of anxiety, exhibited a significant reduction of CSF CRH 
levels and peripheral cortisol levels while watching a trauma-related film. Importantly, 
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this effect was not observed when the same combat veterans were exposed to a neutral 
film about oil painting. Some animal models of PTSD have also reported a blunted 
glucocorticoid response to acute stress in animals that have developed PTSD-like 
behaviors. Harvey et al. (2006) found that previously-stressed rats exhibited significantly 
lower corticosterone levels than control animals following 20 minutes of acute swim 
stress. In addition, Louvart et al. (2005) reported that previously-shocked animals 
displayed a smaller increase in corticosterone levels in response to a situational reminder 
of the shock than controls. Investigators have contended that these findings are a result of 
stress-induced changes in HPA axis function that results in enhanced negative feedback 
inhibition. Thus, in these referenced studies, the same acute stress-induced increase in 
corticosterone levels that was observed in control animals would theoretically result in 
significantly greater glucocorticoid receptor occupancy in previously stressed animals 
and, ultimately, lead to a much greater suppression of their corticosterone levels. 
 The findings of Experiment One indicate that the our laboratory’s animal model 
of PTSD, composed of two acute predator exposures and daily social instability, produces 
changes in HPA axis functioning that are comparable to those observed in people with 
PTSD. Specifically, rats exposed to this chronic psychosocial stress paradigm exhibited 
significantly lower baseline glucocorticoid levels than control animals, and this effect 
was observed at a time of the circadian rhythm during which similar effects have been 
reported in PTSD patients. Therefore, this study provides further validation of our 
laboratory’s animal model of PTSD and promotes its use to further investigate the 
mechanisms underlying trauma-induced changes in brain and behavior. 
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Chapter Three: Experiment Two 
Chronic Psychosocial Stress Results in Enhanced Suppression of Corticosterone Levels 
following Dexamethasone Administration: Evidence for Enhanced Negative Feedback of 
the Hypothalamus-Pituitary-Adrenal Axis  
 Extensive work has suggested that people with PTSD may exhibit abnormally low 
baseline levels of cortisol due to the presence of enhanced negative feedback of the HPA 
axis (de Kloet et al., 2006). Several studies have found that PTSD patients have an 
increased number and sensitivity of glucocorticoid receptors (Rohleder et al., 2004; Stein 
et al., 1997b; Yehuda et al., 1991; Yehuda et al., 1993a; Yehuda et al., 1995). In addition, 
a majority of the PTSD literature has reported an increased suppression of cortisol and 
ACTH in people with PTSD following the administration of dexamethasone, a synthetic 
glucocorticoid (Duval et al., 2004; Goenjian et al., 1996; Grossman et al., 2003; Newport 
et al., 2004; Stein et al., 1997b; Yehuda et al., 1993b; Yehuda et al., 1995; Yehuda et al., 
2002; Yehuda et al., 2004b). These findings suggest that dexamethasone results in greater 
negative feedback inhibition of the HPA axis, presumably due to the presence of more 
glucocorticoid receptors, in PTSD patients, which leads to a greater suppression of 
cortisol and ACTH in these individuals. Taking these findings into consideration, 
Experiment Two was designed to examine the effects of chronic psychosocial stress, 
composed of two acute predator exposures and daily social instability, on the 
corticosterone response in rats to the dexamethasone suppression test. I hypothesized that 
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psychosocially stressed rats would exhibit a significantly greater suppression of 
corticosterone levels than control rats following the administration of dexamethasone. 
Methods 
Rats 
The same weight range and strain of rats, as well as the housing conditions, that 
were employed in Experiment One were used in the present experiment. Upon arrival, all 
rats were given 1 week to acclimate to the housing room environment and cage changing 
procedures before any experimental manipulations took place. All procedures were 
approved by the Institutional Animal Care and Use Committee at the University of South 
Florida. 
Psychosocial Stress Procedure 
Following the 1-week acclimation phase, rats were brought to the laboratory, 
weighed and assigned to “psychosocial stress” or “no psychosocial stress” groups (N = 
40 rats/group). Afterwards, each group of rats was exposed to the same respective 
manipulations that were utilized in Experiment One. That is, rats in the psychosocial 
stress group were given two acute cat exposures in conjunction with daily social stress, 
while rats in the no psychosocial stress group were given two laboratory exposures 
(remaining in their home cages) and had the same cage mates throughout the duration of 
the experiment. 
Assessment of Post-Dexamethasone Basal and Stress-Induced Glucocorticoid Levels 
Preparation. Twenty days after the second stress session, rats in the psychosocial 
stress and no psychosocial stress groups were brought to the laboratory and weighed. As 
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in Experiment One, the hind legs of all rats were then shaved to allow access to their 
saphenous veins. The rats were then taken back to the housing room and left undisturbed 
for the remainder of the day. 
Pharmacological Manipulations. On the following day, between 1100 and 1400 
hours, rats were taken to the procedure room, one cage at a time, where they were 
administered subcutaneous (s.c.) injections of dexamethasone (10 μg/kg, 25 μg/kg, 50 
μg/kg) or vehicle at a volume of 1 ml/kg. These doses were chosen because previous 
work indicated that they produced a modest suppression of corticosterone levels in 
control rats (Lurie et al., 1989). Ten rats from each of the psychosocial stress and no 
psychosocial stress groups were randomly assigned to receive s.c. injections of one of the 
three doses of dexamethasone or the vehicle solution, for a total of 10 rats per group.  
Dexamethasone (Sigma-Aldrich, St. Louis, MO) was dissolved in a vehicle solution 
consisting of sodium sulfite (1 mg/ml) and sodium citrate (19.4 mg/ml), which were both 
dissolved in distilled water. Immediately following the administration of dexamethasone 
or vehicle, the rats were returned to the housing room until the commencement of blood 
sampling. 
Blood Sampling and Post-Mortem Dissection. Six hours following 
dexamethasone or vehicle administration, three blood samples (baseline, stress and 
return-to-baseline) were obtained from all rats, following the procedures utilized in 
Experiment One. Following rapid decapitation, the adrenal and thymus glands were 
removed and weighed. All blood sampling took place between 1700 and 2100 hours. 
Once all of the blood had clotted at room temperature, it was centrifuged (3000 rpm for 8 
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minutes), and the serum was extracted and stored at -80º C until assayed by Monika 
Fleshner at the University of Colorado at Boulder.  
Statistical Analyses 
 Experimental Design. The present study utilized a between-subjects, 2 x 4 
factorial design. The between-subjects factors were psychosocial stress (psychosocial 
stress, no psychosocial stress) and dexamethasone (vehicle and 10 μg/kg, 25 μg/kg or 50 
μg/kg of dexamethasone). 
Growth Rate, Adrenal Gland Weights and Thymus Weights. Growth rates, 
expressed as grams per day (g/day), were calculated for all rats by dividing their total 
body weight gained during the course of the experiment by the total number of days in 
the experiment (i.e., 31 days). The adrenal glands and thymuses were weighed and 
expressed as milligrams per 100 grams of body weight (mg/100 g b.w.). Two-way 
ANOVAs were used to analyze the growth rates, adrenal gland weights and thymus 
weights, with psychosocial stress and dexamethasone serving as the between-subjects 
factors in each case. 
Corticosterone Levels. A mixed-model ANOVA was employed to analyze the 
corticosterone levels of all groups from the three time points. In the ANOVA, 
psychosocial stress and dexamethasone served as the between-subjects factors, and time 
point (baseline, stress, return-to-baseline) served as the within-subjects factor. 
For all statistical analyses, alpha was set at 0.05, and Holm-Sidak post hoc 
comparisons were employed when necessary. Since dexamethasone administration took 
place on the final day of the experiment, it was predicted that the drug would have no 
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effect on growth rate and adrenal gland or thymus weights. As this was confirmed via the 
statistical analyses below, Table 2 presents the predicted effects of psychosocial stress on 
growth rate and adrenal gland and thymus weights, collapsed across all drug conditions. 
Results 
Growth Rates (see Table 2) 
 The growth rate analysis revealed a significant main effect of psychosocial stress, 
F(1,72) = 9.67, p < 0.01, indicating that the psychosocial stress group had a significantly 
lower growth rate than the no psychosocial stress group. There was no significant main 
effect of dexamethasone, F(3,72) = 1.80, and the Psychosocial Stress x Dexamethasone 
interaction was not significant, F(3,72) = 1.01 (p’s > 0.05). 
Adrenal Gland Weights (see Table 2) 
 The analysis of adrenal gland weights revealed a significant main effect of 
psychosocial stress, F(1,72) = 8.42, p < 0.01, indicating that the psychosocial stress group 
had significantly larger adrenal glands than the no psychosocial stress group. There was 
no significant main effect of dexamethasone, F(3,72) = 1.56, and the Psychosocial Stress 
x Dexamethasone interaction was not significant, F(3,72) = 0.03 (p’s > 0.05). 
Thymus Weights (see Table 2) 
 The analysis of thymus weights revealed a significant main effect of psychosocial 
stress, F(1,70) = 35.89, p < 0.001, indicating that the psychosocial stress group had 
significantly smaller thymuses than the no psychosocial stress group. There was no 
significant main effect of dexamethasone, F(3,70) = 2.67, and the Psychosocial Stress x 
Dexamethasone interaction was not significant, F(3,70) = 1.77 (p’s > 0.05). 
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Table 2 
Growth Rates, Adrenal Gland Weights and Thymus Weights (± SEM) for the 
Psychosocial Stress and No Psychosocial Stress Groups (collapsed across all 
dexamethasone conditions) in Experiment 2 
 
    Growth Rate          Adrenal Gland       Thymus Weight 
            (g/day)               Weight       (mg/100 g b.w.) 
              (mg/100 g b.w.) 
 
 
No Psychosocial Stress  5.39 ± 0.18            9.70 ± 0.39             113.77 ± 3.34 
 
Psychosocial Stress   4.65 ± 0.16           11.32 ± 0.39             90.08 ± 2.59 
 
 
Corticosterone Levels (See Figures 2 and 3) 
 The mixed-model ANOVA revealed a significant main effect of time point, 
F(2,126) = 102.31, p < 0.001. Post hoc tests indicated that, overall, rats demonstrated a 
significant increase in corticosterone levels following 20 minutes of acute immobilization 
stress and that these levels significantly declined, yet remained elevated relative to 
baseline, 1 hour later (p’s < 0.05). There was also a significant main effect of 
dexamethasone, F(3,63) = 67.47, p < 0.001. Post hoc tests revealed that, as expected, 
dexamethasone led to a significant reduction in circulating corticosterone levels. More 
specifically, the rats treated with 10 μg/kg or 25 μg/kg of dexamethasone displayed 
significantly lower corticosterone levels than the rats treated with vehicle, and the rats 
treated with 50 μg/kg of dexamethasone exhibited significantly lower corticosterone 
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levels than the rats treated with vehicle or the two lower doses of dexamethasone. There 
was no significant main effect of psychosocial stress, F(1,63) = 1.28, p > 0.05. 
Chronic Psychosocial Stress Increases Sensitivity of the
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Figure 2. Chronic psychosocial stress increases sensitivity of the HPA axis to 
dexamethasone. The data are presented as mean corticosterone levels (µg/dL) ± SEM. * = 
p < 0.05 (all dexamethasone-treated groups relative to the vehicle-treated groups); β = p < 
0.05 relative to 25 μg/kg dexamethasone-treated no psychosocial stress group; # = p < 
0.05 relative to 10 μg/kg dexamethasone-treated no psychosocial stress group. 
The Time Point x Dexamethasone, F(6,126) = 8.68, and Time Point x 
Psychosocial Stress x Dexamethasone, F(6,126) = 4.12, interactions were significant (p’s 
< 0.001). Post hoc tests indicated that 10 μg/kg of dexamethasone did not prevent the 
acute stress-induced increase in corticosterone levels in either the psychosocial stress or 
no psychosocial stress groups; however, it did lead to a greater suppression of post-
immobilization corticosterone levels in the psychosocial stress group. The administration 
of 25 μg/kg of dexamethasone prevented the acute stress-induced increase in 
corticosterone levels in the psychosocial stress group only. Finally, 50 μg/kg of 
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dexamethasone tended to produce lower baseline and post-immobilization corticosterone 
levels in the psychosocial stress group, relative to the no psychosocial stress group, 
although these comparisons did not achieve statistical significance (p’s = 0.07). The Time 
Point x Psychosocial Stress, F(2,126) = 0.92, and Psychosocial Stress x Dexamethasone, 
F(3,63) = 1.38, interactions were not significant (p’s > 0.05). 
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Effects of Chronic Psychosocial Stress on Corticosterone Responses
following Different Doses of Dexamethasone Administration
 
Figure 3. Effects of chronic psychosocial stress on corticosterone responses following 
different doses of dexamethasone. The data are presented as mean corticosterone levels 
(µg/dL) ± SEM. * = p < 0.05 relative to the no psychosocial stress group; β = p = 0.07 
relative to the no psychosocial stress group. 
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Discussion of Findings 
In contrast to Experiment One, vehicle-treated psychosocially stressed rats did not 
display significantly lower baseline corticosterone levels than vehicle-treated control 
animals. This null effect is likely due to the fact that rats in the present experiment were 
not left undisturbed for the entire day leading up to blood sampling, as was the case in 
Experiment One. Rats in the present experiment were injected 6 hours prior to blood 
sampling, which could have potentially influenced baseline HPA axis functioning for the 
remainder of the day.  
As expected, dexamethasone-treated animals, in general, displayed significantly 
lower baseline corticosterone levels than vehicle-treated animals. In addition, relative to 
vehicle, the two higher doses of dexamethasone significantly blunted the immobilization-
induced increase in corticosterone levels and led to significantly lower corticosterone 
levels in all rats an hour later. As in Experiment One, psychosocially stressed rats also 
exhibited significantly larger adrenal glands, significantly smaller thymuses and a 
significant reduction in growth rate, relative to control rats. 
The most important finding of the present experiment, however, is that chronic 
psychosocial stress, involving two acute predator exposures and daily social instability, 
resulted in enhanced negative feedback sensitivity to the synthetic glucocorticoid, 
dexamethasone. Psychosocially stressed animals displayed a greater suppression of post-
dexamethasone corticosterone levels in a dose- and time-dependent manner. In response 
to 10 µg/kg of dexamethasone, psychosocially stressed rats exhibited a greater recovery 
of corticosterone levels than controls animals an hour following exposure to 20 minutes 
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of immobilization. The 25 µg/kg dose of dexamethasone prevented the acute 
immobilization-induced increase in corticosterone levels in only the psychosocial stress 
group, and the 50 µg/kg dose led to marginally lower corticosterone levels in the 
psychosocial stress group, relative to controls, at baseline and an hour following the 20 
minutes of immobilization. These findings suggest that the stress regimen employed in 
this experiment results in enhanced negative feedback inhibition of the HPA axis. More 
specifically, since the doses of dexamethasone that were used in this study do not cross 
the blood-brain barrier (Meijer et al., 1998; Schinkel et al., 1995), the findings indicate 
that this enhanced negative feedback occurs at the level of the pituitary gland. 
These findings are consistent with a majority of the PTSD literature. A number of 
studies have reported that PTSD patients have an increased number and sensitivity of 
glucocorticoid receptors (Rohleder et al., 2004; Stein et al., 1997b; Yehuda et al., 1991; 
Yehuda et al., 1993a; Yehuda et al., 1995) and display an increased suppression of 
cortisol and ACTH following the administration of dexamethasone (Duval et al., 2004; 
Goenjian et al., 1996; Grossman et al., 2003; Newport et al., 2004; Stein et al., 1997b; 
Yehuda et al., 1993b; Yehuda et al., 1995; Yehuda et al., 2002; Yehuda et al., 2004b). 
Some studies have also observed increased activation of the pituitary gland in PTSD 
patients following the administration of metyrapone, which investigators believe to be 
due to the fact that metyrapone removes the enhanced negative feedback inhibition 
initially present in these individuals (Otte et al., 2006; Yehuda et al., 1996a). 
Collectively, these findings have implicated enhanced negative feedback inhibition in the 
HPA axis abnormalities observed in people with PTSD. 
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Rarely have investigators tested for the presence of enhanced negative feedback 
inhibition of the HPA axis in animal models of PTSD. Only two studies have conducted 
such assessments. Liberzon et al. (1997) found that rats exposed to a single prolonged 
stress paradigm subsequently (i.e., 1 week later) exhibited a blunted restraint stress-
induced increase in ACTH levels following the administration of cortisol. In addition, 
similar to the present findings, Kohda et al. (2007) reported that rats exposed to a single 
prolonged stress paradigm subsequently (i.e., 1 week later) exhibited a blunted restraint 
stress-induced increase in corticosterone levels following the administration of 
dexamethasone. Both of these findings suggest that the single prolonged stress paradigm 
produces changes in HPA axis function that resemble enhanced negative feedback 
inhibition and are comparable to the present set of data. 
The commonalities in HPA responses between psychosocially stressed rats from 
the present studies and traumatized people with PTSD further validate the use of this 
chronic psychosocial stress paradigm to explore the mechanisms underlying emotional 
trauma-induced changes in brain and behavior. Nevertheless, future work concerning the 
neurobiological bases of the present effects should examine other markers of enhanced 
negative feedback inhibition of the HPA axis, such as enhanced glucocorticoid receptor 
expression in key areas of the brain (e.g., anterior pituitary gland, hippocampus). Future 
studies will also need to explore the effect of metyrapone or dexamethasone-CRH 
challenge paradigms on pituitary function (e.g., ACTH release). Our laboratory already 
has preliminary data indicating that rats exposed to the psychosocial stress regimen 
exhibit significantly greater baseline levels of CRH mRNA in the paraventricular nucleus 
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of the hypothalamus than control animals (unpublished findings). This finding suggests 
that psychosocially stressed rats might also display abnormally high CRH levels, which 
would also be consistent with the PTSD literature. Future work, however, must be 
conducted to verify this hypothesis. 
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Chapter Four: Experiment Three 
Differential Effectiveness of the Pharmacological Agents Amitriptyline, Clonidine and 
Tianeptine in Blocking the PTSD-Like Physiological and Behavioral Sequelae in Rats 
A subset of people with PTSD exhibit significant improvement in their symptoms 
following treatment with SSRIs (Asnis et al., 2004; Davidson, 2003; Davis et al., 2006; 
Hidalgo & Davidson, 2000; Ipser et al., 2006; Stein et al., 2006). At this time, the SSRIs 
sertraline and paroxetine are the only two medications that have been approved by the 
Food and Drug Administration (FDA) for the treatment of PTSD (Albucher & Liberzon, 
2002; Barrett et al., 2005; Van der Kolk, 2001; Vaswani et al., 2003). However, SSRIs 
tend to blunt only the depressive components of PTSD, while having little effect on the 
memory- and anxiety-related symptoms of the disorder (Asnis et al., 2004; Boehnlein & 
Kinzie, 2007; Brady et al., 2000; Van der Kolk et al., 1994). In addition, some forms of 
PTSD, such as combat-related PTSD, are incredibly resistant to SSRI treatment 
(Jakovljevic et al., 2003; Rothbaum et al., 2008; Stein et al., 2002). They can even 
produce severe adverse side effects, including sleep disruption, headache, abdominal 
pain, sexual dysfunction, agitation, nausea and weight gain, which significantly interfere 
with an individual’s daily life (Asnis et al., 2004; Boehnlein & Kinzie, 2007; Brady et al., 
2000; Van der Kolk et al., 1994). Thus, there is a need for additional pharmacological 
research in people with PTSD and in animal models of the disorder to facilitate the 
development of more effective pharmacotherapy for PTSD patients. 
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 The purpose of Experiment Three was to ascertain whether chronic prophylactic 
administration of amitriptyline, clonidine and tianeptine would ameliorate the 
physiological and behavioral sequelae induced by chronic psychosocial stress in rats. 
Amitriptyline is a tricyclic antidepressant that has been reported to significantly 
ameliorate many symptoms of PTSD, especially those related to intrusion, avoidance and 
re-experiencing (Davidson et al., 1990; Davidson et al., 1993). Clonidine is an anxiolytic 
and α2 adrenergic receptor agonist that, via the facilitation of adrenergic autoreceptor 
activity, leads to a significant reduction in NE levels throughout the central nervous 
system. As PTSD is characterized by abnormally high levels of NE, researchers have 
contended that clonidine should ameliorate many of the symptoms of PTSD, and 
especially those related to hyperarousal (Boehnlein & Kinzie, 2007). However, as of 
now, there have been no randomized, placebo-controlled studies on the efficacy of 
clonidine in treating people with PTSD. The final experimental treatment was tianeptine, 
an antidepressant. While this agent is most commonly known to exert antidepressant 
effects and ameliorate symptoms of major depression, it has been shown to have 
beneficial effects in PTSD patients as well (Onder et al., 2006). Moreover, numerous 
studies in rodents have provided support for tianeptine’s use in treating stress-related 
psychopathologies, as it blocks the adverse effects of stress on cognitive, 
electrophysiological, morphological and molecular measures of hippocampal functioning 
(Diamond et al., 2004; Kasper & McEwen, 2008; McEwen et al., 2002; McEwen & Olie, 
2005; Uzbay, 2008). To emphasize that the design of the present experiment had clinical 
relevance, administration of the pharmacological agents did not begin until the day after 
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the stress paradigm commenced. Treatment beginning 24 hours after exposing rats to an 
intense stressor is potentially relevant to treatment applications begun in people within 24 
hours of a traumatic experience and may highlight the importance of quickly beginning a 
treatment regimen soon after experiencing intense trauma. 
Methods 
Rats 
The same weight range and strain of rats, as well as the housing conditions, that 
were employed in Experiments One and Two were used in the present experiment. Upon 
arrival, all rats were given 1 week to acclimate to the housing room environment and 
cage changing procedures before any experimental manipulations took place. All 
procedures were approved by the Institutional Animal Care and Use Committee at the 
University of South Florida. 
Psychosocial Stress Procedure 
PTSD is a disorder of memory, and individuals suffering from PTSD experience 
chronic psychological distress by repeatedly reliving their trauma through intrusive, 
flashback memories (Ehlers et al., 2004; Hackmann et al., 2004; Reynolds & Brewin, 
1998; Reynolds & Brewin, 1999; Speckens et al., 2006; Speckens et al., 2007). 
Therefore, to incorporate a rat analog of a traumatic memory into our animal model of 
PTSD, we developed a paradigm to quantify the memory for the acute cat exposures that 
are a part of the psychosocial stress procedure (Halonen et al., 2006). This paradigm was 
included in the psychosocial stress procedure in the present experiment to assess, during 
behavioral testing, the long-term memory of the acute cat exposures. 
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Following the 1-week acclimation phase, rats were brought to the laboratory and 
then assigned to “psychosocial stress” or “no psychosocial stress” groups (N = 60 
rats/group). Afterwards, rats from each group were exposed to a chamber for 3 minutes. 
During the last 30 seconds of the 3-minute chamber exposure, a 74-dB, 2500 Hz tone was 
presented to the rats. The chamber (25.50 x 30 x 29 cm; Coulbourn Instruments; 
Allentown, PA) consisted of two aluminum sides, an aluminum ceiling, and a Plexiglas 
front and back. The floor of the chamber consisted of 18 stainless steel rods, spaced 1.25 
cm apart. The rats were not exposed to footshock at any time in the chamber. The sole 
purpose of exposing rats to the chamber was to allow rats in the psychosocial stress group 
to associate the chamber (contextual fear conditioning) and tone [auditory (cue) fear 
conditioning] with the acute stress experience (i.e., immobilization plus cat exposure) and 
measure their memory for the experience (via an assessment of immobility in the 
chamber) during behavioral testing. Locomotor activity in the chamber was measured 
during the acute stress sessions and behavioral testing by a 24-cell infrared activity 
monitor (Coulbourn Instruments; Allentown, PA) mounted on the top of the chamber, 
which used the emitted infrared body heat image (1300 nm) from the animals to detect 
their movement. Immobility was defined as periods of inactivity lasting at least seven 
seconds. Following the 3-minute chamber exposure, rats in the psychosocial stress group 
were exposed to 1 hour of immobilization during cat exposure (as per the methods in 
Experiments One and Two), while rats in the no psychosocial stress group remained in 
their home cages in the laboratory for a yoked period of time. Both groups of rats were 
weighed following the 1-hour period and then returned to their housing rooms. As per 
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Experiments One and Two, this entire process (i.e., acute stress session) was repeated 10 
days later (during the dark cycle on Day 11), and beginning with the day of the first stress 
session, rats in the psychosocial stress group were exposed to unstable housing conditions 
for the next 31 days. 
Pharmacological Agents 
 Twenty-four hours after the first stress session (i.e., Day 2), all rats began 
receiving daily intraperitoneal (i.p.) injections of amitriptyline (5 or 10 mg/kg), clonidine 
(0.01 or 0.05 mg/kg), tianeptine (10 mg/kg), or vehicle (distilled water). The injections 
occurred every day throughout the 31-day period of psychosocial stress and also during 
behavioral testing. Drug administration was continued during behavioral testing to 
prevent withdrawal effects from influencing rat behavior. The injections were always 
administered in the morning (between 0900 and 1200 hours) at a volume of 1 ml/kg. Ten 
rats from each of the psychosocial stress and no psychosocial stress groups were 
randomly assigned to each of the drug conditions, for a total of 10 rats per group. 
Amitriptyline and clonidine were obtained from Sigma-Aldrich (St. Louis, MO), while 
tianeptine was provided by Servier Pharmaceuticals (France). 
Behavioral Testing 
 Three weeks after the second stress session (Day 32), rats were given tests to 
measure their fear memory, anxiety, startle, learning and memory, cardiovascular activity 
and corticosterone activity. The 3-week delay from the second stress session to 
behavioral testing was based on comparable time periods employed in other studies on 
the effects of stress on brain and behavior (Adamec & Shallow, 1993; Cook & Wellman, 
  63
2004; Magarinos et al., 1996; McLaughlin et al., 2007; Park et al., 2001; Watanabe et al., 
1992a; Watanabe et al., 1992c; Watanabe et al., 1992b). Additionally, work from our 
laboratory has previously shown that the chronic psychosocial stress paradigm employed 
in the present experiment produces significant changes in rat physiology and behavior 
that can be detected 3 weeks following the second stress session (Zoladz et al., 2008). On 
the first 4 days of behavioral testing (Days 32-35), all rats were taken to the procedure 
room across from the rat housing rooms, where they received i.p. injections of the drug 
appropriate to the condition to which they had been assigned. Then, they were taken to 
the laboratory and left undisturbed for 30 minutes before testing began. All behavioral 
testing took place during the light cycle, between 0800 and 1500 hours. 
Behavioral Apparatus 
 Contextual and Cue Fear Memory. On Day 32, rat behavior in response to the 
chamber (context test) and tone (cue test) that were previously paired with the acute 
stress sessions was examined. Rats were placed in the same chamber that they were 
exposed to during each of the two stress sessions for 5 minutes, and their immobility was 
recorded, as per the methods described above. An hour after the 5-minute context test, the 
rats were placed in a novel chamber that had different lighting, walls and flooring from 
that of the chamber in which they were placed during each of the two stress sessions. The 
rats were placed in the novel chamber for a total of 6 minutes (cue test). Three minutes 
into the cue test, the rats were presented with a 74-dB, 2500 Hz tone that continuously 
played for the remainder of the 6-minute testing period. The amount of immobility 
recorded during the first 3 minutes of the cue test (i.e., no tone) provided a measure of the 
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general fear of a novel place, while the amount of immobility recorded during the last 3 
minutes of the cue test (i.e., tone) provided a measure of the fear response to the cue that 
was, in the psychosocial stress group, specifically associated with the two acute cat 
exposures. 
Elevated Plus Maze. The elevated plus maze (EPM) is a routine test of anxiety in 
rodents (Korte & De Boer, 2003) and consists of two open arms (10.80 x 50.17 cm) and 
two closed arms (10.80 x 50.17 cm) that intersect each other to form the shape of a plus 
sign. On Day 33, the rats were placed on the EPM for 5 minutes, and their behavior was 
scored by 48 infrared photobeams (located along the perimeter of the open and closed 
arms), which were connected to a computer program (Motor Monitor, Hamilton-Kinder, 
San Diego, CA). The primary dependent measures of interest were the amount of time 
rats spent in the open arms and the number of ambulations made by each rat. An arm 
entry was scored by the computer program only when a rat’s entire body had moved from 
one arm into a new arm (e.g., the entire body of the rat moved from the closed arms into 
an open arm). Thus, the computer program would begin tallying open arm time only after 
a rat had completely entered an open arm. An ambulation was scored by the computer 
program each time a rat crossed a photobeam sensor. Thus, the ambulations score 
consisted of the total number of beam breaks made by each rat during the 5-minute trial 
and served as a measure of motor activity. Between each testing session, the EPM was 
wiped down with a 25% ethanol solution. 
Startle Response. One hour after the EPM assessment, acoustic startle testing was 
administered. The rats were placed inside a small Plexiglas box (18.50 x 9.75 x 9.75 cm), 
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which was inside a larger startle monitor cabinet (Hamilton-Kinder; San Diego, CA; 
35.56 x 27.62 x 49.53 cm). The small Plexiglas box within this cabinet contained a 
sensory transducer on which the rats were placed at the beginning of the trial. The 
sensory transducer was connected to a computer (Startle Monitor computer program; 
Hamilton-Kinder; San Diego, CA), which recorded the startle responses by measuring the 
maximum amount of force (in Newtons) that rats exerted on the sensory transducer for a 
period of 250 ms after the presentation of each auditory stimulus. To control for any 
differences in body weight, the sensitivity of the sensory transducer was adjusted prior to 
each trial via a Vernier adjustment with a sensitivity range of 0-7 arbitrary units. The 
startle trial began with a 5-minute acclimation period, followed by the presentation of 24 
bursts of white noise (50 ms each), eight from each of three auditory intensities (90, 100, 
and 110 dB). The noise bursts were presented in sequential order (i.e. eight bursts at 90 
dB, followed by eight bursts at 100 dB, followed by eight bursts at 110 dB), and the time 
between each noise burst varied pseudorandomly between 25 and 55 seconds. Upon the 
commencement of the first noise burst, the startle apparatus provided uninterrupted 
background white noise (57 dB). 
Novel Object Recognition. The novel object recognition (NOR) task was a 
modified version of that which was employed by Baker and Kim (2002). On Day 34, the 
rats were placed in an open field (Hamilton-Kinder, San Diego, CA – 40 x 47 x 70 cm) 
for 5 minutes to acclimate to the environment. Their behavior was monitored by a 
Logitech camera that was mounted on the ceiling overlooking the open field. This camera 
was connected to a computer program known as ANY-Maze (Stoelting; Wood Dale, IL), 
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which scored rat behavior. Twenty-four hours later (Day 35), the rats were placed in the 
same open field with two identical (plastic/metal) objects for 5 minutes. The objects were 
in opposite corners of the open field and secured to the flooring to prevent the rats from 
displacing them. The objects were counterbalanced across rats, as were the corners in 
which the objects were placed. Three hours later, the rats were returned to the open field 
for a final 5-minute test trial, but this time the open field contained a replica of the object 
that had been there before and a novel object. During this testing session, greater time 
spent by the rats in proximity to the novel versus familiar object was an indication of 
intact memory for the familiar object. The time that each rat spent with the objects during 
training and testing was quantified by specifying a 16 cm2 zone around the objects for the 
ANY-maze software to score the duration of investigatory behavior. 
Preparation for Blood Sampling. Immediately following the 3-hour object 
recognition test, the hind legs of all rats were shaved to allow access to their saphenous 
veins, as per Experiments One and Two. 
Blood Sampling and Cardiovascular Activity. On the final day of behavioral 
testing (Day 36), rats were brought, one cage at a time, to a nearby procedure room for 
blood sampling. Then, baseline and post-stress samples of blood were collected from the 
rats, as per the methods employed in Experiments One and Two. Immediately after 
collecting the post-immobilization blood sample, the rats were placed in Plexiglas tubes 
within a warming test chamber to increase their body temperature. This enhanced blood 
flow to their tails, and allow HR and BP to be assessed using a tail cuff fitted with 
photoelectric sensors (IITC Life Science; Woodland Hills, CA). Once their body 
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temperature reached approximately 32º C, three HR and BP recordings were obtained 
from each rat (these three recordings were averaged to create single HR and BP data 
points for each rat). An hour later, one last blood sample (trunk blood) was collected 
following rapid decapitation. Then, the adrenal glands and thymuses were removed and 
weighed. Once all of the blood had clotted at room temperature, it was centrifuged (3000 
rpm for 8 minutes), and the serum was extracted and stored at -80º C until assayed by 
Monika Fleshner at the University of Colorado at Boulder.  
Statistical Analyses 
 Experimental Design and General Analyses. The present study utilized a 
between-subjects, 2 x 6 factorial design. The independent variables were psychosocial 
stress (psychosocial stress, no psychosocial stress) and drug (vehicle, amitriptyline – 5 
and 10 mg/kg, clonidine – 0.01 and 0.05 mg/kg, tianeptine – 10 mg/kg). In most cases, 
two-way, between-subjects ANOVAs were used to analyze the data from the 
physiological and behavioral assessments, with psychosocial stress and drug serving as 
the between-subjects factors. Planned comparisons (independent samples t-tests) were 
also conducted between groups that were predicted to differ a priori. For all analyses, 
alpha was set at 0.05, and Holm Sidak post hoc tests were employed when necessary.   
Fear Memory. The amount of immobility from each chamber exposure (Stress 
Session 1, Stress Session 2, Context Test, Cue Test – No Tone, Cue Test – Tone) was 
analyzed separately. The number of fecal boli that rats produced in the chamber was also 
analyzed for the Context and Cue Tests. For each assessment, two-way, between-subjects 
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ANOVAs were used to analyze behavior. Psychosocial stress and drug served as the 
between-subjects factors in each case. 
Elevated Plus Maze. The amount of time that rats spent in the open arms of the 
EPM was calculated as a percent of the total trial time. The percent time that rats spent in 
the open arms, as well as the number of ambulations that rats made on the EPM were 
analyzed with two-way, between-subjects ANOVAs. Each of these analyses was 
performed for the entire 5-minute testing trial and for the first minute of the testing trial, 
with psychosocial stress and drug serving as the between-subjects factors in each case. 
Startle Response. Startle responses to each of the three auditory stimulus 
intensities (90, 100 and 110 dB) were analyzed separately. In each case, two-way, 
between-subjects ANOVAs were employed to analyze the data, with psychosocial stress 
and drug serving as the between-subjects factors. 
Novel Object Recognition. For habituation, a two-way, between-subjects ANOVA 
was used to compare overall locomotor activity across all groups, with psychosocial 
stress and drug serving as the between-subjects factors. The amount of time that rats 
spent in each area of the open field during the habituation phase was also analyzed to 
assure that the rats did not display a preference for one area of the open field over 
another. For the analysis, the open field was divided into four square quadrants via the 
ANY-Maze computer program. The amount of time that rats spent in each of the 
quadrants was analyzed with a mixed-model ANOVA, with psychosocial stress and drug 
serving as the between-subjects factors and time spent in each quadrant serving as the 
within-subjects factor. For training, paired samples t-tests were first conducted to 
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determine whether the rats within each group spent a comparable amount of time with 
each object replica (to rule out object preference effects). Then, the total time that rats 
spent with both object replicas during training was compared across groups by using two-
way, between-subjects ANOVAs, with psychosocial stress and drug serving as the 
between-subjects factors. For testing, a “ratio time” score was calculated for each group 
by taking the time that rats spent with the novel object and dividing it by the time that rats 
spent with the familiar object (i.e., ratio time = time with novel object / time with familiar 
object). The ratio times were compared across groups by utilizing two-way, between-
subjects ANOVAs, with psychosocial stress and drug again serving as the between-
subjects factors. This was performed for the entire 5-minute testing trial and for the first 
minute of the testing trial. 
Corticosterone Levels. A mixed-model ANOVA was used to analyze 
corticosterone levels at the three time points. Psychosocial stress and drug served as the 
between-subjects factors, and time point (baseline, stress, return-to-baseline) served as 
the within-subjects factor. 
Heart Rate and Blood Pressure. The HR, systolic BP and diastolic BP data were 
analyzed with two-way, between-subjects ANOVAs, with psychosocial stress and drug 
serving as the between-subjects factors. 
Growth Rates, Adrenal Gland Weights and Thymus Weights. Growth rates, 
expressed as grams per day (g/day), were calculated for all rats by dividing their total 
body weight gained during the course of the experiment by the total number of days in 
the experiment (i.e., 31 days). The adrenal glands and thymuses were weighed and 
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expressed as milligrams per 100 grams of body weight (mg/100 g b.w.). Two-way, 
between-subjects ANOVAs were used to analyze the growth rates, adrenal gland weights 
and thymus weights, with psychosocial stress and drug serving as the between-subjects 
factors in each case. 
Results 
Fear Memory 
 Stress Session One (see Figure 4). For the analysis of immobility during the 3-
minute chamber exposure during stress session one, there were no significant main 
effects of psychosocial stress, F(1,104) = 0.48, or drug, F(5,104) = 0.84, and the 
Psychosocial Stress x Drug interaction was not significant, F(5,104) = 1.13 (p’s > 0.05). 
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Figure 4. Amount of immobility during the 3-minute chamber exposure during stress 
session one. The data are presented as mean percent immobility ± SEM. 
Stress Session Two (see Figure 5). For the analysis of immobility during the 3-
minute chamber exposure during stress session two, there was a significant main effect of 
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psychosocial stress, indicating that the psychosocial stress groups spent significantly 
more time immobile than the no psychosocial stress groups, F(1,103) = 7.55, p < 0.01. 
There was no significant main effect of drug, F(5,103) = 0.48, and the Psychosocial 
Stress x Drug interaction was not significant, F(5,103) = 0.96 (p’s > 0.05). Planned 
comparisons were also conducted between groups that were predicted to differ a priori. 
The vehicle-treated psychosocial stress group spent significantly more time immobile 
than the vehicle-treated no psychosocial stress group, t(17) = 2.73, p < 0.05. Groups of 
psychosocially stressed rats that were treated with 0.01, t(18) = 2.19, or 0.05, t(16) = 
2.26, of clonidine were the only other psychosocial stress groups that displayed 
significantly greater immobility than their respective control groups (p’s < 0.05). 
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Figure 5. Amount of immobility during the 3-minute chamber exposure during stress 
session two. The data are presented as mean percent immobility ± SEM. * = p < 0.05 
relative to the vehicle-treated no psychosocial stress group; τ = p < 0.05 relative to the 
respective drug-treated no psychosocial stress group. 
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Effects of Chronic Psychosocial Stress and Drug
Treatment on Immobility during the Context Test
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Figure 6. Effects of chronic psychosocial stress and drug treatment on immobility during 
the 5-minute context test. The data are presented as mean percent immobility ± SEM. * = 
p < 0.05 relative to the vehicle-treated no psychosocial stress group; β = p < 0.05 relative 
to the vehicle-treated psychosocial stress group; τ = p < 0.05 relative to the respective 
drug-treated no psychosocial stress group. 
Context Test Immobility (see Figure 6). For the analysis of immobility during the 
5-minute context test, there were significant main effects of psychosocial stress, F(1,97) 
= 11.96, and drug, F(5,97) = 3.90, and the Psychosocial Stress x Drug interaction was 
significant, F(5,97) = 2.56 (p’s < 0.05). Post hoc tests indicated that the vehicle-treated 
psychosocial stress group spent significantly more time immobile than the vehicle-treated 
no psychosocial stress group. Chronic treatment with 5 or 10 mg/kg of amitriptyline or 10 
mg/kg of tianeptine in groups that were psychosocially stressed prevented the chronic 
stress-induced increase in immobility, as evidenced by significantly less immobility than 
the vehicle-treated psychosocial stress group and a lack of statistical significance relative 
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to each of the group’s respective drug-treated no psychosocial stress group. The group of 
psychosocially stressed rats treated with 0.01 mg/kg of clonidine also did not exhibit 
significantly greater immobility than its respective drug-treated control group; however, 
the amount of immobility displayed by this group was not statistically different from that 
of the vehicle-treated psychosocial stress group. 
 Context Test Fecal Boli (see Figure 7). The analysis of fecal boli produced during 
the context test revealed significant main effects of psychosocial stress, F(1,97) = 15.45, 
and drug, F(5,97) = 4.09 (p’s < 0.01). The psychosocial stress groups produced 
significantly more fecal boli than the no psychosocial stress groups, and groups that were 
treated with 5 mg/kg of amitriptyline produced significantly more fecal boli than groups 
that were treated with 10 mg/kg of amitriptyline or tianeptine. The Psychosocial Stress x 
Drug interaction was not significant, F(5,97) = 0.87, p > 0.05. Planned comparisons were 
also conducted between groups that were predicted to differ a priori. The vehicle-treated 
psychosocial stress group produced significantly more fecal boli than the vehicle-treated 
no psychosocial stress group, t(17) = 2.81, p < 0.05. Chronic treatment with 10 mg/kg of 
amitriptyline, 0.01 mg/kg of clonidine or 10 mg/kg of tianeptine in groups that were 
psychosocially stressed prevented the stress-induced increase in fecal boli, as evidenced 
by the presence of significantly fewer fecal boli deposits than the vehicle-treated 
psychosocial stress group and a lack of statistical significance relative to each of the 
group’s respective drug-treated no psychosocial stress groups. While the group of 
psychosocially stressed rats treated with 0.05 mg/kg of clonidine did not defecate more 
than the vehicle-treated control animals, t(17) = 1.14, p > 0.05, they did produce 
  74
significantly more fecal boli than their respective drug-treated controls, t(18) = 2.40, p < 
0.05. 
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Figure 7. Effects of chronic psychosocial stress and drug treatment on fecal boli 
produced during the 5-minute context test. The data are presented as mean number of 
fecal boli ± SEM. * = p < 0.05 relative to the vehicle-treated no psychosocial stress 
group; β = p < 0.05 relative to the vehicle-treated psychosocial stress group; τ = p < 0.05 
relative to the respective drug-treated no psychosocial stress group. 
Cue Test Immobility – No Tone (i.e., Novel Environment) (see Figure 8). For the 
analysis of immobility during the first 3 minutes of the cue test, there were significant 
main effects of psychosocial stress, F(1,100) = 9.40, and drug, F(5,100) = 2.72, and the 
Psychosocial Stress x Drug interaction was significant, F(5,100) = 5.73 (p’s < 0.05). Post 
hoc tests indicated that chronic treatment with 0.05 mg/kg of clonidine in rats that were 
psychosocially stressed led to significantly greater immobility than all other groups. 
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Effects of Chronic Psychosocial Stress and Drug
Treatment on Immobility in a Novel Environment
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Figure 8. Effects of chronic psychosocial stress and drug treatment on immobility during 
the first 3 minutes of the cue test. The data are presented as mean percent immobility ± 
SEM. # = p < 0.05 relative to all other groups. 
 Cue Test Immobility – Tone (see Figure 9). For the analysis of immobility during 
the tone, there was no significant main effect of drug, F(5,100) = 2.02, p > 0.05. There 
was a significant main effect of psychosocial stress, F(1,100) = 12.04, and the 
Psychosocial Stress x Drug interaction was significant, F(5,100) = 2.71 (p’s < 0.05). Post 
hoc tests indicated that the vehicle-treated psychosocial stress group spent significantly 
more time immobile than the vehicle-treated no psychosocial stress group. Additionally, 
chronic treatment with 10 mg/kg of amitriptyline in groups that were not psychosocially 
stressed led to significantly greater immobility than the vehicle-treated no psychosocial 
stress group. Chronic treatment with 5 or 10 mg/kg of amitriptyline or 10 mg/kg of 
tianeptine in groups that were psychosocially stressed prevented the chronic stress-
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induced increase in immobility, as evidenced by a lack of statistical significance relative 
to each of the group’s respective drug-treated no psychosocial stress group. 
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Figure 9. Effects of chronic psychosocial stress and drug treatment on immobility during 
the tone. The data are presented as mean percent immobility ± SEM. * = p < 0.05 relative 
to the vehicle-treated no psychosocial stress group; τ = p < 0.05 relative to the respective 
drug-treated no psychosocial stress group. 
Cue Test Fecal Boli (see Figure 10). The analysis of fecal boli produced during 
the cue test revealed a significant main effect of psychosocial stress, F(1,100) = 7.34. The 
psychosocial stress groups produced significantly more fecal boli during the cue test than 
the no psychosocial stress groups. There was no significant main effect of drug, F(5,100) 
= 2.19, and the Psychosocial Stress x Drug interaction was not significant, F(5,100) = 
0.57 (p’s > 0.05). Planned comparisons were also conducted between groups that were 
predicted to differ a priori. There was no significant difference between the vehicle-
treated psychosocial stress group and the vehicle-treated no psychosocial stress group, 
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t(17) = 1.90, p > 0.05. The psychosocial stress group that was chronically treated with 
0.05 mg/kg of clonidine produced significantly less fecal boli than the vehicle-treated 
psychosocial stress group, t(18) = 3.36, p < 0.01. 
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Figure 10. Effects of chronic psychosocial stress and drug treatment on fecal boli 
produced during the 6-minute cue test. The data are presented as mean number of fecal 
boli ± SEM. β = p < 0.05 relative to the vehicle-treated psychosocial stress group. 
Elevated Plus Maze 
 Percent Time in Open Arms, 5-Minute Trial (see Figure 11). For the analysis of 
percent time in the open arms during the 5-minute trial on the EPM, there were no 
significant main effects of psychosocial stress, F(1,100) = 2.89, or drug, F(5,100) = 1.14, 
and the Psychosocial Stress x Drug interaction was not significant, F(5,100) = 1.16 (p’s > 
0.05). Planned comparisons were also conducted between groups that were predicted to 
differ a priori. The vehicle-treated psychosocial stress group spent significantly less time 
in the open arms of the EPM than the vehicle-treated no psychosocial stress group, t(15) 
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= 2.44, p < 0.05. Chronic treatment with 10 mg/kg of amitriptyline, 0.01 or 0.05 mg/kg of 
clonidine or 10 mg/kg of tianeptine in groups that were psychosocially stressed prevented 
the chronic stress-induced decrease in open arm exploration, as evidenced by the 
presence of significantly greater percent time spent in the open arms than the vehicle-
treated psychosocial stress group or a lack of statistical significance relative to each of the 
group’s respective drug-treated no psychosocial stress group. 
Effects of Chronic Psychosocial Stress and Drug
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Figure 11. Effects of chronic psychosocial stress and drug treatment on percent time 
spent in the open arms during the 5-minute trial on the elevated plus maze. The data are 
presented as mean percent time spent in the open arms ± SEM. * = p < 0.05 relative to 
the vehicle-treated no psychosocial stress group; β = p < 0.05 relative to the vehicle-
treated psychosocial stress group. 
Percent Time in Open Arms, First Minute (see Figure 12). For the analysis of 
percent time in the open arms during the first minute of the 5-minute trial on the EPM, 
there was a significant main effect of psychosocial stress, F(1,102) = 4.79, and the 
Psychosocial Stress x Drug interaction was significant, F(5,102) = 3.03 (p’s < 0.05). The 
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vehicle-treated psychosocial stress group spent significantly less time in the open arms of 
the EPM than the vehicle-treated no psychosocial stress group. Chronic treatment with 
0.01 mg/kg of clonidine in the group that was not psychosocially stressed led to 
significantly less open arm exploration on the EPM, relative to the vehicle-treated no 
psychosocial stress group. Chronic treatment with 5 or 10 mg/kg of amitriptyline, 0.01 or 
0.05 mg/kg of clonidine or 10 mg/kg of tianeptine in groups that were psychosocially 
stressed prevented the chronic stress-induced decrease in open arm exploration, as 
evidenced by the presence of significantly greater percent time spent in the open arms 
than the vehicle-treated psychosocial stress group or a lack of statistical significance 
relative to each of the group’s respective drug-treated no psychosocial stress group. 
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Figure 12. Effects of chronic psychosocial stress and drug treatment on percent time 
spent in the open arms during the first minute of the 5-minute trial on the elevated plus 
maze. The data are presented as mean percent time spent in the open arms ± SEM. * = p 
< 0.05 relative to the vehicle-treated no psychosocial stress group; β = p < 0.05 relative to 
the vehicle-treated psychosocial stress group. 
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Effects of Chronic Psychosocial Stress and Drug
Treatment on Motor Activity on the EPM (5-Minute Trial)
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Figure 13. Effects of chronic psychosocial stress and drug treatment on ambulations 
made during the 5-minute trial on the elevated plus maze. The data are presented as mean 
number of ambulations ± SEM. * = p < 0.05 relative to the vehicle-treated no 
psychosocial stress group. 
Ambulations, 5-Minute Trial (see Figure 13). For the analysis of ambulations 
made during the 5-minute trial on the EPM, there was no significant main effect of 
psychosocial stress, F(1,100) = 3.70, and the Psychosocial Stress x Drug interaction was 
not significant, F(5,100) = 0.52 (p’s > 0.05). There was a significant main effect of drug, 
F(5,100) = 4.48, p < 0.001. Planned comparisons were also conducted between groups 
that were predicted to differ a priori. There was no significant difference between the 
number of ambulations made by the vehicle-treated psychosocial stress group and the 
vehicle-treated no psychosocial stress group on the EPM, t(16) = 0.16, p > 0.05. Chronic 
treatment with 10 mg/kg of amitriptyline, t(15) = 2.67, or 10 mg/kg of tianeptine, t(16) = 
2.38, in groups that were not psychosocially stressed led to a significantly greater number 
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of ambulations on the EPM, relative to the vehicle-treated no psychosocial stress group 
(p’s < 0.05). 
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Figure 14. Effects of chronic psychosocial stress and drug treatment on ambulations 
made during the first minute of the 5-minute trial on the elevated plus maze. The data are 
presented as mean number of ambulations ± SEM. * = p < 0.05 relative to the vehicle-
treated no psychosocial stress group. 
Ambulations, First Minute (see Figure 14). For the analysis of ambulations made 
during the first minute of the 5-minute trial on the EPM, there was no significant main 
effect of psychosocial stress, F(1,100) = 0.16, and the Psychosocial Stress x Drug 
interaction was not significant, F(5,100) = 1.57 (p’s > 0.05). There was a significant main 
effect of drug, F(5,100) = 2.43, p < 0.05. Planned comparisons were also conducted 
between groups that were predicted to differ a priori. There was no significant difference 
between the number of ambulations made by the vehicle-treated psychosocial stress 
group and the vehicle-treated no psychosocial stress group on the EPM, t(16) = 1.37, p > 
  82
0.05. Chronic treatment with 5 mg/kg, t(15) = 2.24, or 10 mg/kg, t(15) = 2.96, of 
amitriptyline in groups that were not psychosocially stressed and 5 mg/kg of 
amitriptyline, t(15) = 2.24, or 0.01 mg/kg of clonidine, t(16) = 2.16, in groups that were 
psychosocially stressed led to a significantly greater number of ambulations on the EPM, 
relative to the vehicle-treated no psychosocial stress group (p’s < 0.05). 
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Figure 15. Effects of chronic psychosocial stress and drug treatment on startle responses 
to the 90 dB auditory stimuli. The data are presented as mean startle response (Newtons) 
± SEM. * = p < 0.05 relative to the vehicle-treated no psychosocial stress group; β = p < 
0.05 relative to the vehicle-treated psychosocial stress group. 
Startle Response 
 90 dB Auditory Stimuli (see Figure 15). For the analysis of startle responses to the 
90 dB auditory stimuli, there was no significant main effect of psychosocial stress, 
F(1,102) = 3.40, p > 0.05. There was a significant main effect of drug, F(5,102) = 3.84, 
and the Psychosocial Stress x Drug interaction was significant, F(5,102) = 2.74 (p’s < 
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0.05). Post hoc tests indicated that the vehicle-treated psychosocial stress group exhibited 
significantly greater startle responses than the vehicle-treated no psychosocial stress 
group. Chronic treatment with 5 or 10 mg/kg of amitriptyline, 0.01 or 0.05 mg/kg of 
clonidine or 10 mg/kg of tianeptine in groups that were psychosocially stressed prevented 
the chronic stress-induced increase in startle response, as evidenced by the presence of 
significantly lower startle responses than the vehicle-treated psychosocial stress group or 
a lack of statistical significance relative to each of the group’s respective drug-treated no 
psychosocial stress group. 
 100 dB Auditory Stimuli (see Figure 16). For the analysis of startle responses to 
the 100 dB auditory stimuli, there was no significant main effect of drug, F(5,98) = 1.39, 
p > 0.05. There was a significant main effect of psychosocial stress, F(1,98) = 7.29, and 
the Psychosocial Stress x Drug interaction was significant, F(5,98) = 2.32 (p’s < 0.05). 
Post hoc tests indicated that the vehicle-treated psychosocial stress group exhibited 
significantly greater startle responses than the vehicle-treated no psychosocial stress 
group. Chronic treatment with 10 mg/kg of amitriptyline, 0.05 mg/kg of clonidine or 10 
mg/kg of tianeptine in groups that were psychosocially stressed prevented the chronic 
stress-induced increase in startle response, as evidenced by the presence of significantly 
lower startle responses than the vehicle-treated psychosocial stress group. The 
psychosocial stress groups treated with 5 mg/kg of amitriptyline or 0.01 mg/kg of 
clonidine did not exhibit significantly greater startle responses than the vehicle-treated 
control group; however, neither of the groups displayed significantly lower startle 
responses than the vehicle-treated psychosocial stress group, and the psychosocial stress 
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group treated with 5 mg/kg of amitriptyline demonstrated significantly greater startle 
responses than its respective drug-treated control group. 
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Figure 16. Effects of chronic psychosocial stress and drug treatment on startle responses 
to the 100 dB auditory stimuli. The data are presented as mean startle response (Newtons) 
± SEM. * = p < 0.05 relative to the vehicle-treated no psychosocial stress group; β = p < 
0.05 relative to the vehicle-treated psychosocial stress group; τ = p < 0.05 relative to the 
respective drug-treated no psychosocial stress group. 
 110 dB Auditory Stimuli (see Figure 17). For the analysis of startle responses to 
the 110 dB auditory stimuli, there were no significant main effects of psychosocial stress, 
F(1,100) = 1.42, or drug, F(5,100) = 1.49, and the Psychosocial Stress x Drug interaction 
was not significant, F(5,100) = 1.92 (p’s > 0.05). Planned comparisons were also 
conducted between groups that were predicted to differ a priori. The vehicle-treated 
psychosocial stress group tended to exhibit greater startle responses than the vehicle-
treated no psychosocial stress group, although this difference did not achieve statistical 
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significance, t(16) = 2.06, p = 0.056. Chronic treatment with 5 or 10 mg/kg of 
amitriptyline, 0.01 or 0.05 mg/kg of clonidine or 10 mg/kg of tianeptine in groups that 
were psychosocially stressed prevented this marginally significant, chronic stress-induced 
increase in startle response, as evidenced by the presence of significantly lower startle 
responses than the vehicle-treated psychosocial stress group or a lack of statistical 
significance relative to each of the group’s respective drug-treated no psychosocial stress 
group. 
Effects of Chronic Psychosocial Stress and Drug
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Figure 17. Effects of chronic psychosocial stress and drug treatment on startle responses 
to the 110 dB auditory stimuli. The data are presented as mean startle response (Newtons) 
± SEM. * = p < 0.056 relative to the vehicle-treated no psychosocial stress group; β = p < 
0.05 relative to the vehicle-treated psychosocial stress group. 
Novel Object Recognition 
 Habituation (see Figure 18). The analysis of locomotor activity in the open field 
during the 5-minute habituation phase revealed significant main effects of psychosocial 
stress, F(1,104) = 8.25, and drug, F(5,104) = 9.27 (p’s < 0.01). In general, rats that had 
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been psychosocially stressed traveled significantly less distance in the open field than rats 
that had not been psychosocially stressed. In addition, rats that were treated with 0.05 
mg/kg of clonidine, independent of psychosocial stress, traveled significantly less 
distance than all other groups. The Psychosocial Stress x Drug interaction was not 
significant, F(5,104) = 0.40, p > 0.05. 
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Figure 18. Effects of chronic psychosocial stress and drug treatment on locomotor 
activity during the 5-minute object recognition habituation period. The data are presented 
as mean distance traveled (m) ± SEM. # = p < 0.05 relative to all groups that were not 
treated with 0.05 mg/kg of clonidine. 
 The analysis of time that the rats spent in each area of the open field revealed no 
significant main effect of quadrant, F(3,309) = 1.26, psychosocial stress, F(1,103) = 0.54, 
or drug, F(5,103) = 1.00, and the Quadrant x Psychosocial Stress, F(3,309) = 2.54, 
Quadrant x Drug, F(15,309) = 1.33, Psychosocial Stress x Drug, F(5,103) = 0.43, and 
Quadrant x Psychosocial Stress x Drug, F(15,309) = 1.61, interactions were not 
significant (p’s > 0.05; data not shown). 
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Table 3 
Time (seconds ± SEM) Spent with Each Object during Object Recognition Training for 
all Groups in Experiment 3 
 
                    Paired t-test 
            Object 1                  Object 2            * = p < 0.05 
             
 
No Psychosocial Stress 
 
   Vehicle       10.54 ± 1.89    9.87 ± 1.19  t(9) = 0.03 
 
   5 mg/kg Amitriptyline       5.87 ± 0.88    6.26 ± 1.50  t(9) = 0.37 
 
   10 mg/kg Amitriptyline             9.03 ± 2.37    7.77 ± 1.29  t(9) = 0.46 
 
0.01 mg/kg Clonidine              11.85 ± 1.94    7.13 ± 0.85  t(9) = 2.78* 
 
0.05 mg/kg Clonidine                6.70 ± 1.89    9.55 ± 2.90  t(9) = 0.83 
 
Tianeptine                                  8.07 ± 1.50    9.76 ± 0.98  t(9) = 0.84 
 
Psychosocial Stress 
 
   Vehicle         6.31 ± 1.38   13.88 ± 5.32  t(9) = 1.34 
 
   5 mg/kg Amitriptyline       5.90 ± 0.91    9.46 ± 1.63  t(9) = 1.86 
 
   10 mg/kg Amitriptyline       8.41 ± 1.12    9.53 ± 2.82  t(9) = 0.36 
 
0.01 mg/kg Clonidine       7.80 ± 1.30    6.32 ± 0.87  t(9) = 1.02 
 
0.05 mg/kg Clonidine     12.20 ± 3.30    5.05 ± 1.91  t(9) = 1.55 
 
Tianeptine         7.40 ± 1.49    6.38 ± 0.96  t(9) = 0.93 
 
 
Training (see Table 3). Within-group comparisons indicated that most groups 
spent a comparable amount of time with each of the objects that were placed in the open 
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field during object recognition training (see Table 3), suggesting that no object preference 
effects were present. Only one group, the 0.01 mg/kg clonidine-treated no psychosocial 
stress group, spent more time with one object than the other. A between-groups 
comparison of the total amount of time spent with both objects during training revealed 
no significant main effects of psychosocial stress, F(1,103) = 0.27, or drug, F(5,103) = 
0.82, and the Psychosocial Stress x Drug interaction was not significant, F(5,103) = 0.99 
(p’s > 0.05; data not shown). These findings indicated that all groups spent a comparable 
amount of time with both objects during training. 
Effects of Chronic Psychosocial Stress and Drug
Treatment on Object Recognition Memory (5-Minute Trial)
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Figure 19. Effects of chronic psychosocial stress and drug treatment on object 
recognition memory during the entire 5-minute testing trial. The data are presented as 
mean ratio time ± SEM. 
Testing, 5-Minute Trial (see Figure 19). The analysis comparing the ratio times of 
all groups during the 5-minute object recognition testing session revealed no significant 
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main effects of psychosocial stress, F(1,87) = 0.80, or drug, F(5,87) = 0.52, and the 
Psychosocial Stress x Drug interaction was not significant, F(5,87) = 1.17 (p’s > 0.05). 
Effects of Chronic Psychosocial Stress and Drug
Treatment on Object Recognition Memory (First Minute)
VEH
R
at
io
 T
im
e
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0 No Psychosocial Stress
Psychosocial Stress
AMI-5 AMI-10 C-0.01 C-0.05 TIA-10  
Figure 20. Effects of chronic psychosocial stress and drug treatment on object 
recognition memory during the first minute of the testing trial. The data are presented as 
mean ratio time ± SEM. 
Testing, First Minute (see Figure 20). The analysis comparing the ratio times of 
all groups during the first minute of the testing trial revealed no significant main effects 
of psychosocial stress, F(1,68) = 1.56, or drug, F(5,68) = 1.34, and the Psychosocial 
Stress x Drug interaction was not significant, F(5,68) = 1.44 (p’s > 0.05). 
Corticosterone Levels (see Figure 21) 
 For the analysis of serum corticosterone levels, there was no significant main 
effect of psychosocial stress, F(1,97) = 0.02, p > 0.05. There was, however, a significant 
main effect of time point, F(2,194) = 487.29, p < 0.001. Post hoc tests indicated that rats 
demonstrated a significant increase in corticosterone levels following 20 minutes of acute 
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immobilization stress and that these levels declined, but remained significantly elevated 
relative to baseline, 1 hour later.  
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Figure 21. Effects of chronic psychosocial stress and drug treatment on serum 
corticosterone levels. The data are presented as mean serum corticosterone levels (µg/dL) 
± SEM. * = p < 0.05 relative to the respective no psychosocial stress group. 
There was also a significant main effect of drug, F(5,97) = 24.00, p < 0.001. Post 
hoc tests indicated that rats treated with 5 mg/kg of amitriptyline displayed significantly 
lower corticosterone levels than all other groups except for those treated with tianeptine 
or 10 mg/kg of amitriptyline. In addition, rats treated with 10 mg/kg of amitriptyline 
exhibited significantly lower corticosterone levels than all other groups, except for those 
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treated with 5 mg/kg of amitriptyline. Lastly, rats that were treated with tianeptine had 
significantly lower corticosterone levels than rats treated with vehicle or 0.01 mg/kg of 
clonidine. 
 The Time Point x Psychosocial Stress interaction was not significant, F(2,194) = 
0.34, p > 0.05. However, the Time Point x Drug interaction was significant, F(10,194) = 
8.91, p < 0.001. Post hoc tests indicated that both doses of amitriptyline, particularly the 
10 mg/kg dose, significantly blunted the acute immobilization-induced increase in serum 
corticosterone levels. Tianeptine had a similar effect, although not as pronounced as that 
of amitriptyline. The Psychosocial Stress x Drug, F(5,97) = 2.70, and Time Point x 
Psychosocial Stress x Drug, F(10,194) = 2.21, interactions were also significant (p’s < 
0.05). Post hoc tests revealed that psychosocially stressed rats treated with 10 mg/kg of 
amitriptyline exhibited significantly lower corticosterone levels than the controls treated 
with 10 mg/kg of amitriptyline an hour following 20 minutes of immobilization. In 
contrast, 0.01 mg/kg of clonidine prevented the reduction in corticosterone levels an hour 
following immobilization in the psychosocial stress group only. 
Cardiovascular Activity 
 Heart Rate (see Figure 22). For the analysis of heart rate, there were no 
significant main effects of psychosocial stress, F(1,81) = 0.05, or drug, F(5,81) = 1.15 
(p’s > 0.05). The Psychosocial Stress x Drug interaction was significant, F(5,81) = 3.99 
(p < 0.01). Post hoc tests indicated that the vehicle-treated psychosocial stress group 
exhibited significantly greater heart rate than the vehicle-treated no psychosocial stress 
group. Chronic treatment with 5 or 10 mg/kg of amitriptyline, 0.01 or 0.05 mg/kg of 
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clonidine or 10 mg/kg of tianeptine in groups that were psychosocially stressed prevented 
the chronic stress-induced increase in heart rate, as evidenced by the presence of 
significantly lower heart rate than the vehicle-treated psychosocial stress group or a lack 
of statistical significance relative to each of the group’s respective drug-treated no 
psychosocial stress group. 
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Figure 22. Effects of chronic psychosocial stress and drug treatment on heart rate. The 
data are presented as mean heart rate (bpm) ± SEM. * = p < 0.05 relative to the vehicle-
treated no psychosocial stress group; β = p < 0.05 relative to the vehicle-treated 
psychosocial stress group; τ = p < 0.05 relative to the respective drug-treated no 
psychosocial stress group. 
 Systolic Blood Pressure (see Figure 23). For the analysis of systolic blood 
pressure, there was no significant main effect of psychosocial stress, F(1,86) = 1.90, p > 
0.05. There was a significant main effect of drug, F(5,86) = 11.80, and the Psychosocial 
Stress x Drug interaction was significant, F(5,86) = 3.60 (p’s < 0.01). Post hoc tests 
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indicated that the vehicle-treated psychosocial stress group had significantly higher 
systolic blood pressure than the vehicle-treated no psychosocial stress group. Chronic 
treatment with 5 or 10 mg/kg of amitriptyline in groups that were not psychosocially 
stressed led to significantly greater systolic blood pressure than the vehicle-treated no 
psychosocial stress group. Chronic treatment with 5 or 10 mg/kg of amitriptyline, 0.01 or 
0.05 mg/kg of clonidine or 10 mg/kg of tianeptine in groups that were psychosocially 
stressed prevented the chronic stress-induced increase in systolic blood pressure, as 
evidenced by the presence of significantly lower systolic blood pressure than the vehicle-
treated psychosocial stress group or a lack of statistical significance relative to each of the 
group’s respective drug-treated no psychosocial stress group. 
Effects of Chronic Psychosocial Stress and Drug
Treatment on Systolic Blood Pressure
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Figure 23. Effects of chronic psychosocial stress and drug treatment on systolic blood 
pressure. The data are presented as mean systolic blood pressure (mm Hg) ± SEM. * = p 
< 0.05 relative to the vehicle-treated no psychosocial stress group; β = p < 0.05 relative to 
the vehicle-treated psychosocial stress group. 
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Effects of Chronic Psychosocial Stress and Drug
Treatment on Diastolic Blood Pressure
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Figure 24. Effects of chronic psychosocial stress and drug treatment on diastolic blood 
pressure. The data are presented as mean diastolic blood pressure (mm Hg) ± SEM. * = p 
< 0.05 relative to the vehicle-treated no psychosocial stress group; β = p < 0.05 relative to 
the vehicle-treated psychosocial stress group; τ = p < 0.05 relative to the respective drug-
treated no psychosocial stress group. 
Diastolic Blood Pressure (see Figure 24). For the analysis of diastolic blood 
pressure, there were significant main effects of psychosocial stress, F(1,86) = 9.67, and 
drug, F(5,86) = 21.78, and the Psychosocial Stress x Drug interaction was significant, 
F(5,86) = 6.11 (p’s < 0.01). Post hoc tests indicated that the vehicle-treated psychosocial 
stress group had significantly higher diastolic blood pressure than the vehicle-treated no 
psychosocial stress group. Additionally, chronic treatment with 5 or 10 mg/kg of 
amitriptyline in groups that were not psychosocially stressed led to significantly greater 
diastolic blood pressure than the vehicle-treated no psychosocial stress group. Chronic 
treatment with 10 mg/kg of amitriptyline, 0.01 or 0.05 mg/kg of clonidine or 10 mg/kg of 
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tianeptine in psychosocially stressed rats led to significantly lower diastolic blood 
pressure than the vehicle-treated psychosocial stress group. However, psychosocially 
stressed rats that were treated with 10 mg/kg of amitriptyline still displayed significantly 
greater diastolic blood pressure than the vehicle-treated no psychosocial stress group, and 
psychosocially stressed rats that were treated with 0.01 mg/kg of clonidine still exhibited 
significantly greater diastolic blood pressure than its respective drug-treated no 
psychosocial stress group. 
Growth Rates (see Figure 25) 
 For the analysis of growth rate, there was no significant main effect of 
psychosocial stress, F(1,100) = 0.61, p > 0.05. There was a significant main effect of 
drug, F(5,100) = 11.78, and the Psychosocial Stress x Drug interaction was significant, 
F(5,100) = 13.42 (p’s < 0.001). Post hoc tests indicated that the vehicle-treated 
psychosocial stress group had a significantly lower growth rate than the vehicle-treated 
no psychosocial stress group. Additionally, chronic treatment with 5 or 10 mg/kg of 
amitriptyline or 0.05 mg/kg of clonidine in groups that were not psychosocially stressed 
led to significantly lower growth rates than the vehicle-treated no psychosocial stress 
group. Chronic treatment with 5 or 10 mg/kg of amitriptyline, 0.01 mg/kg of clonidine or 
10 mg/kg of tianeptine in groups that were psychosocially stressed prevented the chronic 
stress-induced reduction of growth rate, as evidenced by the presence of significantly 
greater growth rates than the vehicle-treated psychosocial stress group or a lack of 
statistical significance relative to each of the group’s respective drug-treated no 
psychosocial stress group. However, the psychosocial stress group treated with 5 mg/kg 
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of amitriptyline still exhibited a significantly lower growth rate than the vehicle-treated 
no psychosocial stress group. 
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Figure 25. Effects of chronic psychosocial stress and drug treatment on growth rate. The 
data are presented as mean growth rate (g/day) ± SEM. * = p < 0.05 relative to the 
vehicle-treated no psychosocial stress group; # = p < 0.05 relative to all other groups; β = 
p < 0.05 relative to the vehicle-treated psychosocial stress group; τ = p < 0.05 relative to 
the respective drug-treated no psychosocial stress group. 
Adrenal Gland Weights (see Figure 26) 
For the analysis of adrenal gland weights, there was no significant main effect of 
psychosocial stress, F(1,97) = 0.89, p > 0.05. There was a significant main effect of drug, 
F(5,97) = 10.53, and the Psychosocial Stress x Drug interaction was significant, F(5,97) 
= 3.26 (p’s < 0.01). Post hoc tests indicated that the vehicle-treated psychosocial stress 
group had significantly larger adrenal glands than the vehicle-treated no psychosocial 
stress group. Additionally, chronic treatment with 10 mg/kg of amitriptyline or 0.05 
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mg/kg of clonidine in groups that were not psychosocially stressed led to significantly 
larger adrenal glands than the vehicle-treated no psychosocial stress group. Chronic 
treatment with 5 mg/kg of amitriptyline, 0.01 or 0.05 mg/kg of clonidine or 10 mg/kg of 
tianeptine in groups that were psychosocially stressed prevented the chronic stress-
induced hypertrophy of the adrenal glands, as evidenced by a lack of a statistically 
significant increase in adrenal gland weight relative to each of the group’s respective 
drug-treated no psychosocial stress group. Interestingly, the psychosocial stress group 
treated with 10 mg/kg of amitriptyline exhibited significantly lower adrenal gland 
weights than its respective drug-treated control group. 
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Figure 26. Effects of chronic psychosocial stress and drug treatment on adrenal gland 
weight. The data are presented as mean adrenal gland weight (mg/100 g b.w.) ± SEM. * = 
p < 0.05 relative to the vehicle-treated no psychosocial stress group; τ = p < 0.05 relative 
to the respective drug-treated no psychosocial stress group. 
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Effects of Chronic Psychosocial Stress and Drug
Treatment on Thymus Weight
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Figure 27. Effects of chronic psychosocial stress and drug treatment on thymus weight. 
The data are presented as mean thymus weight (mg/100 g b.w.) ± SEM. * = p < 0.05 
relative to the vehicle-treated no psychosocial stress group; β = p < 0.05 relative to the 
vehicle-treated psychosocial stress group; τ = p < 0.05 relative to the respective drug-
treated no psychosocial stress group. 
Thymus Weights (see Figure 27) 
 For the analysis of thymus weights, there was no significant main effect of drug, 
F(5,91) = 1.42, p > 0.05. There was a significant main effect of psychosocial stress, 
F(1,91) = 17.12, and the Psychosocial Stress x Drug interaction was significant, F(5,91) 
= 6.49 (p’s < 0.001). Post hoc analyses indicated that the vehicle-treated psychosocial 
stress group tended to exhibit smaller thymuses than the vehicle-treated no psychosocial 
stress group, yet this difference did not reach statistical significance. Additionally, 
chronic treatment with 10 mg/kg of amitriptyline in groups that were not psychosocially 
stressed led to significantly smaller thymuses than the vehicle-treated no psychosocial 
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stress group. Chronic treatment with 5 mg/kg of amitriptyline or 0.01 or 0.05 mg/kg of 
clonidine in groups that were psychosocially stressed led to significantly smaller 
thymuses than the vehicle-treated no psychosocial stress group. Chronic treatment with 
10 mg/kg of amitriptyline or 10 mg/kg of tianeptine prevented the slight decrease in 
thymus weight induced by chronic psychosocial stress, as evidenced by the presence of 
significantly greater thymus weights than the vehicle-treated psychosocial stress group 
and/or a lack of a statistically significant decreases in thymus weight relative to each of 
the group’s respective drug-treated no psychosocial stress group. 
Discussion of Findings 
Consistent with our previous work (Zoladz et al., 2008), vehicle-treated rats that 
were exposed to chronic psychosocial stress, composed of two acute predator exposures 
and daily social instability, exhibited reduced growth rate, greater adrenal gland weight, 
heightened anxiety, an exaggerated startle response, greater blood pressure reactivity to 
an acute stressor and intact memories for the context and cue that were associated with 
the two cat exposures. In contrast to our prior findings, however, the vehicle-treated 
psychosocially stressed rats did not display a significant impairment of object recognition 
memory or significantly reduced thymus weights, relative to vehicle-treated control (i.e., 
unstressed) animals. Nonetheless, it is important to note that these effects were in the 
hypothesized direction. That is to say, vehicle-treated psychosocially stressed rats spent 
less time with the novel object and had smaller thymuses, albeit both non-significantly, 
than vehicle-treated control animals. One possible explanation for the lack of statistical 
significance is that the chronic injections in the present study acted as a chronic mild 
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stressor in control rats, which added considerable variability to their data on these 
measures. Studies in rodents have reported that chronic mild stress in the form of 
repeated injections can significantly alter the morphology of neurons in the prefrontal 
cortex (Weaver et al., 2005; Wellman, 2001). Therefore, chronic injections in the present 
study could have adversely influenced rat physiology and behavior. 
Another finding that is in conflict with our previous work is that the vehicle-
treated psychosocially stressed rats demonstrated significantly greater HR than vehicle-
treated control rats following exposure to an acute stressor on the final day of testing. 
Previously, we reported that the present psychosocial stress paradigm resulted in 
significantly lower HR, compared to controls, following acute stress on the final day of 
testing (Zoladz et al., 2008). Nevertheless, the HR exhibited by psychosocially stressed 
rats in the present study (409.85 ± 7.30 bpm) was very similar to the HR exhibited by 
psychosocially stressed rats in our previous work (413.25 ± 9.93 bpm). What appears to 
be the cause of the inconsistent effects between the findings of the present study and 
those of our previous work is the HR exhibited by the control animals in each case. 
Vehicle-treated control rats displayed much lower HR in the present study (385.61 ± 8.11 
bpm) than that which was displayed by controls in the prior study (462.88 ± 11.43 bpm). 
In theory, vehicle-treated controls could have exhibited much lower HR in the present 
study because the chronic mild stress of repeated injections protected them against 
responding as strongly to the acute stressor as the more naïve animals that were utilized 
in our prior work. 
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Amitriptyline 
Both doses of the tricyclic antidepressant amitriptyline blocked the expression of 
fear-related behaviors in psychosocially stressed rats in response to the context and cue 
that were paired with the two cat exposures. These fear responses served as a measure of 
memory for the acute stress experiences and rat analogs of a traumatic memory in 
humans. As traumatic memories are a source of psychological distress in people with 
PTSD, these findings suggest that amitriptyline could serve to effectively reduce the 
strength of traumatic memories and consequentially diminish the intrusion and re-
experiencing symptoms endured by PTSD patients. One caveat to this interpretation, 
however, is that extensive work has reported amitriptyline-induced memory impairments 
in both humans (Kerr et al., 1996; Liljequist et al., 1978; Mattila et al., 1978; Spring et 
al., 1992; van Laar et al., 2002) and rodents (Everss et al., 2005; Gonzalez-Pardo et al., 
2008; Kumar & Kulkarni, 1996), findings that may be related to the drug’s anti-
cholinergic side effects (Pavone et al., 1997). Therefore, the attenuation of contextual and 
cue fear conditioning in psychosocially stressed rats treated with amitriptyline could 
simply be due to its amnestic side effects, rather than a specific amelioration of the 
chronic stress-induced behavioral sequelae. On the other hand, studies reporting 
amitriptyline-induced memory impairments have administered the drug prior to learning. 
In the present experiment, amitriptyline treatment did not begin until 24 hours after the 
first pairing of the context and cue with the cat exposure. Therefore, a more likely 
explanation of the present findings is that amitriptyline blunted the augmentation of 
contextual and cue fear conditioning in psychosocially stressed rats that occurred in 
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response to the second cat exposure on Day 11 of the paradigm. Another possible 
explanation of these findings is that amitriptyline increased general locomotor activity, 
thus reducing overall immobility. Amitriptyline-treated control animals did display a 
significantly greater amount of motor activity on the EPM than vehicle-treated animals, 
but the same effect was not observed during the open field habituation period on the 
following day. In addition, the finding that amitriptyline, at least at the higher dose, led to 
significantly fewer fecal boli deposits in psychosocially stressed rats during the context 
test supports the notion that the observed effects were not by-products of drug-induced 
changes in locomotor activity. 
Both doses of amitriptyline were at least partially effective in preventing the 
chronic stress-induced increase in startle responses, but only the 10 mg/kg dose of 
amitriptyline blocked the effects of chronic psychosocial stress on anxiety, as measured 
by rat behavior on the EPM. These findings are consistent with other work in the rodent 
literature reporting that amitriptyline exerts anxiolytic effects in control animals (Bodnoff 
et al., 1988; Zajaczkowski & Gorka, 1993) and blocks stress-induced increases in 
anxiety-like behavior and startle (Orsetti et al., 2007; Poltyrev & Weinstock, 2004; West 
& Weiss, 2005). Research in humans has also shown that amitriptyline significantly 
blunts startle responses (Phillips et al., 2000). Thus, amitriptyline appears to have potent 
anxiolytic effects that may effectively ameliorate the hyperarousal symptoms related to 
PTSD. 
Amitriptyline also led to significantly lower serum corticosterone levels in rats 
and was particularly effective in blunting the immobilization-induced increase in these 
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levels on the final day of testing. This finding is consistent with several studies in the 
rodent literature reporting that chronic amitriptyline administration results in significantly 
reduced basal and stress-induced levels of ACTH and corticosterone in rats (Barden, 
1999; Reul et al., 1993). Amitriptyline appears to accomplish these effects by enhancing 
the negative feedback inhibition of the HPA axis. Investigators have shown that chronic 
amitriptyline administration leads to an up-regulation of glucocorticoid receptor 
expression and enhanced glucocorticoid receptor binding in several brain regions 
(Barden, 1999; Pariante & Miller, 2001; Przegalinski & Budziszewska, 1993; Reul et al., 
1993). Interestingly, in the present study, there was an additive effect of amitriptyline and 
psychosocial stress on the recovery of serum corticosterone levels following 
immobilization. Psychosocially stressed rats that were treated with amitriptyline, 
particularly the 10 mg/kg dose, exhibited significantly lower corticosterone levels at the 
80 minute time point than amitriptyline-treated controls. In theory, chronic amitriptyline 
and psychosocial stress synergistically facilitated the production of enhanced negative 
feedback of the HPA axis, which led to a more rapid recovery of stress-induced serum 
corticosterone levels in these rats. 
Despite the positive effects of amitriptyline on the chronic stress-induced 
physiological and behavioral sequelae in rats, there were adverse side effects of the drug 
that should be considered. For instance, chronic amitriptyline treatment resulted in 
significantly greater stress-induced increases in systolic and diastolic blood pressure than 
vehicle. Most work in both humans and rodents has reported that chronic amitriptyline 
treatment results in increased heart rate, postural hypotension and increased 
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cardiotoxicity (Balcioglu et al., 1991; Fiedler et al., 1986; Hong et al., 1974; Joubert et 
al., 1985; Kopera, 1978; Low & Opfer-Gehrking, 1992; Yokota et al., 1987). The results 
presented here are novel in that they reveal that chronic amitriptyline treatment has 
unfavorable effects on stress-induced changes in cardiovascular activity. 
Amitriptyline also led to a significant reduction in growth rate in rats, particularly 
at the higher dose of the drug. Although counterintuitive, 10 mg/kg of amitriptyline 
significantly reduced growth rates in the control rats, an effect that was reversed by 
exposure to chronic psychosocial stress. Similar findings were observed with regards to 
adrenal gland and thymus weights. The higher dose of amitriptyline led to significantly 
larger adrenal glands and significantly smaller thymuses than vehicle in control animals, 
and exposure to chronic psychosocial stress significantly blunted each of these effects. 
These findings suggest that, in the present experiment, there was an interaction between 
amitriptyline treatment and chronic psychosocial stress, in which the physiological 
consequences of the drug were more prominent in those rats that were unstressed. 
Another finding of interest is that upon dissection of these animals, there were a large 
number of adhesions observed on the internal organs, such as the liver, intestines and 
spleen, and the mortality rate for rats chronically treated with amitriptyline (3 out of 40, 
or 7.5%) was greater than the mortality rates for rats chronically treated with clonidine (0 
out of 40, or 0%) or tianeptine (0 out of 20, or 0%). Thus, despite its ability to prevent the 
effects of psychosocial stress on anxiety-like behavior and startle and the development of 
a powerful traumatic memory, the adverse physiological side effects of amitriptyline 
could be a major limitation to its use in the treatment of people with PTSD. 
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Clonidine 
Neither dose of clonidine prevented the expression of fear-related behaviors in 
psychosocially stressed rats in response to the context and cue that were paired with the 
two cat exposures. Although psychosocially stressed rats chronically treated with 0.01 
mg/kg of clonidine did not display significantly greater immobility during the context test 
than vehicle-treated control rats (p = 0.15), the within-drug contrast (i.e., clonidine-
treated psychosocial stress group vs. clonidine-treated controls) was marginally 
significant (p = 0.06). These findings should be interpreted cautiously, however. Since 
clonidine is an α2-adrenergic receptor agonist and significantly reduces central 
noradrenergic activity, it can have sedative side effects at higher doses (Millan et al., 
2000). In the present study, the higher dose of clonidine did result in a significant 
reduction of locomotor activity in the open field during OR habituation. On the other 
hand, clonidine had no significant effects on motor activity on the EPM, and 
psychosocially stressed rats treated with 0.05 mg/kg of clonidine still produced 
significantly more fecal boli during the context test than the no psychosocial stress group 
treated with 0.05 mg/kg of clonidine. One study also reported that clonidine’s sedative 
effects are not observed until doses greater than 0.1 mg/kg are employed (Millan et al., 
2000). Therefore, the data support the notion that clonidine is ineffective in blunting the 
expression of a traumatic memory in rats. 
Both doses of clonidine, and in particular the 0.05 mg/kg dose, blocked the effects 
of psychosocial stress on anxiety and startle, as well as cardiovascular responses to acute 
immobilization. However, the higher dose of clonidine led to a significantly reduced 
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growth rate in controls, which was exacerbated by chronic psychosocial stress. It also 
resulted in significantly increased adrenal gland weights in control animals. Lastly, 
neither dose of clonidine prevented the chronic psychosocial stress-induced decrease in 
thymus weights. Thus, despite its amelioration of the chronic stress-induced behavioral 
and cardiovascular sequelae, clonidine was ineffective at preventing the remaining 
physiological changes induced by our laboratory’s stress regimen. 
Since people with PTSD have significantly elevated baseline NE levels and 
demonstrate adverse reactions (e.g., panic attacks, flashbacks) to agents that increase 
these levels (e.g., yohimbine), pharmacological agents that reduce noradrenergic activity 
could be effective treatments for people with PTSD (Boehnlein & Kinzie, 2007; Strawn 
& Geracioti, 2008). Some studies have reported that propranolol, a β-adrenergic receptor 
antagonist, may be an effective treatment for PTSD if administered immediately after the 
traumatic event or after the re-experiencing of a traumatic event (Pitman et al., 2002; 
Taylor & Cahill, 2002; Vaiva et al., 2003). Other work has found that prazosin, an α1-
adrenergic receptor antagonist, reduces hyperarousal symptoms, intrusive thoughts, 
recurrent distressing dreams and sleep disturbances in PTSD (Brkanac et al., 2003; 
Peskind et al., 2003; Raskind et al., 2002; Raskind et al., 2003; Taylor & Raskind, 2002; 
Taylor et al., 2006). However, despite the case of clonidine’s use in treating PTSD, no 
randomized, placebo-controlled studies of clonidine’s effects on PTSD have been 
performed. The present findings suggest that clonidine may be particularly effective in 
ameliorating the anxiety, hyperarousal (e.g., exaggerated startle response) and 
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cardiovascular components of PTSD. They also highlight the need for clinical research 
addressing the effectiveness of clonidine as a treatment for the disorder. 
Tianeptine 
In the present experiment, tianeptine was the only pharmacological agent to 
prevent the effects of chronic psychosocial stress on all physiological and behavioral 
measures. Tianeptine completely blocked the expression of fear-related behaviors in 
psychosocially stressed rats in response to the context and cue that were paired with the 
two cat exposures. It also prevented the effects of psychosocial stress on anxiety, startle, 
cardiovascular reactivity to an acute stressor, growth rate, adrenal gland weight and 
thymus weight. These findings suggest that tianeptine could be a premier treatment for 
PTSD. 
The present findings may be related to previous work reporting that chronic, but 
not acute, administration of tianeptine significantly impairs the acquisition and 
expression of conditioned fear in rats (Burghardt et al., 2004). These effects appear to be 
more related to the anxiolytic, rather than memory-impairing, properties of tianeptine, as 
numerous studies have shown that tianeptine treatment enhances, rather than impairs, 
hippocampus-dependent learning and memory (Jaffard et al., 1991; Meneses, 2002; 
Munoz et al., 2005). Interestingly, the same investigators reporting tianeptine’s effects on 
fear conditioning found that acute administration of the SSRI citalopram enhanced the 
acquisition of auditory fear conditioning, while chronic treatment with the drug impaired 
the acquisition and expression of conditioned fear. Thus, tianeptine appears to 
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demonstrate long-term anxiolytic effects that are similar to SSRIs, without having the 
acute anxiogenic effects typically found with these agents. 
In the present study, tianeptine significantly attenuated the immobilization-
induced increase in serum corticosterone levels. This finding is consistent with previous 
work indicating that tianeptine reduces stress-induced activation of the HPA axis 
(Delbende et al., 1991). Additionally, tianeptine, relative to vehicle, resulted in 
significantly lower systolic BP in control animals following 20 minutes of 
immobilization. Few studies have examined the effects of tianeptine on cardiovascular 
activity, but those that have investigated the phenomenon have typically reported no 
effects of the drug on HR or BP (Juvent et al., 1990; Lasnier et al., 1991). On the other 
hand, one study did report that tianeptine resulted in significantly reduced diastolic BP 
(Lechin et al., 2006). The effects of tianeptine on cardiovascular activity in the present 
study are not likely due to acute effects of the drug. Our laboratory has preliminary data 
indicating that tianeptine does not prevent an acute stress-induced increase in BP 
(unpublished findings). In this particular study, rats were treated with 10 mg/kg of 
tianeptine or vehicle 30 minutes prior to a 15-minute exposure to predator stress. Animals 
that were exposed to the cat for 15 minutes exhibited significant elevations of systolic 
and diastolic BP, regardless of whether or not they had received tianeptine. In other 
words, tianeptine was ineffective in preventing the acute stress-induced increase in blood 
pressure. Thus, the ability of tianeptine to prevent the effects of chronic psychosocial 
stress on cardiovascular reactivity to an acute stressor is most likely attributable to its 
effects on general anxiety. Although speculative, tianeptine theoretically enabled the 
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psychosocially stressed rats to cope better with the daily mild stress of social instability 
and also with future acute stressors, such as the 20-minute exposure to immobilization on 
the final day of testing. 
Chronic treatment with tianeptine also prevented the effects of chronic 
psychosocial stress on all of the other physiological endpoints, including growth rate, 
adrenal gland weight and thymus weight. Previous work in rodents has reported that 
tianeptine had no effect on the chronic stress-induced adrenal gland hypertrophy or 
reduction in growth rate (Magarinos et al., 1999; Watanabe et al., 1992b). However, these 
studies utilized a different stressor (restraint stress, 6 hours per day for 21 days) than that 
which was employed here, which could account for the apparent discrepancies. The 
finding that tianeptine prevented any chronic stress-induced atrophy of the thymus is 
consistent with work demonstrating that tianeptine significantly interacts with the 
immune system. For instance, several studies have shown that tianeptine prevents the 
adverse effects of cytokines on brain biochemistry and peripheral measures of 
inflammation in the rat (Castanon et al., 2001; Plaisant et al., 2003b; Plaisant et al., 
2003a). Thus, an interesting avenue of future research would involve exploring the 
contribution of tianeptine-immune system interactions to its anti-stress effects on rat 
physiology and behavior. 
Early studies on tianeptine’s mechanism of action showed that the drug led to 
significantly lower extracellular levels of serotonin, a finding that was hypothesized to 
result from enhanced serotonin reuptake (Fattaccini et al., 1990; Labrid et al., 1992; 
Mennini et al., 1987; Mocaer et al., 1988). However, tianeptine’s effects on the 
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serotonergic system may be an indirect consequence of the drug’s influences on an 
alternative neurotransmitter system because later studies failed to show any direct effects 
of tianeptine on serotonergic neurotransmission (Pineyro et al., 1995a; Pineyro et al., 
1995b). Additionally, research has shown that tianeptine does not alter the density or 
affinity of any serotonin receptor subtype, and tianeptine’s affinity for the serotonin 
transporter is very low (Kato & Weitsch, 1988; Svenningsson et al., 2007). Some have 
also contested the validity of the original studies on tianeptine’s mechanism of action 
based on technical limitations that were present at the time (Malagie et al., 2000). 
Recent work has suggested that its therapeutic effects may be more associated 
with modulation of the glutamatergic system (Brink et al., 2006; Kasper & McEwen, 
2008; Zoladz et al., in press). Extensive work has implicated hyperactivity of the 
glutamatergic system in the deleterious effects of stress on brain structure and function 
(Bagley & Moghaddam, 1997; Bartanusz et al., 1995; Joels et al., 2003; Kim et al., 1996; 
Krugers et al., 1993; Lowy et al., 1993; Lowy et al., 1995; Magarinos & McEwen, 1995; 
McEwen et al., 2002; Moghaddam, 1993; Park et al., 2004; Reznikov et al., 2007; Yang 
et al., 2005), and tianeptine appears to protect brain regions that are highly susceptible to 
stress, such as the hippocampus and prefrontal cortex, from the deleterious effects of 
stress by normalizing the stress-induced modulation of glutamatergic activity. For 
instance, tianeptine has been shown to prevent stress-induced increases in NMDA 
channel currents, as well as the ratio of NMDA:non-NMDA receptor currents, in the CA3 
region of the hippocampus (Kole et al., 2002). It also inhibits the acute stress-induced 
increase in extracellular levels of glutamate in the basolateral amygdala (Reznikov et al., 
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2007). In addition to its glutamatergic modulation, tianeptine reduces the expression of 
CRH mRNA in the amygdala and the bed nucleus of the stria terminalis, a brain region 
that is highly innervated by amygdala fibers (Kim et al., 2006). CRH neurotransmission 
in both of these regions has been implicated in the expression of anxiety-like behaviors 
(Holsboer, 1999; Strohle & Holsboer, 2003). Thus, tianeptine’s effects on glutamatergic 
and CRH activity in these various brain regions may play an important role in its ability 
to reverse the effects of chronic stress on the expression of anxiety-like behaviors. 
Uzbay and colleagues found that tianeptine reduced the intensity (Ceyhan et al., 
2005) and delayed the onset (Uzbay et al., 2007) of pentylenetetrazole-induced seizures 
in rodents. The latter effect was blocked by the administration of caffeine, a nonspecific 
adenosine receptor antagonist, and 8-cyclopentyl-1,3-dipropylxanthine, an A1 receptor-
specific antagonist. However, administration of the A2 receptor-specific antagonist, 8-(3-
chlorostyryl) caffeine, had no effect on the tianeptine-induced delay of seizure onset, 
suggesting that tianeptine’s anticonvulsant properties are dependent upon activation of A1 
adenosine receptors. Since previous work has shown that activation of A1 adenosine 
receptors has anxiolytic effects (Florio et al., 1998; Jain et al., 1995; Prediger et al., 2004; 
Prediger et al., 2006), this specific category of adenosinergic receptors could be 
responsible, at least in part, for tianeptine’s anxiolytic effects in rodents (Burghardt et al., 
2004; File et al., 1993; File & Mabbutt, 1991; Pillai et al., 2004) and in the depressed 
population (Defrance et al., 1988; Wilde & Benfield, 1995). 
In sum, tianeptine was the only pharmacological agent to prevent the effects of 
chronic psychosocial stress on all physiological and behavioral measures. Extensive 
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preclinical research has shown that exposure to stress results in a significant increase in 
glutamate activity, and tianeptine’s antidepressant properties have been attributed to its 
ability to normalize this hyperactivity of the glutamatergic system. It is therefore likely 
that at least some of the behavioral changes observed in our animal model of PTSD are a 
result of stress-induced alterations in glutamate function. Furthermore, it is possible that 
abnormalities in glutamatergic function also underlie the pathology of PTSD (Chambers 
et al., 1999; Nair & Singh, 2008; Reul & Nutt, 2008), in which case tianeptine would 
certainly be an optimal choice to treat individuals with the disorder. 
Limitations and Future Research 
 The design of this experiment does not distinguish between the acute and chronic 
effects of amitriptyline, clonidine and tianeptine on rat physiology and behavior. Rats 
were administered these pharmacological agents not only on Days 2-31 of the chronic 
psychosocial stress paradigm, but throughout behavioral testing as well. The drug 
administration continued during behavioral testing to prevent withdrawal effects from 
influencing rat behavior. Importantly, our laboratory does have preliminary data 
indicating that chronic tianeptine treatment prevents the effects of the current stress 
regimen on all physiological and behavioral measures even if it is administered only 
during Days 2-31 and discontinued at the commencement of behavioral testing. 
Nevertheless, future work should examine the effects of the present compounds on the 
stress-induced changes in rat physiology and behavior when they are administered during 
the chronic stress period only and during behavioral testing only. 
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Summary and Application to Pharmacotherapy for Post-Traumatic Stress Disorder 
A subset of people with PTSD show significant improvement in their symptoms 
following treatment with SSRIs (Asnis et al., 2004; Davidson, 2003; Davis et al., 2006; 
Hidalgo & Davidson, 2000; Ipser et al., 2006; Stein et al., 2006). However, SSRIs tend to 
blunt only the depressive components of PTSD, while having little effect on the memory- 
and anxiety-related symptoms of the disorder (Asnis et al., 2004; Boehnlein & Kinzie, 
2007; Brady et al., 2000; Van der Kolk et al., 1994). In addition, some forms of PTSD, 
such as combat-related PTSD, are incredibly resistant to SSRI treatment (Jakovljevic et 
al., 2003; Rothbaum et al., 2008; Stein et al., 2002). These agents also have anxiogenic 
effects early in the treatment phase and only exert their antidepressant effects after a 
substantial delay (Browning et al., 2007; Burghardt et al., 2004; Humble & Wistedt, 
1992). Thus, there is an urgent need to develop alternative pharmacotherapeutic 
interventions for the treatment of PTSD. 
The present experiment examined the ability of amitriptyline, clonidine and 
tianeptine to prevent the development of PTSD-like sequelae in rats exposed to chronic 
psychosocial stress. The tricyclic antidepressant amitriptyline was effective in reducing 
the memories for the context and cue that were associated with the acute cat exposures, 
and it ameliorated the stress-induced increase in anxiety and startle. However, this agent 
had adverse side effects, as it significantly increased cardiovascular reactivity in control 
animals and led to adverse physiological reactions, including reduced growth rate, 
increase adrenal gland weight and internal adhesions. Thus, despite its positive effects, 
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the adverse physiological side effects of amitriptyline could be a major limitation to its 
use in the treatment of people with PTSD. 
Clonidine also blocked the effects of chronic psychosocial stress on anxiety and 
startle, but in contrast to amitriptyline, prevented the stress-induced changes in 
cardiovascular reactivity to an acute stressor as well. However, it did not prevent the 
expression of fear-related behaviors in psychosocially stressed rats upon exposed to the 
context and cue that were paired with the acute cat exposures. Clonidine also had some 
adverse side effects of its own, including a significant reduction in growth rate and a 
significant increase in adrenal gland weight. Thus, clonidine may be particularly effective 
in ameliorating the anxiety, hyperarousal (e.g., exaggerated startle response) and 
cardiovascular components of PTSD, but have little effect on the strength of a traumatic 
memory. 
Lastly, tianeptine was the only pharmacological agent to prevent the effects of 
chronic psychosocial stress on all physiological and behavioral endpoints. It completely 
blocked the expression of fear-related behaviors in psychosocially stressed rats in 
response to the context and cue that were paired with the two cat exposures and 
prevented the effects of psychosocial stress on anxiety, startle, cardiovascular reactivity 
to an acute stressor, growth rate, adrenal gland weight and thymus weight. Collectively, 
these findings illustrate the differential effectiveness of these three treatments in blocking 
the PTSD-like sequelae in rats, and the profile of tianeptine as the most effective agent 
provides guidance for pharmacotherapeutic approaches in the treatment of individuals 
suffering from PTSD. 
  115
 
 
Chapter Five: Experiment Four 
Temporal Dynamics of the Physiological and Behavioral Sequelae Induced by Chronic 
Psychosocial Stress 
 People with chronic PTSD display physiological and behavioral symptoms of the 
disorder years after the original trauma took place. These symptoms develop acutely after 
experiencing the trauma and progressively worsen to eventually produce full-blown 
PTSD. A valid animal model of PTSD should be able to demonstrate PTSD-like effects 
on physiology and behavior long after the initial stress exposure. Therefore, the purpose 
of Experiment Four was to examine whether or not the stress regimen employed in the 
previous experiments would produce physiological and behavioral changes in rats that 
would be present for a longer period of time. It was also designed to explore the 
contribution of an additional, third, acute stress session and irregular, rather than just 
daily, social instability to the maintenance of the PTSD-like effects for this extended 
period of time. 
Methods 
Rats 
The same weight range and strain of rats, as well as the housing conditions, that 
were employed in Experiments One, Two and Three were used in the present experiment. 
Upon arrival, all rats were given 1 week to acclimate to the housing room environment 
and cage changing procedures before any experimental manipulations took place. All 
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procedures were approved by the Institutional Animal Care and Use Committee at the 
University of South Florida. 
Psychosocial Stress Procedure 
Following the 1-week acclimation phase, rats were brought to the laboratory and 
then randomly assigned to one of four groups (see Figure 28; N = 10 rats per group). In 
contrast to Experiments One through Three, each of the four groups was exposed to three, 
as opposed to two, acute stress sessions. During each stress session, as in Experiment 
Three, the rats were exposed to a chamber for 3 minutes (with a 30-second tone presented 
at the end of the 3-minute period). Then, the rats were either immobilized and exposed to 
a cat or placed back in their home cages for 1 hour. As before, the first stress session 
occurred during the light cycle, between 0800 and 1300 hours, while the second stress 
session occurred 10 days later during the dark cycle, between 1900 and 2100 hours. The 
third and final stress session took place 3 weeks following the second stress session 
during the light cycle, between 0800 and 1300 hours. 
Of the four groups in the present experiment, three were exposed to chronic 
psychosocial stress and one was a control, no psychosocial stress, group. Each of the 
three psychosocial stress groups was exposed to the same manipulations until the third 
stress session. That is, these groups were exposed to the chamber followed by 
immobilization plus cat exposure during the first and second stress sessions, as well as 
daily randomized housing throughout the 31-day period leading up to the third stress 
session. During the third stress session (Day 32), rats in “psychosocial stress group 1” 
were exposed to the chamber for 3 minutes followed by a 1-hour exposure to their home 
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cages. Rats in “psychosocial stress group 2” and “psychosocial stress group 3” were 
exposed to the chamber for 3 minutes followed by 1 hour of immobilization during cat 
exposure. These procedures are illustrated in Figure 28. 
 
Figure 28. Experimental groups in Experiment 4. 
Following the third stress session, each of the three psychosocial stress groups 
was exposed to randomized housing. As in the previous experiments, psychosocial 
groups 1 and 2 were exposed to daily randomized housing for the 12 weeks following the 
third stress session. In contrast, psychosocial stress group 3 was exposed to irregular 
randomized housing for the next 12 weeks. In other words, the cage mates in this group 
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were randomized every 1-4 days. The strategy behind this manipulation was to add an 
additional element of unpredictability to the stress experience. The typical daily 
randomized housing procedure, although effective for the 31-day paradigm, is somewhat 
predictable in that it occurs at approximately the same time every day, and if continued 
for an extended period of time, could eventually become ineffective. 
Behavioral Testing 
Twelve weeks after the third stress session (i.e., Day 116), rats were given tests to 
measure their fear memory, anxiety, startle, learning and memory, cardiovascular activity 
and corticosterone activity. On the first 4 days of behavioral testing (Days 116-119), all 
rats were brought to the laboratory and left undisturbed for 30 minutes before testing 
began. All behavioral testing took place during the light cycle, between 0800 and 1500 
hours. 
Behavioral Apparatus 
 All rats in the present experiment were exposed to the same physiological and 
behavioral testing procedures that were employed in Experiment Three. Thus, these 
procedures will only be briefly addressed here. 
Contextual and Cue Fear Memory. On Day 116, rat behavior in response to the 
chamber (context test) and tone (cue test) that were previously paired with the acute 
stress sessions was examined. Testing adhered to the procedures employed in Experiment 
Three. 
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Elevated Plus Maze. On Day 117, the rats were placed on the EPM for 5 minutes, 
and their behavior was scored according to the procedures employed in Experiment 
Three. 
Startle Response. One hour after the EPM assessment, acoustic startle testing was 
administered according to the procedures employed in Experiment Three. 
Novel Object Recognition. On Day 118, the rats were placed in an open field for 5 
minutes to acclimate to the environment. Their behavior was monitored and scored 
according to the procedures employed in Experiment Three. Twenty-four hours later 
(Day 119), the rats were given novel object recognition training and testing according to 
the procedures employed in Experiment Three. 
Preparation for Blood Sampling. Immediately following the 3-hour object 
recognition test, the hind legs of all rats were shaved to allow access to their saphenous 
veins, as per Experiments One through Three. 
Blood Sampling and Cardiovascular Activity. On the final day of behavioral 
testing (Day 120), three blood samples, as well as measures of heart rate and blood 
pressure, were collected, according to the procedures utilized in Experiment Three. 
Following rapid decapitation, the adrenal and thymus glands were removed and weighed. 
Once all of the blood had clotted at room temperature, it was centrifuged (3000 rpm for 8 
min), and the serum was extracted and stored at -80º C until assayed by Monika Fleshner 
at the University of Colorado at Boulder.  
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Statistical Analyses 
 Experimental Design and General Analyses. The present study utilized a single 
factor, between-subjects design. The independent variable was psychosocial stress 
(psychosocial stress group 1, psychosocial stress group 2, psychosocial stress group 3, no 
psychosocial stress). In most cases, one-way, between-subjects ANOVAs were used to 
analyze the data from the physiological and behavioral assessments, with psychosocial 
stress serving as the between-subjects factors. Planned comparisons (independent 
samples t-tests) were also conducted between each of the psychosocial stress groups and 
the no psychosocial stress group. For all analyses, alpha was set at 0.05, and Holm-Sidak 
post hoc tests were employed when necessary. 
Fear Memory. The amount of immobility during each chamber exposure (Stress 
Session 1, Stress Session 2, Stress Session 3, Context Test, Cue Test – No Tone, Cue 
Test – Tone) was analyzed separately. For each test, one-way, between-subjects 
ANOVAs were used to analyze behavior. Psychosocial stress served as the between-
subjects factor in each case. 
Elevated Plus Maze. The amount of time that rats spent in the open arms of the 
EPM was calculated as a percent of the total trial time. The percent time that rats spent in 
the open arms, as well as the number of ambulations that rats made on the EPM were 
analyzed with one-way, between-subjects ANOVAs. Each of these analyses was 
performed for the entire 5-minute testing trial and for the first minute of the testing trial, 
with psychosocial stress serving as the between-subjects factor in each case. 
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Startle Response. Startle responses to each of the 3 auditory stimulus intensities 
(90, 100 and 110 dB) were analyzed separately. In each case, one-way, between-subjects 
ANOVAs were employed to analyze the data, with psychosocial stress serving as the 
between-subjects factor. 
Novel Object Recognition. For habituation, a one-way, between-subjects ANOVA 
was used to compare overall locomotor activity across all groups, with psychosocial 
stress serving as the between-subjects factor. The amount of time that rats spent in each 
area of the open field during the habituation phase was also analyzed to assure that the 
rats did not display a preference for one area of the open field over another. For the 
analysis, the open field was divided into four square quadrants via the ANY-Maze 
computer program. The amount of time that rats spent in each of the quadrants was 
analyzed with a mixed-model ANOVA, with psychosocial stress serving as the between-
subjects factor and time spent in each quadrant serving as the within-subjects factor. For 
training, paired samples t-tests were first conducted to determine whether the rats within 
each group spent a comparable amount of time with each object replica (to rule out object 
preference effects). Then, the total time that rats spent with both object replicas during 
training was compared across groups by using one-way, between-subjects ANOVAs, 
with psychosocial stress serving as the between-subjects factor. For testing, a “ratio time” 
score was calculated for each group by taking the time that rats spent with the novel 
object and dividing it by the time that rats spent with the familiar object (i.e., ratio time = 
time with novel object / time with familiar object). The ratio times were compared across 
groups by utilizing one-way, between-subjects ANOVAs, with psychosocial stress again 
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serving as the between-subjects factor. This was performed for the entire 5-minute testing 
trial and for the first minute of the testing trial. 
Corticosterone Levels. A mixed-model ANOVA was used to analyze 
corticosterone levels at the three time points. Psychosocial stress served as the between-
subjects factor, and time point (baseline, stress, return-to-baseline) served as the within-
subjects factor. 
Heart Rate and Blood Pressure. The HR, systolic BP and diastolic BP data were 
analyzed with one-way, between-subjects ANOVAs, with psychosocial stress serving as 
the between-subjects factor. 
Growth Rates, Adrenal Gland Weights and Thymus Weights. Growth rates, 
expressed as grams per day (g/day), were calculated for all rats by dividing their total 
body weight gained during the course of the experiment by the total number of days in 
the experiment (i.e., 115 days). The adrenal glands and thymuses were weighed and 
expressed as milligrams per 100 grams of body weight (mg/100 g b.w.). The growth rate, 
adrenal gland weights and thymus weights were analyzed with one-way, between-
subjects ANOVAs, with psychosocial stress serving as the between-subjects factor. 
Results 
Fear Memory 
 Stress Session One (see Figure 29). The analysis of immobility during the 3-
minute chamber exposure during stress session one revealed a significant main effect of 
psychosocial stress, F(3,35) = 3.07, p < 0.05. However, post hoc analyses did not indicate 
any significant differences between the groups. 
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Figure 29. Amount of immobility upon chamber exposure during stress session one. The 
data are presented as mean percent immobility ± SEM. 
 Stress Session Two (see Figure 30). The analysis of immobility during the 3-
minute chamber exposure during stress session two revealed no significant main effect of 
psychosocial stress, F(3,35) = 1.79, p > 0.05. 
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Figure 30. Amount of immobility upon chamber exposure during stress session two. The 
data are presented as mean percent immobility ± SEM. 
  124
 Stress Session Three (see Figure 31). The analysis of immobility during the 3-
minute chamber exposure during stress session three revealed no significant main effect 
of psychosocial stress, F(3,33) = 2.63, p = 0.067. However, planned comparisons 
indicated that psychosocial stress group 1, t(16) = 2.31, and psychosocial stress group 2, 
t(16) = 2.85, spent significantly more time immobile than the no psychosocial stress 
group (p’s < 0.05). 
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Figure 31. Amount of immobility upon chamber exposure during stress session three. 
The data are presented as mean percent immobility ± SEM. * = p < 0.05 relative to the no 
psychosocial stress group. 
 Context Test Immobility (see Figure 32). The analysis of immobility during the 5-
minute context test revealed a significant main effect of psychosocial stress, F(3,34) = 
14.79, p < 0.001. Post hoc tests indicated that psychosocial stress group 1 spent 
significantly more time immobile than the no psychosocial stress group, and psychosocial 
stress group 2 spent significantly more time immobile than all other groups. 
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Effects of Differential Chronic Psychosocial Stress
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Figure 32. Effects of differential chronic psychosocial stress paradigms on immobility 
during the 5-minute context test. The data are presented as mean percent immobility ± 
SEM. * = p < 0.05 relative to the no psychosocial stress group; # = p < 0.05 relative to all 
other groups. 
 Context Test Fecal Boli (see Figure 33). The analysis of fecal boli produced 
during the 5-minute context test revealed a significant main effect of psychosocial stress, 
F(3,35) = 7.51, p < 0.001. Post hoc tests indicated that psychosocial stress group 2 
produced significantly more fecal boli than the no psychosocial stress group, and 
psychosocial stress group 1 produced significantly more fecal boli than all other groups. 
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Figure 33. Effects of differential chronic psychosocial stress paradigms on fecal boli 
produced during the 5-minute context test. The data are presented as mean number of 
fecal boli ± SEM. * = p < 0.05 relative to the no psychosocial stress group; # = p < 0.05 
relative to all other groups. 
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Figure 34. Effects of differential chronic psychosocial stress paradigms on immobility 
during the first 3 minutes of the cue test. The data are presented as mean percent 
immobility ± SEM. 
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 Cue Test Immobility – No Tone (i.e., Novel Environment) (see Figure 34). The 
analysis of immobility during the first 3 minutes of the cue test revealed no significant 
main effect of psychosocial stress, F(3,34) = 2.09, p > 0.05. 
Cue Test Immobility – Tone (see Figure 35). The analysis of immobility during 
the last 3 minutes of the cue test revealed no significant main effect of psychosocial 
stress, F(3,33) = 2.73, p = 0.059. However, planned comparisons indicated that 
psychosocial stress group 1, t(16) = 2.23, and psychosocial stress group 2, t(16) = 3.30, 
spent significantly more time immobile than the no psychosocial stress group (p’s < 
0.05). 
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Figure 35. Effects of differential chronic psychosocial stress paradigms on immobility 
during the tone. The data are presented as mean percent immobility ± SEM. * = p < 0.05 
relative to the no psychosocial stress group. 
Cue Test Fecal Boli (see Figure 36). The analysis of fecal boli produced during 
the 6-minute cue test revealed no significant main effect of psychosocial stress, F(3,35) = 
1.73, p > 0.05.  
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Effects of Differential Chronic Psychosocial Stress
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Figure 36. Effects of differential chronic psychosocial stress paradigms on fecal boli 
produced during the 6-minute cue test. The data are presented as mean number of fecal 
boli ± SEM. 
Elevated Plus Maze 
Percent Time in Open Arms, 5-Minute Trial (see Figure 37). The analysis of 
percent time spent in the open arms during the 5-minute trial on the EPM revealed no 
significant main effect of psychosocial stress, F(3,33) = 0.43, p > 0.05.  
Percent Time in Open Arms, First Minute (see Figure 38). The analysis of percent 
time spent in the open arms during the first minute of the 5-minute trial on the EPM 
revealed a significant main effect of psychosocial stress, F(3,31) = 5.28, p < 0.01. Post 
hoc tests indicated that each of the psychosocial stress groups spent significantly less 
time in the open arms than the no psychosocial stress group. 
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Effects of Differential Chronic Psychosocial Stress
Paradigms on Anxiety on the EPM (5-Minute Trial)
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Figure 37. Effects of differential chronic psychosocial stress paradigms on percent time 
spent in the open arms during the 5-minute trial on the elevated plus maze. The data are 
presented as mean percent time spent in the open arms ± SEM. 
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Figure 38. Effects of differential chronic psychosocial stress paradigms on percent time 
spent in the open arms during the first minute of the 5-minute trial on the elevated plus 
maze. The data are presented as mean percent time spent in the open arms ± SEM. * = p 
< 0.05 relative to the no psychosocial stress group. 
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 Ambulations, 5-Minute Trial (see Figure 39). The analysis of ambulations made 
during the 5-minute trial on the EPM revealed no significant main effect of psychosocial 
stress, F(3,35) = 0.73, p > 0.05. 
Effects of Differential Chronic Psychosocial Stress
Paradigms on Motor Activity on the EPM (5-Minute Trial)
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Figure 39. Effects of differential chronic psychosocial stress paradigms on ambulations 
made during the 5-minute trial on the elevated plus maze. The data are presented as mean 
percent time spent in the open arms ± SEM. 
Ambulations, First Minute (see Figure 40). The analysis of ambulations made 
during the first minute of the 5-minute trial on the EPM revealed no significant main 
effect of psychosocial stress, F(3,35) = 1.77, p > 0.05. 
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Effects of Differential Chronic Psychosocial Stress
Paradigms on Motor Activity on the EPM (First Minute)
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Figure 40. Effects of differential chronic psychosocial stress paradigms on ambulations 
made during the first minute of the 5-minute trial on the elevated plus maze. The data are 
presented as mean percent time spent in the open arms ± SEM. 
Effects of Differential Chronic Psychosocial Stress
Paradigms on Startle Response to 90 dB Auditory Stimuli
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Figure 41. Effects of differential chronic psychosocial stress paradigms on startle 
responses to the 90 dB auditory stimuli. The data are presented as mean startle response 
(Newtons) ± SEM. 
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Startle Response 
 90 dB Auditory Stimuli (see Figure 41). The analysis of startle responses to the 90 
dB auditory stimuli revealed no significant main effect of psychosocial stress, F(3,35) = 
1.57, p > 0.05. 
100 dB Auditory Stimuli (see Figure 42). The analysis of startle responses to the 
100 dB auditory stimuli revealed no significant main effect of psychosocial stress, 
F(3,34) = 2.30, p > 0.05. 
Effects of Differential Chronic Psychosocial Stress
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Figure 42. Effects of differential chronic psychosocial stress paradigms on startle 
responses to the 100 dB auditory stimuli. The data are presented as mean startle response 
(Newtons) ± SEM. 
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Effects of Differential Chronic Psychosocial Stress
Paradigms on Startle Response to 110 dB Auditory Stimuli
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Figure 43. Effects of differential chronic psychosocial stress paradigms on startle 
responses to the 110 dB auditory stimuli. The data are presented as mean startle response 
(Newtons) ± SEM. 
110 dB Auditory Stimuli (see Figure 43). The analysis of startle responses to the 
110 dB auditory stimuli revealed no significant main effect of psychosocial stress, 
F(3,34) = 1.62, p > 0.05. 
Novel Object Recognition 
 Habituation. The analysis of locomotor activity in the open field during the 5-
minute habituation phase revealed no significant main effect of psychosocial stress, 
F(3,35) = 0.68, p > 0.05 (data not shown). The analysis of time that the rats spent in each 
area of the open field revealed no significant main effects of quadrant, F(3,105) = 1.05, 
or psychosocial stress, F(3,35) = 0.91, and the Quadrant x Psychosocial Stress interaction 
was not significant, F(9,105) = 0.40 (p’s > 0.05; data not shown). These findings 
  134
indicated that the rats did not display a preference for one area of the open field over 
another. 
Training. Within-group comparisons showed that the no psychosocial stress 
group, t(9) = 0.81, psychosocial stress group 1, t(9) = 0.72, psychosocial stress group 2, 
t(9) = 1.30, and psychosocial stress group 3, t(8) = 0.91, spent a comparable amount of 
time with each of the objects that were placed in the open field during object recognition 
training (p’s > 0.05; data not shown), indicating that no object preference effects were 
present. Moreover, a between-groups comparison of the total amount of time spent with 
both objects during training revealed no significant main effect of psychosocial stress, 
F(3,35) = 1.44, p > 0.05, indicating that all groups spent a comparable amount of time 
with both objects during training (data not shown). 
Effects of Differential Chronic Psychosocial Stress
Paradigms on Object Recognition Memory (5-Minute Trial)
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Figure 44. Effects of differential chronic psychosocial stress paradigms on object 
recognition memory during the entire 5-minute testing trial. The data are presented as 
mean ratio time ± SEM. * = p < 0.05 relative to the no psychosocial stress group. 
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Effects of Differential Chronic Psychosocial Stress
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Figure 45. Effects of differential chronic psychosocial stress paradigms on object 
recognition memory during the first minute of the testing trial. The data are presented as 
mean ratio time ± SEM. * = p < 0.05 relative to the no psychosocial stress group. 
 Testing. The analysis comparing the ratio times of all groups during the 5-minute 
object recognition testing session revealed no significant main effect of psychosocial 
stress, F(3,29) = 1.23, p > 0.05 (see Figure 44). The analysis comparing the ratio times of 
all groups during the first minute of the testing trial revealed a significant main effect of 
psychosocial stress, F(3,20) = 6.29, p < 0.01 (see Figure 45). Post hoc contrasts indicated 
that each of the 3 psychosocial stress groups exhibited significantly lower ratio times than 
the no psychosocial stress group (p’s < 0.05). 
  136
Effects of Differential Chronic Psychosocial Stress Paradigms
on Serum Corticosterone Levels
C
or
tic
os
te
ro
ne
 ( μ
g/
dL
)
0
5
10
15
20
No Psychosocial Stress
Psychosocial Stress 1
Psychosocial Stress 2
Psychosocial Stress 3
Immobilization Home Cage
0 min 20 min 80 min
 
Figure 46. Effects of differential chronic psychosocial stress paradigms on serum 
corticosterone levels. The data are presented as mean corticosterone levels (μg/dL) ± 
SEM. 
Corticosterone Levels (see Figure 46) 
 The analysis of corticosterone levels revealed a significant main effect of time 
point, F(2,62) = 138.41, p < 0.001. Post hoc tests indicated that all groups displayed 
significantly elevated serum corticosterone levels, relative to baseline, following 20 
minutes of acute immobilization stress and that these levels remained elevated an hour 
later (p’s < 0.05). There was no significant main effect of psychosocial stress, F(3,31) = 
1.11, and the Time Point x Psychosocial Stress interaction was not significant, F(6,62) = 
0.93 (p’s > 0.05). 
Cardiovascular Activity 
 Heart Rate (see Figure 47). The analysis of heart rate revealed no significant 
main effect of psychosocial stress, F(3,22) = 0.17,  p > 0.05. 
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Effects of Differential Chronic Psychosocial Stress
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Figure 47. Effects of differential chronic psychosocial stress paradigms on heart rate. The 
data are presented as mean heart rate (bpm) ± SEM. 
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Figure 48. Effects of differential chronic psychosocial stress paradigms on systolic blood 
pressure. The data are presented as mean systolic blood pressure (mm Hg) ± SEM. * = p 
< 0.05 relative to the no stress group. 
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Systolic Blood Pressure (see Figure 48). The analysis of systolic blood pressure 
revealed a significant main effect of psychosocial stress, F(3,22) = 3.46, p < 0.05. Post 
hoc tests indicated that psychosocial stress group 3 exhibited significantly greater systolic 
blood pressure than the no psychosocial stress group. 
Effects of Differential Chronic Psychosocial Stress
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Figure 49. Effects of differential chronic psychosocial stress paradigms on diastolic 
blood pressure. The data are presented as mean diastolic blood pressure (mm Hg) ± SEM. 
* = p < 0.05 relative to the no psychosocial stress group. 
Diastolic Blood Pressure (see Figure 49). The analysis of diastolic blood pressure 
revealed a significant main effect of psychosocial stress, F(3,22) = 3.13, p < 0.05. Post 
hoc tests indicated that psychosocial stress group 3 exhibited significantly greater 
diastolic blood pressure than the no psychosocial stress group. 
Growth Rates (see Figure 50) 
 The analysis of growth rate revealed no significant main effect of psychosocial 
stress, F(3,34) = 0.54, p > 0.05. 
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Effects of Differential Chronic Psychosocial Stress
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Figure 50. Effects of differential chronic psychosocial stress paradigms on growth rate. 
The data are presented as mean growth rate (g/day) ± SEM. 
Effects of Differential Chronic Psychosocial Stress
Paradigms on Adrenal Gland Weight
No Psych
Stress
A
dr
en
al
 G
la
nd
 W
ei
gh
t (
m
g 
/ 1
00
 g
 b
.w
.)
0
2
4
6
8
10
Psych
Stress 1
Psych
Stress 2
Psych
Stress 3  
Figure 51. Effects of differential chronic psychosocial stress paradigms on adrenal gland 
weight. The data are presented as mean adrenal gland weight (mg/100 g b.w.) ± SEM. 
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Adrenal Gland Weights (see Figure 51) 
 The analysis of adrenal glands weight revealed no significant main effect of 
psychosocial stress, F(3,34) = 0.73, p > 0.05. 
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Figure 52. Effects of differential chronic psychosocial stress paradigms on thymus 
weight. The data are presented as mean thymus weight (mg/100 g b.w.) ± SEM. * = p < 
0.05 relative to the no psychosocial stress group; β = p = 0.057 relative to the no 
psychosocial stress group. 
Thymus Weights (see Figure 52) 
 The analysis of thymus weight revealed a significant main effect of psychosocial 
stress, F(3,35) = 3.76, p < 0.05. Post hoc tests indicated that psychosocial stress group 3 
exhibited significantly smaller thymuses than the no psychosocial stress group. 
Moreover, psychosocial stress group 2 tended to display smaller thymuses than the no 
psychosocial stress group, although this difference did not reach statistical significance. 
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Discussion of Findings 
 The most important finding of the present experiment is that at least some of the 
PTSD-like physiological and behavioral effects induced by the chronic psychosocial 
stress paradigm employed in Experiments One through Three could be maintained for at 
least 4 months following the initial stress session. Psychosocial stress group 1, which was 
given two acute cat exposures and daily social instability throughout the entire 
experiment, displayed significantly greater fear responses to the context and cue that 
were paired with the acute cat exposures, heightened anxiety on the EPM and impaired 
object recognition memory, relative to the no psychosocial stress (i.e., control) group. 
However, psychosocial stress group 1 did not exhibit an exaggerated startle response to 
any auditory stimulus intensity or reduced growth rate, larger adrenal glands or smaller 
thymuses than the controls. These findings suggest that some of the effects of our chronic 
stress regimen, and in particular the physiological effects, diminish over time, even with 
the continued presence of daily social instability. 
 Psychosocial stress group 2 exhibited physiological and behavioral effects (i.e., 
significant fear responses to the context and cue tests, heightened anxiety on the EPM, 
impaired object recognition memory) that were very similar to those observed in 
psychosocial stress group 1. Like psychosocial stress group 1, psychosocial stress group 2 
did not exhibit an exaggerated startle response to any auditory stimulus intensity or a 
reduced growth rate, larger adrenal glands or smaller thymuses than the controls. One 
major difference between these two groups, however, was that psychosocial stress group 
2 displayed a significantly greater fear response, at least with regards to immobility, to 
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the context that was paired with the acute cat exposures than all other groups. These 
findings indicate that the additional cat exposure resulted only in a stronger contextual 
fear memory for the acute cat exposures and did not reinforce the physiological and 
behavioral changes that were lacking in psychosocial stress group 1. 
 Similar to psychosocial stress groups 1 and 2, psychosocial stress group 3 
exhibited heightened anxiety on the EPM and impaired object recognition memory. 
Interestingly, however, psychosocial stress group 3 displayed some physiological and 
behavioral effects that were markedly different from those of the other psychosocial 
stress groups. First, psychosocial stress group 3 did not exhibit a significant fear response 
to the context or tone that was paired with the acute cat exposures. Moreover, 
psychosocial stress group 3 was the only psychosocial stress group to display 
significantly greater blood pressure and smaller thymuses than the control group. Since 
the only difference between psychosocial stress groups 2 and 3 was the type of social 
instability to which each was exposed, these findings suggest that the irregular social 
instability resulted in stronger effects on contextual and cue fear memory, as well as the 
physiological responses of rats to an acute stressor, than daily social instability.  
Conclusions and Limitations 
 The results of this final experiment provide insight into the temporal and social 
factors that mediate the length of time that trauma-induced changes in rat physiology and 
behavior last. This is the first study to report physiological and behavioral changes in rats 
subjected to a chronic psychosocial stress paradigm more than 4 months after the stress 
regimen began. The findings of this experiment indicate that some of the PTSD-like 
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behavioral changes (i.e., intact fear memory, heightened anxiety, cognitive impairments) 
produced by our laboratory’s stress paradigm can be maintained up to 115 days post-
stress. One caveat to these findings is that in every psychosocial stress group, the social 
instability manipulation continued until the beginning of behavioral testing. Thus, the 
observed effects may have been caused, at least in part, by the presence of social 
instability until behavioral testing. 
Perhaps the most interesting finding of the present experiment was that irregular 
social instability led to an impairment of the memories for the context and cue that were 
previously paired with the acute cat exposures and exacerbated the stress-induced 
physiological changes in rats. Psychosocial stress group 3 was the only stress group to 
display significantly greater cardiovascular reactivity to an acute stressor and a 
significantly smaller thymus than the no psychosocial stress group. Most studies, and 
even those from our own laboratory, that have employed unstable housing conditions in a 
stress paradigm have used daily social instability to demonstrate its adverse effects on rat 
physiology and behavior (Baran et al., 2005; Baranyi et al., 2005; Gerges et al., 2004; 
Haller et al., 2004; Lemaire et al., 1997; Park et al., 2001). The strategy behind using the 
irregular social stress in the present experiment was to make the unstable housing more 
unpredictable. The typical daily randomized housing procedure, although effective for the 
31-day paradigm, is somewhat predictable in that it occurs at approximately the same 
time every day, and if continued for an extended period of time, could eventually become 
ineffective. Therefore, I reasoned that the irregular social stress could exacerbate the 
physiological and behavioral effects of the daily social instability and increase the 
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likelihood that rats would exhibit PTSD-like abnormalities for a longer period of time. 
The present findings demonstrate that the element of predictability in day-to-day stressors 
may play a major role in the development of chronic PTSD. 
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Chapter Six: Concluding Remarks 
PTSD is a debilitating mental illness that is characterized by the repeated reliving 
of a life-threatening traumatic event through intrusive, flashback memories. People with 
PTSD display an array of physiological and behavioral symptoms, including persistent 
anxiety, exaggerated startle, heightened autonomic activity, impaired HPA axis 
functioning, cognitive impairments and impaired extinction of conditioned fear. Despite 
scientific advances over the past couple of decades, the neurobiological mechanisms 
underlying the development and maintenance of PTSD remain unclear. Moreover, there 
are currently no pharmacological agents that effectively treat both the dynamic memory 
(e.g., intrusive memories, re-experiencing symptoms) and stable trait (e.g., anxiety, 
hyperarousal) components of the disorder. Thus, the need for a valid animal model of 
PTSD to use for preclinical research has become an issue of growing importance. 
 Many of the symptoms of PTSD (e.g., heightened anxiety, exaggerated startle 
response, cognitive impairments, etc.) can be experienced by people suffering from other 
mental illnesses such as major depressive disorder, panic disorder or generalized anxiety 
disorder. Thus, an animal model of PTSD should produce physiological and behavioral 
changes that are unique to the disorder as it is observed in humans. Some of the 
symptoms of PTSD that set it apart from other disorders include the presence of a 
powerful and intrusive memory of the traumatic event, abnormally low levels of 
glucocorticoids and enhanced suppression of glucocorticoid levels following the 
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administration of dexamethasone. While other mental illnesses have also been 
characterized by abnormal HPA axis functioning, PTSD is the only disorder to be 
characterized by abnormal reductions in basal cortisol levels and an enhanced 
suppression of cortisol in the dexamethasone suppression test (Marshall et al., 2002; 
Yehuda, 2002; Yehuda, 2005; Yehuda et al., 1993a). For instance, major depressive 
disorder is characterized by chronically elevated glucocorticoid levels and reduced 
glucocorticoid suppression following the administration of dexamethasone (Pariante & 
Lightman, 2008). In contrast to people with PTSD, patients suffering from MDD also 
display an abnormally low number of glucocorticoid receptors. Previous work from our 
laboratory has already demonstrated that the present psychosocial stress regimen 
produces heightened anxiety, an exaggerated startle response, cognitive impairments, 
heightened cardiovascular reactivity and hyperresponsivity to yohimbine (Zoladz et al., 
2008). The present work has extended these findings by demonstrating that it also results 
in a powerful memory for the two isolated stress experiences and produces HPA 
abnormalities that are commonly observed in people with PTSD. In conjunction with our 
previous work, these findings further support that this psychosocial stress regimen 
produces physiological and behavioral changes that specifically model those found in 
PTSD. 
Experiment Three also indicated that this model demonstrates predictive validity. 
That is to say, compounds that were predicted to ameliorate stress-induced changes in rat 
physiology and behavior and have led to improvements in some symptom clusters of 
PTSD were shown to ameliorate some of the physiological and behavioral sequelae 
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induced by our chronic psychosocial stress paradigm. Thus, this paradigm could be used 
in future research to guide the development of new pharmacotherapeutic approaches to 
the treatment of PTSD. The differential effectiveness of the pharmacological agents 
examined in Experiment Three, particularly the profile of tianeptine as the most effective 
agent, suggests that abnormal glutamatergic functioning may be involved in this 
regimen’s stress-induced changes in rat physiology and behavior. 
Finally, the last study provided evidence that some of the effects induced by our 
chronic psychosocial stress paradigm could be maintained for at least 4 months following 
the first stress exposure. As PTSD is often a chronic disorder that affects people for most 
of their lives, such a finding indicates that this paradigm could serve to examine the 
neurobiological correlates of chronic PTSD as well. The reason why the exaggerated 
startle response, along with some of the other effects that we normally detect (e.g., 
reduced growth rate, increase adrenal gland weight, etc.), was not observed in our typical 
psychosocial stress paradigm at 4 months post-stress should be examined further in future 
work. 
Collectively, these studies have provided insight into the mechanisms underlying 
trauma-induced changes in brain and behavior and should advance our understanding of 
the biological basis of PTSD. Yet, much remains to be known regarding the 
neurobiological underpinnings of the present effects. Future studies should examine the 
effects of the present psychosocial stress manipulations on neuroplasticity within brain 
regions that play a major role in PTSD, such as the PFC, amygdala and hippocampus and 
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whether or not these changes correlate with the observed alterations in rat physiology and 
behavior. 
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